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Preamble
It is important that the medical profession play a signiﬁcant
role in critically evaluating the use of diagnostic procedures
and therapies as they are introduced and tested in the
detection, management, or prevention of disease states.
Rigorous and expert analysis of the available data docu-
menting absolute and relative beneﬁts and risks of those
procedures and therapies can produce helpful guidelines
that improve the effectiveness of care, optimize patient
outcomes, and favorably affect the overall cost of care by
focusing resources on the most effective strategies.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly
engaged in the production of such guidelines in the area of
cardiovascular disease since 1980. The ACC/AHA Task Force
on Practice Guidelines, whose charge is to develop,
update, or revise practice guidelines for important cardio-
vascular diseases and procedures, directs this effort. The
Task Force is pleased to have this guideline developed in
conjunction with the European Society of Cardiology (ESC).
Writing committees are charged with the task of performing
an assessment of the evidence and acting as an independent
group of authors to develop or update written recommen-
dations for clinical practice.
Experts in the subject under consideration have been
selected from all 3 organizations to examine subject-speciﬁc
data and write guidelines. The process includes additional
representatives from other medical practitioner and speci-
alty groups when appropriate. Writing committees are
speciﬁcally charged to perform a formal literature review,
weigh the strength of evidence for or against a particular
treatment or procedure, and include estimates of expected
health outcomes where data exist. Patient-speciﬁc modi-
ﬁers, comorbidities, and issues of patient preference that
might inﬂuence the choice of particular tests or therapies
are considered as well as frequency of follow-up and cost-
effectiveness. When available, information from studies on
cost will be considered; however, review of data on efﬁcacy
and clinical outcomes will constitute the primary basis for
preparing recommendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines and the
ESC Committee for Practice Guidelines make every effort
to avoid any actual, potential, or perceived conﬂict of inter-
est that might arise as a result of an outside relationship or
personal interest of the writing committee. Speciﬁcally, all
members of the Writing Committee and peer reviewers of
the document are asked to provide disclosure statements
of all such relationships that might be perceived as real or
potential conﬂicts of interest. Writing committee members
are also strongly encouraged to declare a previous relation-
ship with industry that might be perceived as relevant to
guideline development. If a writing committee member
develops a new relationship with industry during their
tenure, they are required to notify guideline staff in
writing. The continued participation of the writing commit-
tee member will be reviewed. These statements are
reviewed by the parent Task Force, reported orally to all
members of the writing committee at each meeting, and
updated and reviewed by the writing committee as
changes occur. Please refer to the methodology manuals
for further description of the policies used in guideline
development, including relationships with industry,
available online at the ACC, AHA, and ESC World Wide Web
sites (http://www.acc.org/clinical/manual/manual_introltr.
htm, http://circ.ahajournals.org/manual/, and http://
www.escardio.org/knowledge/guidelines/Rules/). Please
see Appendix I for author relationships with industry and
Appendix II for peer reviewer relationships with industry
that are pertinent to these guidelines.
These practice guidelines are intended to assist health-
care providers in clinical decision making by describing a
range of generally acceptable approaches for the diagnosis,
management, and prevention of speciﬁc diseases and con-
ditions. These guidelines attempt to deﬁne practices that
meet the needs of most patients in most circumstances.
These guideline recommendations reﬂect a consensus of
expert opinion after a thorough review of the available,
current scientiﬁc evidence and are intended to improve
patient care. If these guidelines are used as the basis for
regulatory/payer decisions, the ultimate goal is quality of
care and serving the patient’s best interests. The ultimate
judgment regarding care of a particular patient must be
made by the healthcare provider and the patient in light
of all of the circumstances presented by that patient.
There are circumstances in which deviations from these
guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/AHA
Task Force on Practice Guidelines and the ESC Committee
for Practice Guidelines and will be considered current
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unless they are updated, revised, or sunsetted and with-
drawn from distribution. The executive summary and rec-
ommendations are published in the August 15, 2006, issues
of the Journal of the American College of Cardiology and
Circulation and the August 16, 2006, issue of the European
Heart Journal. The full-text guidelines are published in the
August 15, 2006, issues of the Journal of the American
College of Cardiology and Circulation and the September
2006 issue of Europace, as well as posted on the ACC
(www.acc.org), AHA (www.americanheart.org), and ESC
(www.escardio.org) World Wide Web sites. Copies of the
full-text guidelines and the executive summary are available
from all 3 organizations.
Sidney C. Smith Jr, MD, FACC, FAHA, FESC, Chair, ACC/
AHA Task Force on Practice Guidelines.
Silvia G. Priori, MD, PhD, FESC, Chair, ESC Committee for
Practice Guidelines.
1. Introduction
1.1. Organization of committee and evidence
review
Atrial ﬁbrillation (AF) is the most common sustained cardiac
rhythm disturbance, increasing in prevalence with age. AF is
often associated with structural heart disease, although a
substantial proportion of patients with AF have no
detectable heart disease. Hemodynamic impairment and
thromboembolic events related to AF result in signiﬁcant
morbidity, mortality, and cost. Accordingly, the American
College of Cardiology (ACC), the American Heart
Association (AHA), and the European Society of Cardiology
(ESC) created a committee to establish guidelines for
optimum management of this frequent and complex
arrhythmia.
The committee was composed of members representing the
ACC, AHA, and ESC, as well as the European Heart Rhythm
Association (EHRA) and the Heart Rhythm Society (HRS). This
document was reviewed by 2 ofﬁcial reviewers nominated by
the ACC, 2 ofﬁcial reviewers nominated by the AHA, and 2 ofﬁ-
cial reviewers nominated by the ESC, as well as by the ACCF
Clinical Electrophysiology Committee, the AHA ECG and
Arrhythmias Committee, the AHA Stroke Review Committee,
EHRA, HRS, and numerous additional content reviewers nomi-
nated by the writing committee. The document was approved
for publication by the governing bodies of the ACC, AHA, and
ESC and ofﬁcially endorsed by the EHRA and the HRS.
The ACC/AHA/ESC Writing Committee to Revise the 2001
Guidelines for the Management of Patients With Atrial
Fibrillation conducted a comprehensive review of the rel-
evant literature from 2001 to 2006. Literature searches
were conducted in the following databases: PubMed/
MEDLINE and the Cochrane Library (including the Cochrane
Database of Systematic Reviews and the Cochrane
Controlled Trials Registry). Searches focused on English-
language sources and studies in human subjects. Articles
related to animal experimentation were cited when the
information was important to understanding pathophysiolo-
gical concepts pertinent to patient management and com-
parable data were not available from human studies.
Major search terms included atrial ﬁbrillation, age, atrial
remodeling, atrioventricular conduction, atrioventricular
node, cardioversion, classiﬁcation, clinical trial,
complications, concealed conduction, cost-effectiveness,
deﬁbrillator, demographics, epidemiology, experimental,
heart failure (HF), hemodynamics, human, hyperthyroidism,
hypothyroidism, meta-analysis, myocardial infarction,
pharmacology, postoperative, pregnancy, pulmonary
disease, quality of life, rate control, rhythm control, risks,
sinus rhythm, symptoms, and tachycardia-mediated cardio-
myopathy. The complete list of search terms is beyond the
scope of this section.
Classiﬁcation of Recommendations and Level of Evidence
are expressed in the ACC/AHA/ESC format as follows and
described in Table 1. Recommendations are evidence
based and derived primarily from published data.
Classiﬁcation of recommendations
. Class I: Conditions for which there is evidence and/or
general agreement that a given procedure/therapy is ben-
eﬁcial, useful, and effective.
. Class II: Conditions for which there is conﬂicting evidence
and/or a divergence of opinion about the usefulness/efﬁ-
cacy of performing the procedure/therapy.
. Class IIa: Weight of evidence/opinion is in favor of useful-
ness/efﬁcacy.
. Class IIb: Usefulness/efﬁcacy is less well established by
evidence/opinion.
. Class III: Conditions for which there is evidence and/or
general agreement that a procedure/therapy is not
useful or effective and in some cases may be harmful.
Level of evidence
The weight of evidence was ranked from highest (A) to
lowest (C), as follows:
. Level of evidence A: Data derived from multiple random-
ized clinical trials or meta-analyses.
. Level of evidence B: Data derived from a single random-
ized trial or nonrandomized studies.
. Level of evidence C: Only consensus opinion of experts,
case studies, or standard-of-care.
1.2. Contents of these guidelines
These guidelines ﬁrst present a comprehensive review of the
latest information about the deﬁnition, classiﬁcation, epide-
miology, pathophysiological mechanisms, and clinical
characteristics of AF. The management of this complex and
potentially dangerous arrhythmia is then reviewed. This
includes prevention of AF, control of heart rate, prevention
of thromboembolism, and conversion to and maintenance of
sinus rhythm. The treatment algorithms include pharmaco-
logical and nonpharmacological antiarrhythmic approaches,
as well as antithrombotic strategies most appropriate for
particular clinical conditions. Overall, this is a consensus
document that attempts to reconcile evidence and opinion
from both sides of the Atlantic Ocean. The pharmacological
and nonpharmacological antiarrhythmic approaches may
include some drugs and devices that do not have the
approval of all government regulatory agencies. Additional
information may be obtained from the package inserts
when the drug or device has been approved for the stated
indication.
Because atrial ﬂutter can precede or coexist with AF,
special consideration is given to this arrhythmia in each
section. There are important differences in the mechanisms
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of AF and atrial ﬂutter, and the body of evidence available
to support therapeutic recommendations is distinct for the
2 arrhythmias. Atrial ﬂutter is not addressed comprehen-
sively in these guidelines but is addressed in the ACC/
AHA/ESC Guidelines on the Management of Patients with
Supraventricular Arrhythmias.1
1.3. Changes since the initial publication of these
guidelines in 2001
In developing this revision of the guidelines, the Writing
Committee considered evidence published since 2001 and
drafted revised recommendations where appropriate to
incorporate results from major clinical trials such as those
that compared rhythm-control and rate-control approaches
to long-term management. The text has been reorganized
to reﬂect the implications for patient care, beginning with
recognition of AF and its pathogenesis and the general pri-
orities of rate control, prevention of thromboembolism,
and methods available for use in selected patients to
correct the arrhythmia and maintain normal sinus rhythm.
Advances in catheter-based ablation technologies have
been incorporated into expanded sections and recommen-
dations, with the recognition that that such vital details as
patient selection, optimum catheter positioning, absolute
rates of treatment success, and the frequency of compli-
cations remain incompletely deﬁned. Sections on drug
therapy have been condensed and conﬁned to human
studies with compounds that have been approved for clinical
use in North America and/or Europe. Accumulating evidence
from clinical studies on the emerging role of angiotensin
inhibition to reduce the occurrence and complications of
AF and information on approaches to the primary prevention
of AF are addressed comprehensively in the text, as these
may evolve further in the years ahead to form the basis
for recommendations affecting patient care. Finally, data
on speciﬁc aspects of management of patients who are
prone to develop AF in special circumstances have become
more robust, allowing formulation of recommendations
based on a higher level of evidence than in the ﬁrst
edition of these guidelines. An example is the completion
of a relatively large randomized trial addressing prophylac-
tic administration of antiarrhythmic medication for patients
undergoing cardiac surgery. In developing the updated rec-
ommendations, every effort was made to maintain consist-
ency with other ACC/AHA and ESC practice guidelines
addressing, for example, the management of patients
undergoing myocardial revascularization procedures.
2. Deﬁnition
2.1. Atrial ﬁbrillation
AF is a supraventricular tachyarrhythmia characterized by
uncoordinated atrial activation with consequent deterio-
ration of atrial mechanical function. On the electrocardio-
gram (ECG), AF is characterized by the replacement of
consistent P waves by rapid oscillations or ﬁbrillatory waves
that vary in amplitude, shape, and timing, associated with
an irregular, frequently rapid ventricular response when
atrioventricular (AV) conduction is intact2 (Figure 1). The
ventricular response to AF depends on electrophysiological
(EP) properties of the AV node and other conducting
tissues, the level of vagal and sympathetic tone, the presence
or absence of accessory conduction pathways, and the action
of drugs.3 Regular cardiac cycles (R-R intervals) are possible
in the presence of AV block or ventricular or AV junctional
tachycardia. In patients with implanted pacemakers,
Figure 1 Electrocardiogram showing atrial ﬁbrillation with a controlled rate of ventricular response. P waves are replaced by ﬁbrillatory
waves and the ventricular response is completely irregular.
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diagnosis of AF may require temporary inhibition of the pace-
maker to expose atrial ﬁbrillatory activity.4 A rapid, irregular,
sustained, wide-QRS-complex tachycardia strongly suggests
AF with conduction over an accessory pathway or AF with
underlying bundle-branch block. Extremely rapid rates (over
200 beats per minute) suggest the presence of an accessory
pathway or ventricular tachycardia.
2.2. Related arrhythmias
AFmay occur in isolation or in association with other arrhyth-
mias, most commonly atrial ﬂutter or atrial tachycardia.
Atrial ﬂutter may arise during treatment with antiarrhythmic
agents prescribed to prevent recurrent AF. Atrial ﬂutter in
the typical form is characterized by a saw-tooth pattern of
regular atrial activation called ﬂutter (f) waves on the ECG,
particularly visible in leads II, III, aVF, and V1 (Figure 2). In
the untreated state, the atrial rate in atrial ﬂutter typically
ranges from 240 to 320 beats per minute, with f waves
inverted in ECG leads II, III, and aVF and upright in lead V1.
The direction of activation in the right atrium (RA) may be
reversed, resulting in f waves that are upright in leads II,
III, and aVF and inverted in lead V1. Atrial ﬂutter commonly
occurs with 2:1 AV block, resulting in a regular or irregular
ventricular rate of 120 to 160 beats per minute (most charac-
teristically about 150 beats per minute). Atrial ﬂutter may
degenerate into AF and AF may convert to atrial ﬂutter.
The ECG pattern may ﬂuctuate between atrial ﬂutter and
AF, reﬂecting changing activation of the atria. Atrial ﬂutter
is usually readily distinguished from AF, but when atrial
activity is prominent on the ECG in more than 1 lead, AF
may be misdiagnosed as atrial ﬂutter.5
Focal atrial tachycardias, AV reentrant tachycardias, and
AV nodal reentrant tachycardias may also trigger AF. In
other atrial tachycardias, P waves may be readily identiﬁed
and are separated by an isoelectric baseline in 1 or more
ECG leads. The morphology of the P waves may help localize
the origin of the tachycardias.
3. Classiﬁcation
Various classiﬁcation systems have been proposed for AF.
One is based on the ECG presentation.2–4 Another is based
on epicardial6 or endocavitary recordings or noncontact
mapping of atrial electrical activity. Several clinical classiﬁ-
cation schemes have also been proposed, but none fully
accounts for all aspects of AF.7–10 To be clinically useful, a
classiﬁcation system must be based on a sufﬁcient number
of features and carry speciﬁc therapeutic implications.
Assorted labels have been used to describe the pattern of
AF, including acute, chronic, paroxysmal, intermittent, con-
stant, persistent, and permanent, but the vagaries of deﬁ-
nitions make it difﬁcult to compare studies of AF or the
effectiveness of therapeutic strategies based on these desig-
nations. Although the pattern of the arrhythmia can change
over time, it may be of clinical value to characterize the
arrhythmia at a given moment. The classiﬁcation scheme
recommended in this document represents a consensus
driven by a desire for simplicity and clinical relevance.
Figure 2 Electrocardiogram showing typical atrial ﬂutter with variable atrioventricular conduction. Note the saw-tooth pattern, F waves,
particularly visible in leads II, III, and aVF, without an isoelectric baseline between deﬂections.
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The clinician should distinguish a ﬁrst-detected episode of
AF, whether or not it is symptomatic or self-limited, recog-
nizing that there may be uncertainty about the duration of
the episode and about previous undetected episodes
(Figure 3). When a patient has had 2 or more episodes, AF
is considered recurrent. If the arrhythmia terminates spon-
taneously, recurrent AF is designated paroxysmal; when sus-
tained beyond 7 d, AF is designated persistent. Termination
with pharmacological therapy or direct-current cardiover-
sion does not change the designation. First-detected AF
may be either paroxysmal or persistent AF. The category of
persistent AF also includes cases of long-standing AF (e.g.,
greater than 1 y), usually leading to permanent AF, in
which cardioversion has failed or has not been attempted.
These categories are not mutually exclusive in a particular
patient, who may have several episodes of paroxysmal AF
and occasional persistent AF, or the reverse. Regarding par-
oxysmal and persistent AF, it is practical to categorize a
given patient by the most frequent presentation. The deﬁ-
nition of permanent AF is often arbitrary. The duration of
AF refers both to individual episodes and to how long the
patient has been affected by the arrhythmia. Thus, a
patient with paroxysmal AF may have episodes that last
seconds to hours occurring repeatedly for years.
Episodes of AF briefer than 30 s may be important in
certain clinical situations involving symptomatic patients,
pre-excitation or in assessing the effectiveness of thera-
peutic interventions. This terminology applies to episodes
of AF that last more than 30 s without a reversible cause.
Secondary AF that occurs in the setting of acute myocardial
infarction (MI), cardiac surgery, pericarditis, myocarditis,
hyperthyroidism, pulmonary embolism, pneumonia, or
other acute pulmonary disease is considered separately. In
these settings, AF is not the primary problem, and treat-
ment of the underlying disorder concurrently with manage-
ment of the episode of AF usually terminates the arrhythmia
without recurrence. Conversely, because AF is common, it
may occur independently of a concurrent disorder like well-
controlled hypothyroidism, and then the general principles
for management of the arrhythmia apply.
The term ‘lone AF’ has been variously deﬁned but gener-
ally applies to young individuals (under 60 y of age) without
clinical or echocardiographic evidence of cardiopulmonary
disease, including hypertension.11 These patients have a
favorable prognosis with respect to thromboembolism and
mortality. Over time, patients may move out of the lone
AF category due to aging or development of cardiac abnorm-
alities such as enlargement of the left atrium (LA). Then,
the risks of thromboembolism and mortality rise accordingly.
By convention, the term ‘nonvalvular AF’ is restricted to
cases in which the rhythm disturbance occurs in the
absence of rheumatic mitral valve disease, a prosthetic
heart valve, or mitral valve repair.
4. Epidemiology and prognosis
AF is the most common arrhythmia in clinical practice,
accounting for approximately one-third of hospitalizations
for cardiac rhythm disturbances. Most data regarding the
epidemiology, prognosis, and quality of life in AF have
been obtained in the United States and western Europe. It
has been estimated that 2.2 million people in America and
4.5 million in the European Union have paroxysmal or per-
sistent AF.12 During the past 20 y, there has been a 66%
increase in hospital admissions for AF13–15 due to a combi-
nation of factors including the aging of the population, a
rising prevalence of chronic heart disease, and more fre-
quent diagnosis through use of ambulatory monitoring
devices. AF is an extremely costly public health
problem,16,17 with hospitalizations as the primary cost
driver (52%), followed by drugs (23%), consultations (9%),
further investigations (8%), loss of work (6%), and paramedi-
cal procedures (2%). Globally, the annual cost per patient is
close to E3000 (approximately U.S. $3600).16 Considering
the prevalence of AF, the total societal burden is huge, for
example, about EE13.5 billion (approximately U.S. $15.7
billion) in the European Union.
4.1. Prevalence
The estimated prevalence of AF is 0.4% to 1% in the general
population, increasing with age.18,19 Cross-sectional studies
have found a lower prevalence in those below the age of
60 y, increasing to 8% in those older than 80 y
(Figure 4).20–22 The age-adjusted prevalence of AF is higher
Figure 4 Estimated age-speciﬁc prevalence of atrial ﬁbrillation
(AF) based on 4 population-based surveys. Prevalence, age, distri-
bution, and gender of patients with AF analysis and implications.
Modiﬁed with permission from Feinberg WM, Blackshear JL,
Laupacis A, et al. Prevalence, age distribution, and gender of
patients with atrial ﬁbrillation. Analysis and implications. Arch
Intern Med 1995;155:469–73.19 Copyright & 1995, American
Medical Association. All rights reserved.
Figure 3 Patterns of atrial ﬁbrillation (AF). 1, Episodes that gener-
ally last 7 d or less (most less than 24 h); 2, episodes that usually last
longer than 7 d; 3, cardioversion failed or not attempted; and 4,
both paroxysmal and persistent AF may be recurrent.
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in men,22,23 in whom the prevalence has more than doubled
from the 1970s to the 1990s, while the prevalence in
women has remained unchanged.24 The median age of AF
patients is about 75 y. Approximately 70% are between 65
and 85 y old. The overall number of men and women with
AF is about equal, but approximately 60% of AF patients
over 75 y are female. Based on limited data, the
age-adjusted risk of developing AF in blacks seems less than
half that in whites.18,25,26 AF is less common among African-
American than Caucasian patients with heart failure (HF).
In population-based studies, patients with no history of
cardiopulmonary disease account for fewer than 12% of all
cases of AF.11,22,27,28 In some series, however, the observed
proportion of lone AF was over 30%.29,30
These differences may depend on selection bias when
recruiting patients seen in clinical practice compared with
population-based observations. In the Euro Heart Survey
on AF,31 the prevalence of idiopathic AF amounted to 10%,
with an expected highest value of 15% in paroxysmal AF,
14% in ﬁrst-detected AF, 10% in persistent AF, and only 4%
in permanent AF. Essential hypertension, ischemic heart
disease, HF (Table 2), valvular heart disease, and diabetes
are the most prominent conditions associated with AF.14
4.2. Incidence
In prospective studies, the incidence of AF increases from less
than 0.1% per year in those under 40 y old to exceed 1.5% per
year in women and 2% in men older than 80 (Figure 5).25,32,33
The age-adjusted incidence increased over a 30-y period in
the Framingham Study,32 and this may have implications for
the future impact of AF.34 During 38 y of follow-up in the
Framingham Study, 20.6% of men who developed AF had HF
at inclusion versus 3.2% of those without AF; the correspond-
ing incidences in women were 26.0% and 2.9%.35 In patients
referred for treatment of HF, the 2- to 3-y incidence of AF
was 5% to 10%.25,36,37 The incidence of AF may be lower in
HF patients treated with angiotensin inhibitors.38–40
Similarly, angiotensin inhibition may be associated with a
reduced incidence of AF in patients with hypertension,41,42
although this may be conﬁned to those with left ventricular
hypertrophy (LVH).43–45
4.3. Prognosis
AF is associated with an increased long-term risk of stroke,47
HF, and all-cause mortality, especially in women.48 The mor-
tality rate of patients with AF is about double that of
patients in normal sinus rhythm and linked to the severity of
underlying heart disease20,23,33 (Figure 6). About two-thirds
of the 3.7% mortality over 8.6 mo in the Etude en Activite´ Lib-
e´rale sur la Fibrillation Auriculaire Study (ALFA) was attributed
to cardiovascular causes.29 Table 3 shows a list of associated
heart diseases in the population of the ALFA study.29
Figure 5 Incidence of atrial ﬁbrillation in 2 American epidemiolo-
gical studies. Framingham indicates the Framingham Heart Study.
Data are from Wolf PA, Abbott RD, Kannel WB. Atrial ﬁbrillation: a
major contributor to stroke in the elderly. The Framingham Study.
Arch Intern Med 1987;147:1561–4.32 CHS indicates the Cardiovascu-
lar Health Study. Data are from Psaty BM, Manolio TA, Kuller LH,
et al. Incidence of and risk factors for atrial ﬁbrillation in older
adults. Circulation 1997;96:2455–6125; and Furberg CD, Psaty BM,
Manolio TA, et al. Prevalence of atrial ﬁbrillation in elderly subjects
(the Cardiovascular Health Study). Am J Cardiol 1994;74:236–41,22
and Farrell B, Godwin J, Richards S, et al. The United Kingdom tran-
sient ischaemic attack (UK-TIA) aspirin trial: ﬁnal results. J Neurol
Neurosurg Psychiatry 1991;54:1044–54.46
Table 2 Prevalence of AF in patients with heart failure as
reﬂected in several heart failure trials
Predominant
NYHA Class
Prevalence
of AF (%)
Study
I 4 SOLVD-prevention (1992)14a
II–III 10 to 26 SOLVD-treatment (1991)14b
CHF-STAT (1995)14c
MERIT-HF (1999)14d
DIAMOND-CHF (1999)501
II–IV 12 to 27 CHARM (2003) Val-HeFT (2003)848
III–IV 20 to 29 Middlekauff (1991)14e
Stevenson (1996) GESICA (1994)14f
IV 50 CONSENSUS (1987)14g
AF indicates atrial ﬁbrillation; NYHA, New York Heart Association;
SOLVD, Studies Of Left Ventricular Dysfunction; CHF-STAT, Survival Trial
of Antiarrhythmic Therapy in Congestive Heart Failure; MERIT-HF,
Metropolol CR/XL Randomized Intervention Trial in Congestive Heart
Failure; DIAMOND-CHF, Danish Investigations of Arrhythmia and
Mortality on Dofetilide-Congestive Heart Failure; CHARM, Candesartan
in Heart failure, Assessment of Reduction in Mortality and morbidity;
Val-HeFT, Valsartan Heart Failure Trial; GESICA, Grupo Estudio de la
Sobrevida en la Insufﬁcienca Cardiaca en Argentina (V); CONSENSUS,
Co-operative North Scandinavian Enalapril Survival Study.
Figure 6 Relative risk of stroke and mortality in patients with
atrial ﬁbrillation (AF) compared with patients without AF. Source
data from the Framingham Heart Study (Kannel WB, Abbott RD,
Savage DD, et al. Coronary heart disease and atrial ﬁbrillation:
the Framingham Study. Am Heart J 1983;106:389–96),23 the
Regional Heart Study and the Whitehall study (Flegel KM, Shipley
MJ, Rose G. Risk of stroke in non-rheumatic atrial ﬁbrillation), and
the Manitoba study (Krahn AD, Manfreda J, Tate RB, et al. The
natural history of atrial ﬁbrillation: incidence, risk factors, and
prognosis in the Manitoba follow-up study. Am J Med
1995;98:476–84).33
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Mortality in the Veterans Administration Heart Failure
Trials (V-HeFT) was not increased among patients with con-
comitant AF,49 whereas in the Studies of Left Ventricular
Dysfunction (SOLVD), mortality was 34% for those with AF
versus 23% for patients in sinus rhythm (p less than
0.001).50 The difference was attributed mainly to deaths
due to HF rather than to thromboembolism. AF was a
strong independent risk factor for mortality and major mor-
bidity in large HF trials. In the Carvedilol Or Metoprolol
European Trial (COMET), there was no difference in all-cause
mortality in those with AF at entry, but mortality increased
in those who developed AF during follow-up.51 In the
Val-HeFT cohort of patients with chronic HF, development
of AF was associated with signiﬁcantly worse outcomes.40
HF promotes AF, AF aggravates HF, and individuals with
either condition who develop the alternate condition share
a poor prognosis.52 Thus, managing the association is a
major challenge53 and the need for randomized trials to
investigate the impact of AF on the prognosis in HF is
apparent.
The rate of ischemic stroke among patients with nonvalv-
ular AF averages 5% per year, 2 to 7 times that of people
without AF20,21,29,32,33,47 (Figure 6). One of every 6 strokes
occurs in a patient with AF.54 Additionally, when transient
ischemic attacks (TIAs) and clinically ‘silent’ strokes
detected by brain imaging are considered, the rate of
brain ischemia accompanying nonvalvular AF exceeds 7%
per year.35,55–58 In patients with rheumatic heart disease
and AF in the Framingham Heart Study, stroke risk was
increased 17-fold compared with age-matched controls,59
and attributable risk was 5 times greater than that in
those with nonrheumatic AF.21 In the Manitoba Follow-up
Study, AF doubled the risk of stroke independently of
other risk factors,33 and the relative risks for stroke in non-
rheumatic AF were 6.9% and 2.3% in the Whitehall and the
Regional Heart studies, respectively. Among AF patients
from general practices in France, the Etude en Activite´ Lib-
e´rale sur le Fibrillation Auriculaire (ALFA) study found a 2.4%
incidence of thromboembolism over a mean of 8.6 mo of
follow-up.29 The risk of stroke increases with age; in the
Framingham Study, the annual risk of stroke attributable
to AF was 1.5% in participants 50 to 59 y old and 23.5% in
those aged 80 to 89 y.21
5. Pathophysiological mechanisms
5.1. Atrial factors
5.1.1. Atrial pathology as a cause of atrial ﬁbrillation
The most frequent pathoanatomic changes in AF are atrial
ﬁbrosis and loss of atrial muscle mass. Histological examin-
ation of atrial tissue of patients with AF has shown patchy
ﬁbrosis juxtaposed with normal atrial ﬁbers, which may
account for nonhomogeneity of conduction.60–62 The sino-
atrial (SA) and AV nodes may also be involved, accounting
for the sick sinus syndrome and AV block. It is difﬁcult to
distinguish between changes due to AF and those due to
associated heart disease, but ﬁbrosis may precede the
onset of AF.63
Biopsy of the LA posterior wall during mitral valve surgery
revealed mild to moderate ﬁbrosis in specimens obtained
from patients with sinus rhythm or AF of relatively short dur-
ation, compared with severe ﬁbrosis and substantial loss of
muscle mass in those from patients with long-standing AF.
Table 3 Demographics and associated conditions among patients with atrial ﬁbrillation in the ALFA study
Total Population Paroxysmal AF Chronic AF Recent-onset AF
No. of patients 756 167 389 200
Age, y 69 66 70 68
Male/female ratio 1 1 2 1
Time from ﬁrst episode of AF (mo) 47 39 66 NA
Underlying heart disease (%)
Coronary artery disease 17 12 18 19
Hypertensive heart disease 21 17 22 25
Valvular (rheumatic) 15 10 20 12
Dilated cardiomyopathy 9 2 13 9
Hypertrophic cardiomyopathy 5 3 4 9
Other 9 14 9 7
None 29 46 23 28
Other predisposing or associated factors (%)
Hyperthyroidism 3 4 2 5
Hypertension 39 35 38 46
Bronchopulmonary disease 11 10 13 10
Diabetes 11 7 13 9
Congestive HF 30 14 43 18
Prior embolic events 8 8 11 4
Left atrial size (mm) 44 40 47 42
Left ventricular ejection fraction (%) 59 63 57 58
Persistent atrial ﬁbrillation (AF) includes both recent-onset and chronic AF. Recent-onset AF was deﬁned as persistent AF lasting
greater than or equal to 7 and less than 30 d. Chronic AF was deﬁned as persistent AF of more than 30-d duration. Patients in
whom the diagnosis was deﬁnite and those in whom it was probable were included. Modiﬁed with permission from Levy S, Maarek
M, Coumel P, et al. Characterization of different subsets of atrial ﬁbrillation in general practice in France: the ALFA Study, The
College of French Cardiologists. Circulation 1999;99:3028–35.29 & 1999 American Heart Association.
ALFA indicates Etude en Activite´ Libe´rale sur la Fibrillation Auriculaire, HF, heart failure; NA, not applicable or unavailable.
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Patients with mild or moderate ﬁbrosis responded more suc-
cessfully to cardioversion than did those with severe ﬁbrosis,
which was thought to contribute to persistent AF in cases of
valvular heart disease.64 In atrial tissue specimens from 53
explanted hearts from transplantation recipients with
dilated cardiomyopathy, 19 of whom had permanent, 18 per-
sistent, and 16 no documented AF, extracellular matrix
remodeling including selective downregulation of atrial
insulin-like growth factor II mRNA-binding protein 2 (IMP-2)
and upregulation of matrix metalloproteinase 2 (MMP-2)
and type 1 collagen volume fraction (CVF-1) were associated
with sustained AF.65
Atrial biopsies from patients undergoing cardiac surgery
revealed apoptosis66 that may lead to replacement of
atrial myocytes by interstitial ﬁbrosis, loss of myoﬁbrils,
accumulation of glycogen granules, disruption of cell coup-
ling at gap junctions,67 and organelle aggregates.68 The con-
centration of membrane-bound glycoproteins that regulate
cell-cell and cell-matrix interactions (disintegrin and metal-
loproteinases) in human atrial myocardium has been
reported to double during AF. Increased disintegrin and
metalloproteinase activity may contribute to atrial dilation
in patients with long-standing AF.
Atrial ﬁbrosis may be caused by genetic defects like lamin
AC gene mutations.69 Other triggers of ﬁbrosis include
inﬂammation70 as seen in cardiac sarcoidosis71 and auto-
immune disorders.72 In one study, histological changes con-
sistent with myocarditis were reported in 66% of atrial
biopsy specimens from patients with lone AF,62 but it is
uncertain whether these inﬂammatory changes were a
cause or consequence of AF. Autoimmune activity is
suggested by high serum levels of antibodies against
myosin heavy chains in patients with paroxysmal AF who
have no identiﬁed heart disease.72 Apart from ﬁbrosis,
atrial pathological ﬁndings in patients with AF include amy-
loidosis,73,74 hemochromatosis,75 and endomyocardial ﬁbro-
sis.75,76 Fibrosis is also triggered by atrial dilation in any type
of heart disease associated with AF, including valvular
disease, hypertension, HF, or coronary atherosclerosis.77
Stretch activates several molecular pathways, including
the renin-angiotensin-aldosterone system (RAAS). Both
angiotensin II and transforming growth factor-beta1
(TGF-beta1) are upregulated in response to stretch, and
these molecules induce production of connective tissue
growth factor (CTGF).70 Atrial tissue from patients with per-
sistent AF undergoing open-heart surgery demonstrated
increased amounts of extracellular signal-regulated kinase
messenger RNA (ERK-2-mRNA), and expression of
angiotensin-converting enzyme (ACE) was increased 3-fold
during persistent AF.78 A study of 250 patients with AF and
an equal number of controls demonstrated the association
of RAAS gene polymorphisms with this type of AF.79
Several RAAS pathways are activated in experimen-
tal78,80–84 as well as human AF,78,85 and ACE inhibition and
angiotensin II receptor blockade had the potential to
prevent AF by reducing ﬁbrosis.84,86
In experimental studies of HF, atrial dilation and interstitial
ﬁbrosis facilitates sustained AF.86–92 The regional electrical
silence (suggesting scar), voltage reduction, and conduction
slowing described in patients with HF93 are similar to
changes in the atria that occur as a consequence of aging.
AF is associated with delayed interatrial conduction and
dispersion of the atrial refractory period.94 Thus, AF seems
to cause a variety of alterations in the atrial architecture
and function that contribute to remodeling and perpetuation
of the arrhythmia. Despite these pathological changes in the
atria, however, isolation of the pulmonary veins (PVs) will
prevent AF in many such patients with paroxysmal AF.
5.1.1.1. Pathological changes caused by atrial ﬁbrillation.
Just as atrial stretch may cause AF, AF can cause atrial
dilation through loss of contractility and increased
compliance.61 Stretch-related growth mechanisms and ﬁbro-
sis increase the extracellular matrix, especially during
prolonged periods of AF. Fibrosis is not the primary feature
of AF-induced structural remodeling,95,96 although accumu-
lation of extracellular matrix and ﬁbrosis are associated
with more pronounced myocytic changes once dilation
occurs due to AF or associated heart disease.90,97 These
changes closely resemble those in ventricular myocytes in
the hibernating myocardium associated with chronic
ischemia.98 Among these features are an increase in cell
size, perinuclear glycogen accumulation, loss of sarcoplasmic
reticulum and sarcomeres (myolysis). Changes in gap junc-
tion distribution and expression are inconsistent,61,99 and
may be less important than ﬁbrosis or shortened refractori-
ness in promoting AF. Loss of sarcomeres and contractility
seems to protect myocytes against the high metabolic
stress associated with rapid rates. In fact, in the absence of
other pathophysiological factors, the high atrial rate typical
of AF may cause ischemia that affects myocytes more than
the extracellular matrix and interstitial tissues.
Aside from changes in atrial dimensions that occur over
time, data on human atrial structural remodeling are
limited96,100 and difﬁcult to distinguish from degenerative
changes related to aging and associated heart disease.96
One study that compared atrial tissue specimens from
patients with paroxysmal and persistent lone AF found degen-
erative contraction bands in patients with either pattern of
AF, while myolysis and mitochondria hibernation were
limited to those with persistent AF. The activity of calpain
I, a proteolytic enzyme activated in response to cytosolic
calcium overload, was upregulated in both groups and corre-
lated with ion channel protein and structural and electrical
remodeling. Hence, calpain activation may link calcium over-
load to cellular adaptation in patients with AF.341
5.1.2. Mechanisms of atrial ﬁbrillation
The onset and maintenance of a tachyarrhythmia require
both an initiating event and an anatomical substrate. With
respect to AF, the situation is often complex, and available
data support a ‘focal’ mechanism involving automaticity or
multiple reentrant wavelets. These mechanisms are not
mutually exclusive and may at various times coexist in the
same patient (Figure 7).
5.1.2.1. Automatic focus theory. A focal origin of AF is
supported by experimental models of aconitine and
pacing-induced AF102,103 in which the arrhythmia persists
only in isolated regions of atrial myocardium. This theory
received minimal attention until the important observation
that a focal source for AF could be identiﬁed in humans
and ablation of this source could extinguish AF.104 While
PVs are the most frequent source of these rapidly atrial
impulses, foci have also been found in the superior vena
cava, ligament of Marshall, left posterior free wall, crista
terminalis, and coronary sinus.79,104–110
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In histological studies, cardiac muscle with preserved
electrical properties extends into the PV,106,111–116 and the
primacy of PVs as triggers of AF has prompted substantial
research into the anatomical and EP properties of these
structures. Atrial tissue on the PV of patients with AF has
shorter refractory periods than in control patients or other
parts of the atria in patients with AF.117,118 The refractory
period is shorter in atrial tissue in the distal PV than at
the PV-LA junction. Decremental conduction in PV is more
frequent in AF patients than in controls, and AF is more
readily induced during pacing in the PV than in the LA.
This heterogeneity of conduction may promote reentry and
form a substrate for sustained AF.119 Programmed electrical
stimulation in PV isolated by catheter ablation initiated sus-
tained pulmonary venous tachycardia, probably as a conse-
quence of reentry.120 Rapidly ﬁring atrial automatic foci
may be responsible for these PV triggers, with an anatomical
substrate for reentry vested within the PV.
Whether the source for AF is an automatic focus or a
microreentrant circuit, rapid local activation in the LA
cannot extend to the RA in an organized way. Experiments
involving acetylcholine-induced AF in Langendorf-perfused
sheep hearts demonstrated a dominant ﬁbrillation fre-
quency in the LA with decreasing frequency as activation
progressed to the RA. A similar phenomenon has been
shown in patients with paroxysmal AF.121 Such variation in
conduction leads to disorganized atrial activation, which
could explain the ECG appearance of a chaotic atrial
rhythm.122 The existence of triggers for AF does not
negate the role of substrate modiﬁcation. In some patients
with persistent AF, disruption of the muscular connections
between the PV and the LA may terminate the arrhythmia.
In others, AF persists following isolation of the supposed
trigger but does not recur after cardioversion. Thus, in
some patients with abnormal triggers, sustained AF may
depend on an appropriate anatomical substrate.
5.1.2.2. Multiple-wavelet hypothesis. The multiple-wavelet
hypothesis as the mechanism of reentrant AF was advanced
by Moe and colleagues,123 who proposed that fractionation
of wavefronts propagating through the atria results in
self-perpetuating ‘daughter wavelets’. In this model, the
number of wavelets at any time depends on the refractory
period, mass, and conduction velocity in different parts of
the atria. A large atrial mass with a short refractory period
and delayed conduction increases the number of wavelets,
favoring sustained AF. Simultaneous recordings from
multiple electrodes supported the multiple-wavelet hypo-
thesis in human subjects.127
For many years, the multiple-wavelet hypothesis was the
dominant theory explaining the mechanism of AF, but the
data presented above and from experimental127a and clini-
cal127b,127c mapping studies challenge this notion. Even so,
a number of other observations support the importance of
an abnormal atrial substrate in the maintenance of AF. For
over 25 y, EP studies in humans have implicated atrial vul-
nerability in the pathogenesis of AF.128–132 In one study of
43 patients without structural heart disease, 18 of whom
had paroxysmal AF, the coefﬁcient of dispersion of atrial
refractoriness was signiﬁcantly greater in the patients with
AF.128 Furthermore, in 16 of 18 patients with a history of
AF, the arrhythmia was induced with a single extrastimulus,
while a more aggressive pacing protocol was required in 23
of 25 control patients without previously documented AF.
In patients with idiopathic paroxysmal AF, widespread
distribution of abnormal electrograms in the RA predicted
development of persistent AF, suggesting an abnormal sub-
strate.132 In patients with persistent AF who had undergone
conversion to sinus rhythm, there was signiﬁcant pro-
longation of intra-atrial conduction compared with a
control group, especially among those who developed recur-
rent AF after cardioversion.130
Patients with a history of paroxysmal AF, even those with
lone AF, have abnormal atrial refractoriness and conduction
compared with patients without AF. An abnormal
signal-averaged P-wave ECG reﬂects slowed intra-atrial con-
duction and shorter wavelengths of reentrant impulses. The
resulting increase in wavelet density promotes the onset
and maintenance of AF. Among patients with HF, pro-
longation of the P wave was more frequent in those prone
to paroxysmal AF.133 In specimens of RA appendage tissue
obtained from patients undergoing open-heart surgery,
P-wave duration was correlated with amyloid deposition.73
Because many of these observations were made prior to
the onset of clinical AF, the ﬁndings cannot be ascribed to
atrial remodeling that occurs as a consequence of AF.
Atrial refractoriness increases with age in both men and
women, but concurrent age-related ﬁbrosis lengthens effec-
tive intra-atrial conduction pathways. This, coupled with
the shorter wavelengths of reentrant impulses, increases
the likelihood that AF will develop.134,135 Nonuniform
alterations of refractoriness and conduction throughout
the atria may provide a milieu for the maintenance of AF.
However, the degree to which changes in the atrial architec-
ture contribute to the initiation and maintenance of AF is
not known. Isolation of the PV may prevent recurrent AF
even in patients with substantial abnormalities in atrial
size and function. Finally, the duration of episodes of AF cor-
relates with both a decrease in atrial refractoriness and
shortening of the AF cycle length, attesting to the import-
ance of electrical remodeling in the maintenance of AF.136
The anatomical and electrophysiological substrates are
detailed in Table 4.
Figure 7 Posterior view of principal electrophysiological mechan-
isms of atrial ﬁbrillation. (A), Focal activation. The initiating focus
(indicated by the star) often lies within the region of the pulmonary
veins. The resulting wavelets represent ﬁbrillatory conduction, as in
multiple-wavelet reentry. (B), Multiple-wavelet reentry. Wavelets
(indicated by arrows) randomly reenter tissue previously activated
by the same or another wavelet. The routes the wavelets travel
vary. Reproduced with permission from Konings KT, Kirchhof CJ,
Smeets JR, et al. High-density mapping of electrically induced
atrial ﬁbrillation in humans. Circulation 1994;89:1665–80.101 LA
indicates left atrium; PV, pulmonary vein; ICV, inferior vena cava;
SCV, superior vena cava; and RA, right atrium.
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5.1.3. Atrial electrical remodeling
Pharmacological or direct-current cardioversion of AF has a
higher success rate when AF has been present for less than
24 h,137 whereas more prolonged AF makes restoring and
maintaining sinus rhythm less likely. These observations gave
rise to the adage ‘atrial ﬁbrillation begets atrial ﬁbrillation’.
The notion that AF is self-perpetuating takes experimental
support from a goat model using an automatic atrial ﬁbrillator
that detected spontaneous termination of AF and reinduced
the arrhythmia by electrical stimulation.138 Initially, electri-
cally induced AF terminated spontaneously. After repeated
inductions, however, the episodes became progressively
more sustained until AF persisted at a more rapid atrial
rate.138 The increasing propensity to AF was related to pro-
gressive shortening of effective refractory periods with
increasing episode duration, a phenomenon known as EP remo-
deling. These measurements support clinical observations139
that the short atrial effective refractory period in patients
with parox-ysmal AF fails to adapt to rate, particularly
during bradycardia. Conﬁrmation came from recordings of
action potentials in isolated ﬁbrillating atrial tissue and from
patients after cardioversion.140 The duration of atrial mono-
phasic action potentials was shorter after cardioversion and
correlated with the instability of sinus rhythm.141
Tachycardia-induced AF may result from AV node reentry,
an accessory pathway, atrial tachycardia, or atrial
ﬂutter.142–144 After a period of rapid atrial rate, electrical
remodeling stimulates progressive intracellular calcium
loading that leads to inactivation of the calcium
current.145,146 Reduction of the calcium current in turn short-
ens the action potential duration and atrial refractory period,
which may promote sustained AF. The role of potassium cur-
rents in this situation is less clear.145 Electrical remodeling
has also been demonstrated in PV myocytes subjected to sus-
tained rapid atrial pacing, resulting in shorter action potential
durations and both early and delayed afterdepolarizations.147
In addition to remodeling and changes in electrical refrac-
toriness, prolonged AF disturbs atrial contractile function.
With persistent AF, recovery of atrial contraction can be
delayed for days or weeks following the restoration of sinus
rhythm, which has important implications for the duration
of anticoagulation after cardioversion. (See Section 8.1.4,
Preventing Thromboembolism.) Both canine and preliminary
human data suggest that prolonged AF may also lengthen
sinus node recovery time.148,149 The implication is that AF
may be partly responsible for sinus node dysfunction in
some patients with the tachycardia-bradycardia syndrome.
Reversal of electrical remodeling in human atria may
occur at different rates depending on the region of the
atrium studied.150 When tested at various times after cardi-
oversion, the effective refractory period of the lateral RA
increased within 1 h after cardioversion, while that in the
coronary sinus was delayed for 1 wk. In another study, recov-
ery of normal atrial refractoriness after cardioversion of
persistent AF was complete within 3 to 4 d,151 after which
there was no difference in refractoriness between the RA
appendage and the distal coronary sinus. The disparities
between studies may reﬂect patient factors or the duration
or pattern of AF before cardioversion.
5.1.4. Counteracting atrial electrical remodeling
Data are accumulating on the importance of the RAAS in the
genesis of AF.145 Irbesartan plus amiodarone was associated
with a lower incidence of recurrent AF after cardioversion
than amiodarone alone,39 and use of angiotensin inhibitors
and diuretics signiﬁcantly reduced the incidence of AF
after catheter ablation of atrial ﬂutter.152 Amiodarone
may reverse electrical remodeling even when AF is
ongoing,153 and this explains how amiodarone can convert
persistent AF to sinus rhythm. Inhibition of the RAAS,
alone or in combination with other therapies, may therefore
prevent the onset or maintenance of AF43 through several
Table 4 Anatomical and electrophysiological substrates promoting the initiation and/or maintenance of atrial ﬁbrillation
Diseases Anatomical Substratesa
Cellular Electrophysiological
Part A. substrate develops during sinus rhythm (remodeling related to stretch and dilatation). The main pathways involve the RAAS,
TGF-beta, and CTGF.
Hypertension Atrial dilatation Myolysis Conduction abnormalities
Heart failure PV dilatation Apoptosis, necrosis ERP dispersion
Coronary disease Fibrosis Channel expression change Ectopic activity
Valvular disease
Part B. substrate develops due to tachycardia (tachycardia-related remodeling, downregulation of calcium channel and calcium handling).
Focal AF None orb None orb Ectopic activity
Atrial ﬂutter Atrial dilatation Calcium channel downregulation Microreentry
PV dilatation Myolysis Short ERPc
Large PV sleeves Connexin downregulation ERP dispersiond
Reduced contractility&cjs0952; Adrenergic supersensitivity Slowed conduction
Fibrosis Changed sympathetic innervation
CTGF indicates connective tissue growth factor; ERP, effective refractory period; PV, pulmonary vein; RAAS, renin-angiotensin-aldosterone system;
TGF-beta, transforming growth factor-beta1.
aSubstrate develops either while in sinus rhythm, usually caused by ventricular remodeling, atrial pressure overload and subsequent atrial dilatation (Part A),
or due to the rapid atrial rate during atrial ﬁbrillation (AF), according to the principle that ‘AF begets AF’ (Part B).
bThe listed changes may only occur with prolonged episodes of AF at high atrial rate.
cShort ERP and slow conduction may produce short wavelength, thereby promoting further AF.
dERP dispersion together with spontaneous or stretch-induced ectopic activity may initiate AF. Long ERPs occur in Bachmann’s bundle among other tissues.
&cjs0952;The reduction of atrial contractility during AF may enhance atrial dilatation, leading to persistent AF.
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mechanisms. These include hemodynamic changes (lower
atrial pressure and wall stress), prevention of structural
remodeling (ﬁbrosis, dilation, and hypertrophy) in both the
LA and left ventricle (LV), inhibition of neurohumoral acti-
vation, reduced blood pressure, prevention or amelioration
of HF, and avoidance of hypokalemia. Treatment with tran-
dolapril reduced the incidence of AF in patients with LV dys-
function following acute MI,36 but it remains to be clariﬁed
whether the antiarrhythmic effect of these agents is related
to reversal of structural or electrical remodeling in the atria
or to these other mechanisms.
5.1.5. Other factors contributing to atrial ﬁbrillation
Other factors potentially involved in the induction or main-
tenance of AF include inﬂammation, autonomic nervous
system activity, atrial ischemia,154 atrial dilation,155 anisotro-
pic conduction,156 and structural changes associated with
aging.3 It has been postulated that oxidative stress and
inﬂammation may be involved in the genesis of AF.157–159 In
a case-control study, levels of C-reactive protein (CRP), a
marker of systemic inﬂammation, were higher in patients
with atrial arrhythmias than in those without rhythm disturb-
ances,159 and those with persistent AF had higher CRP levels
than those with paroxysmal AF. In a population-based cohort
of nearly 6000 patients, AF was more prevalent among
patients in the highest quartile for CRP than those in the
lowest quartile. In patients without AF at baseline, CRP
levels were associated with the future development of AF.158
The effects of HMG CoA-reductase inhibitors (‘statins’),
which have both anti-inﬂammatory and antioxidant proper-
ties, on electrical remodeling have been evaluated in a
canine model of atrial tachycardia160 but have not been ade-
quately studied in human subjects. In the experimental
model, tachycardia-related electrical remodeling was sup-
pressed by pretreatment with simvastatin but not by the
antioxidant vitamins C and E. The mechanism responsible
for the salutary effect of simvastatin requires further inves-
tigation, and the utility of drugs in the statin class to
prevent clinical AF has not yet been established.
Increased sympathetic or parasympathetic tone has been
implicated in the initiation of AF. Autonomic ganglia con-
taining parasympathetic and sympathetic ﬁbers are
present on the epicardial surface of both the RA and LA,
clustered on the posterior wall near the ostia of the PV,
superior vena cava (SVC), and coronary sinus. In animal
models, parasympathetic stimulation shortens atrial and
PV refractory periods, potentiating initiation and mainten-
ance of AF,161,162 and vagal denervation of the atria prevents
induction of AF.163 In 297 patients with paroxysmal AF, vagal
denervation concomitant with extensive endocardial cath-
eter ablation was associated with signiﬁcant reduction in
subsequent AF in a third of cases.162 Pure autonomic
initiation of clinical AF is uncommon and seen only in situ-
ations of high sympathetic or high vagal tone, but recordings
of heart rate variability (HRV) disclose autonomic pertur-
bations in some patients that precede the onset of AF.164–169
There is a strong association between obstructive sleep
apnea, hypertension, and AF.170 It is likely that LV diastolic
dysfunction plays a role in the genesis of AF, either by
increasing pressure that affects stretch receptors in PV trig-
gers and other areas of the atria or by inducing direct struc-
tural changes in atrial myocardium.171,172 Familial factors
are discussed in Section 6.1.5.
5.2. Atrioventricular conduction
5.2.1. General aspects
In the absence of an accessory pathway or His-Purkinje
dysfunction, the AV node limits conduction during AF.144
Multiple atrial inputs to the AV node have been identiﬁed,
2 of which seem dominant: one directed posteriorly via
the crista terminalis and the other aimed anteriorly via
the interatrial septum. Other factors affecting AV conduc-
tion are the intrinsic refractoriness of the AV node, con-
cealed conduction, and autonomic tone. Concealed
conduction, which occurs when atrial impulses traverse
part of the AV node but are not conducted to the ventricles,
plays a prominent role in determining the ventricular
response during AF.173,174 These impulses alter AV nodal
refractoriness, slowing or blocking subsequent atrial
impulses, and may explain the irregularity of ventricular
response during AF.125 When the atrial rate is relatively
slow during AF, the ventricular rate tends to rise.
Conversely, a higher atrial rate is associated with slower
ventricular rate.
Increased parasympathetic and reduced sympathetic tone
exert negative dromotropic effects on AV nodal conduction,
while the opposite is true in states of decreased parasympa-
thetic and increased sympathetic tone.173,175,176 Vagal tone
also enhances the negative chronotropic effects of concealed
conduction in the AV node.175,176 Fluctuations in autonomic
tone can produce disparate ventricular responses to AF in a
given patient as exempliﬁed by a slow ventricular rate
during sleep but accelerated ventricular response during
exercise. Digitalis, which slows the ventricular rate during
AF predominantly by increasing vagal tone, is more effective
for controlling heart rate at rest in AF but less effective
during activity. Wide swings in rate due to variations in auto-
nomic tone may create a therapeutic challenge.
Conducted QRS complexes are narrow during AF unless
there is ﬁxed or rate-related bundle-branch block or acces-
sory pathway. Aberrant conduction is common and facili-
tated by the irregularity of the ventricular response. When
a long interval is followed by a relatively short interval,
the QRS complex that closes the short interval is often aber-
rantly conducted (Ashman phenomenon).177
5.2.2. Atrioventricular conduction in patients with
preexcitation syndromes
Conduction across an accessory pathway during AF can result
in a dangerously rapid ventricular rate.3,178,179 Whereas a
substantial increase in sympathetic tone may increase the
preexcited ventricular response, alterations in vagal tone
have little effect on conduction over accessory pathways.
Transition of AV reentry into AF in patients with the
Wolff-Parkinson-White (WPW) syndrome can produce a
rapid ventricular response that degenerates into ventricular
ﬁbrillation, leading to death.178,180 Intravenous adminis-
tration of drugs such as digitalis, verapamil, or diltiazem,
which lengthen refractoriness and slow conduction across
the AV node, does not block conduction over the accessory
pathway and may accelerate the ventricular rate. Hence,
these agents are contraindicated in this situation.181
Although the potential for beta blockers to potentiate con-
duction across the accessory pathway is controversial,
caution should be exercised in the use of these agents as
well as in patients with AF associated with preexcitation.
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5.3. Myocardial and hemodynamic consequences
of atrial ﬁbrillation
Among factors that affect the hemodynamic function during
AF are loss of synchronous atrial mechanical activity, irregu-
lar ventricular response, rapid heart rate, and impaired cor-
onary arterial blood ﬂow. Loss of atrial contraction may
markedly decrease cardiac output, especially when diastolic
ventricular ﬁlling is impaired by mitral stenosis, hyperten-
sion, hypertrophic cardiomyopathy (HCM), or restrictive car-
diomyopathy. Hemodynamic impairment due to variation in
R-R intervals during AF has been demonstrated in a canine
model with complete heart block, in which cardiac output
fell by approximately 9% during irregular ventricular
pacing at the same mean cycle length as a regularly paced
rhythm.182 In patients undergoing AV nodal ablation, irregu-
lar right ventricular (RV) pacing at the same rate as regular
ventricular pacing resulted in a 15% reduction in cardiac
output.183 Myocardial contractility is not constant during
AF because of force-interval relationships associated with
variations in cycle length.184 Although one might expect res-
toration of sinus rhythm to improve these hemodynamic
characteristics, this is not always the case.185,186
Myocardial blood ﬂow is determined by the presence or
absence of coronary obstructive disease, the difference
between aortic diastolic pressure and LV end-diastolic
pressure (myocardial perfusion pressure), coronary vascular
resistance, and the duration of diastole. AF may adversely
impact all of these factors. An irregular ventricular rhythm
is associated with coronary blood ﬂow compared with a
regular rhythm at the same average rate.186 Animal
studies have consistently shown that the decrease in coro-
nary ﬂow caused by experimentally induced AF relates to
an increase in coronary vascular resistance mediated by
sympathetic activation of alpha-adrenergic receptors that
is less pronounced than during regular atrial pacing at the
same ventricular rate.187 Similarly, coronary blood ﬂow is
lower during AF than during regular atrial pacing in patients
with angiographically normal coronary arteries.188 The
reduced coronary ﬂow reserve during AF may be particularly
important in patients with coronary artery disease (CAD), in
whom compensatory coronary vasodilation is limited. These
ﬁndings may explain why patients without previous angina
sometimes develop chest discomfort with the onset of AF.
In patients with persistent AF, mean LA volume increased
over time from 45 to 64 cm3 while RA volume increased from
49 to 66 cm3.189 Restoration and maintenance of sinus
rhythm decreased atrial volumes.190 Moreover, transesopha-
geal echocardiography (TEE) has demonstrated that con-
tractile function and blood ﬂow velocity in the LA
appendage (LAA) recover after cardioversion, consistent
with a reversible atrial cardiomyopathy in patients
with AF.191,192
Beyond its effects on atrial function, a persistently elev-
ated ventricular rate during AF—greater than or equal to
130 beats per minute in one study193—can produce dilated
ventricular cardiomyopathy (tachycardia-induced cardio-
myopathy).3,193–196 It is critically important to recognize
this cause of cardiomyopathy, in which HF is a consequence
rather than the cause of AF. Control of the ventricular rate
may lead to reversal of the myopathic process. In one
study, the median LV ejection fraction increased with rate
control from 25% to 52%.194 This phenomenon also has
implications for timing measurements of ventricular per-
formance in patients with AF. A reduced ejection fraction
during or in the weeks following tachycardia may not
reliably predict ventricular function once the rate has
been consistently controlled. A variety of hypotheses have
been proposed to explain tachycardia-mediated cardiomyo-
pathy: myocardial energy depletion, ischemia, abnormal
calcium regulation, and remodeling, but the actual mechan-
isms are still unclear.197
Because of the relationship between LA and LV pressure, a
rapid ventricular rate during AF may adversely impact mitral
valve function, increasing mitral regurgitation. In addition,
tachycardia may be associated with rate-related intraventri-
cular conduction delay (including left bundle-branch block),
which further compromises the synchrony of LV wall motion
and reduces cardiac output. Such conduction disturbances
may exacerbate mitral regurgitation and limit ventricular
ﬁlling. Controlling the ventricular rate may reverse these
effects.
5.4. Thromboembolism
Although ischemic stroke and systemic arterial occlusion in
AF are generally attributed to embolism of thrombus from
the LA, the pathogenesis of thromboembolism is
complex.198 Up to 25% of strokes in patients with AF may
be due to intrinsic cerebrovascular diseases, other cardiac
sources of embolism, or atheromatous pathology in the
proximal aorta.199,200 In patients 80 to 89 y old, 36% of
strokes occur in those with AF. The annual risk of stroke
for octogenarians with AF is in the range of 3% to 8% per
year, depending on associated stroke risk factors.21 About
half of all elderly AF patients have hypertension (a major
risk factor for cerebrovascular disease),47 and approxi-
mately 12% harbor carotid artery stenosis.201 Carotid ather-
osclerosis is not substantially more prevalent in AF patients
with stroke than in patients without AF and is probably a
relatively minor contributing epidemiological factor.202
5.4.1. Pathophysiology of thrombus formation
Thrombotic material associated with AF arises most fre-
quently in the LAA, which cannot be regularly examined
by precordial (transthoracic) echocardiography.203 Doppler
TEE is a more sensitive and speciﬁc method to assess LAA
function204 and to detect thrombus formation. Thrombi
are more often encountered in AF patients with ischemic
stroke than in those without stroke.205 Although clinical
management is based on the presumption that thrombus
formation requires continuation of AF for approximately
48 h, thrombi have been identiﬁed by TEE within shorter
intervals.206,207 Thrombus formation begins with Virchow’s
triad of stasis, endothelial dysfunction, and a hypercoagul-
able state. Serial TEE studies of the LA208 and LAA209
during conversion of AF to sinus rhythm demonstrated
reduced LAA ﬂow velocities related to loss of organized
mechanical contraction during AF. Stunning of the LAA210
seems responsible for an increased risk of thromboembolic
events after successful cardioversion, regardless of
whether the method is electrical, pharmacological, or spon-
taneous.210 Atrial stunning is at a maximum immediately
after cardioversion, with progressive improvement of atrial
transport function within a few days but sometimes as
long as 3 to 4 wk, depending on the duration of AF.210,211
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This corroborates the observation that following cardiover-
sion, more than 80% of thromboembolic events occur
during the ﬁrst 3 d and almost all occur within 10 d.212
Atrial stunning is more pronounced in patients with AF
associated with ischemic heart disease than in those with
hypertensive heart disease or lone AF.210 Although stunning
may be milder with certain associated conditions or a
short duration of AF, anticoagulation is recommended
during cardioversion in all patients with AF lasting longer
than 48 h or of unknown duration, including lone AF
except when anticoagulation is contraindicated.
Decreased ﬂow within the LA/LAA during AF has been
associated with spontaneous echo contrast (SEC), thrombus
formation, and embolic events.213–218 Speciﬁcally, SEC, or
‘smoke,’ a swirling haze of variable density, may be
detected by transthoracic or transesophageal echocardio-
graphic imaging of the cardiac chambers and great vessels
under low-ﬂow conditions.219 This phenomenon relates to
ﬁbrinogen-mediated erythrocyte aggregation220 and is not
resolved by anticoagulation.221 There is evidence that SEC
is a marker of stasis caused by AF.222–224 Independent predic-
tors of SEC in patients with AF include LA enlargement,
reduced LAA ﬂow velocity,213,225 LV dysfunction, ﬁbrinogen
level,218 and hematocrit.217,218 The utility of SEC for pro-
spective thromboembolic risk stratiﬁcation beyond that
achieved by clinical assessment alone has, however, not
been conﬁrmed.
LAA ﬂow velocities are lower in patients with atrial ﬂutter
than are usually seen during sinus rhythm but higher than in
AF. Whether this accounts for any lower prevalence of LAA
thrombus or thromboembolism associated with atrial
ﬂutter is uncertain. As in AF, atrial ﬂutter is associated
with low appendage emptying velocities following cardio-
version with the potential for thromboembolism226,227 and
anticoagulation is similarly recommended. (See Section
8.1.4.1.3, Therapeutic Implications.)
Although endothelial dysfunction has been difﬁcult to
demonstrate as distinctly contributing to thrombus for-
mation in AF, it may, along with stasis, contribute to a hyper-
coagulable state. Systemic and/or atrial tissue levels of
P-selectin and von Willebrand factor are elevated in some
patients,228–233 and AF has been associated with biochemical
markers of coagulation and platelet activation that reﬂect a
systemic hypercoagulable state.228,234–236 Persistent and
paroxysmal AF have been associated with increased systemic
ﬁbrinogen and ﬁbrin D-dimer levels, indicating active
intravascular thrombogenesis.228,236,237 Elevated thrombo-
globulin and platelet factor 4 levels in selected patients
with AF indicate platelet activation,235,238,239 but these
data are less robust, in line with the lower efﬁcacy of
platelet-inhibitor drugs for prevention of thromboembolism
in clinical trials. Fibrin D-dimer levels are higher in patients
with AF than in patients in sinus rhythm, irrespective of
underlying heart disease.240 The levels of some markers of
coagulation fall to normal during anticoagulation therapy,234
and some increase immediately after conversion to sinus
rhythm and then normalize.241 These biochemical markers
do not, however, distinguish a secondary reaction to intra-
vascular coagulation from a primary hypercoagulable state.
C-reactive protein (CRP) is increased in patients with AF
compared with controls159,242 and correlates with clinical
and echocardiographic stroke risk factors.243 Although
these ﬁndings do not imply a causal relationship, the
association may indicate that a thromboembolic milieu in
the LA may involve mechanisms linked to inﬂammation.243
In patients with rheumatic mitral stenosis undergoing
trans-septal catheterization for balloon valvuloplasty,
levels of ﬁbrinopeptide A, thrombin-antithrombin III
complex, and prothrombin fragment F1.2 are increased in
the LA compared with the RA and femoral vein, indicating
regional activation of the coagulation system.244,245
Whether such elevations are related to AF, for example,
through atrial pressure overload or due to another mechan-
ism has not been determined. Regional coagulopathy is
associated with SEC in the LA and hence with atrial stasis.245
Contrary to the prevalent concept that systemic anticoa-
gulation for 4 wk results in organization and endocardial
adherence of LAA thrombus, TEE studies have veriﬁed resol-
ution of thrombus in the majority of patients.246 Similar
observations have deﬁned the dynamic nature of LA/LAA
dysfunction following conversion of AF, providing a mechan-
istic rationale for anticoagulation for several weeks before
and after successful cardioversion. Conversely, increased
ﬂow within the LA in patients with mitral regurgitation has
been associated with less prevalent LA SEC247,248 and
fewer thromboembolic events, even in the presence of LA
enlargement.249
5.4.2. Clinical implications
Because the pathophysiology of thromboembolism in
patients with AF is uncertain, the mechanisms linking risk
factors to ischemic stroke in patients with AF are incomple-
tely deﬁned. The strong association between hypertension
and stroke in AF is probably mediated primarily by embolism
originating in the LAA,200 but hypertension also increases
the risk of noncardioembolic strokes in patients with
AF.200,250 Hypertension in patients with AF is associated
with reduced LAA ﬂow velocity, SEC, and thrombus for-
mation.225,251,252 Ventricular diastolic dysfunction might
underlie the effect of hypertension on LA dynamics, but
this relationship is still speculative.253,254 Whether control
of hypertension lowers the risk for cardioembolic stroke in
patients with AF is a vital question, because LV diastolic
abnormalities associated with hypertension in the elderly
are often multifactorial and difﬁcult to reverse.254,255
The increasing stroke risk in patients with AF with advan-
cing age is also multifactorial. In patients with AF, aging is
associated with LA enlargement, reduced LAA ﬂow velocity,
and SEC, all of which predispose to LA thrombus for-
mation.225,251,256 Aging is a risk factor for atherosclerosis,
and plaques in the aortic arch are associated with stroke
independent of AF.257 Levels of prothrombin activation frag-
ment F1.2, an index of thrombin generation, increase with
age in the general population258–260 as well as in those
with AF,12,261 suggesting an age-related prothrombotic dia-
thesis. In the Stroke Prevention in Atrial Fibrillation (SPAF)
studies, age was a more potent risk factor when combined
with other risk factors such as hypertension or female
gender,261,262 placing women over age 75 y with AF at par-
ticular risk for cardioembolic strokes.263
LV systolic dysfunction, as indicated by a history of HF
or echocardiographic assessment, predicts ischemic stroke
in patients with AF who receive no antithrombotic
therapy264–267 but not in moderate-risk patients given
aspirin.261,268 Mechanistic inferences are contradictory; LV
systolic dysfunction has been associated both with LA
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thrombus and with noncardioembolic strokes in patients
with AF.200,269
In summary, complex thromboembolic mechanisms are
operative in AF and involve the interplay of risk factors
related to atrial stasis, endothelial dysfunction, and sys-
temic and possibly local hypercoagulability.
6. Causes, associated conditions, clinical
manifestations, and quality of life
6.1. Causes and associated conditions
6.1.1. Reversible causes of atrial ﬁbrillation
AF may be related to acute, temporary causes, including
alcohol intake (‘holiday heart syndrome’), surgery, electro-
cution, MI, pericarditis, myocarditis, pulmonary embolism or
other pulmonary diseases, hyperthyroidism, and other meta-
bolic disorders. In such cases, successful treatment of the
underlying condition often eliminates AF. AF that develops
in the setting of acute MI portends an adverse prognosis
compared with preinfarct AF or sinus rhythm.270,271 AF
may be associated with atrial ﬂutter, the WPW syndrome,
or AV nodal reentrant tachycardias, and treatment of the
primary arrhythmias reduces or eliminates the incidence of
recurrent AF.172 AF is a common early postoperative compli-
cation of cardiac or thoracic surgery.
6.1.2. Atrial ﬁbrillation without associated heart disease
AF is often an electrical manifestation of underlying cardiac
disease. Nonetheless, approximately 30% to 45% of cases of
paroxysmal AF and 20% to 25% of cases of persistent AF occur
in younger patients without demonstrable underlying
disease (‘lone AF’).27,29 AF can present as an isolated104 or
familial arrhythmia, although a responsible underlying
disease may appear over time.272 Although AF may occur
without underlying heart disease in the elderly, the
changes in cardiac structure and function that accompany
aging, such as an increase in myocardial stiffness, may be
associated with AF, just as heart disease in older patients
may be coincidental and unrelated to AF.
6.1.3. Medical conditions associated with atrial
ﬁbrillation
Obesity is an important risk factor for development of
AF.273–275 After adjusting for clinical risk factors, the
excess risk of AF appears mediated by LA dilation, because
there is a graded increase in LA size as BMI increases from
normal to the overweight and obese categories.273 Weight
reduction has been linked to regression of LA enlarge-
ment.273,276 These ﬁndings suggest a physiological link
between obesity, AF, and stroke and raise the intriguing
possibility that weight reduction may decrease the risk
of AF.
6.1.4. Atrial ﬁbrillation with associated heart disease
Speciﬁc cardiovascular conditions associated with AF include
valvular heart disease (most often, mitral valve disease), HF,
CAD, and hypertension, particularly when LVH is present. In
addition, AF may be associated with HCM, dilated cardio-
myopathy, or congenital heart disease, especially atrial
septal defect in adults. Potential etiologies also include
restrictive cardiomyopathies (e.g., amyloidosis, hemochro-
matosis, and endomyocardial ﬁbrosis), cardiac tumors, and
constrictive pericarditis. Other heart diseases, such as
mitral valve prolapse with or without mitral regurgitation,
calciﬁcation of the mitral annulus, cor pulmonale, and idio-
pathic dilation of the RA, have been associated with a high
incidence of AF. AF is commonly encountered in patients
with sleep apnea syndrome, but whether the arrhythmia is
provoked by hypoxia, another biochemical abnormality,
changes in pulmonary dynamics or RA factors, changes in
autonomic tone, or systemic hypertension has not been
determined. Table 5 lists etiologies and factors predisposing
patients to AF. (For a list of associated heart diseases in the
ALFA study, see Table 3.)
6.1.5. Familial (genetic) atrial ﬁbrillation
Familial AF, deﬁned as lone AF running in a family, is more
common than previously recognized but should be distin-
guished from AF secondary to other genetic diseases like
familial cardiomyopathies. The likelihood of developing AF
is increased among those whose parents had AF, suggesting
a familial susceptibility to the arrhythmia, but the mechan-
isms associated with transmission are not necessarily electri-
cal, because the relationship has also been seen in patients
who have a family history of hypertension, diabetes, or HF.277
The molecular defects responsible for familial AF are
largely unknown. Speciﬁc chromosomal loci278 have been
Table 5 Etiologies and factors predisposing patients to AF
Electrophysiological abnormalities
Enhanced automaticity (focal AF)
Conduction abnormality (reentry)
Atrial pressure elevation
Mitral or tricuspid valve disease
Myocardial disease (primary or secondary, leading to
systolic or diastolic dysfunction)
Semilunar valvular abnormalities (causing ventricular
hypertrophy)
Systemic or pulmonary hypertension (pulmonary embolism)
Intracardiac tumors or thrombi
Atrial ischemia
Coronary artery disease
Inﬂammatory or inﬁltrative atrial disease
Pericarditis
Amyloidosis
Myocarditis
Age-induced atrial ﬁbrotic changes
Drugs
Alcohol
Caffeine
Endocrine disorders
Hyperthyroidism
Pheochromocytoma
Changes in autonomic tone
Increased parasympathetic activity
Increased sympathetic activity
Primary or metastatic disease in or adjacent to the atrial wall
Postoperative
Cardiac, pulmonary, or esophageal
Congenital heart disease Neurogenic
Subarachnoid hemorrhage
Nonhemorrhagic, major stroke
Idiopathic (lone AF)
Familial AF
AF indicates atrial ﬁbrillation.
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linked to AF in some families, suggesting distinct genetic
mutations.279 Two mutations associated with gain of func-
tion leading to short atrial refractoriness have been discov-
ered in several Chinese families.280,281
6.1.6. Autonomic inﬂuences in atrial ﬁbrillation
Autonomic inﬂuences play an important role in the initiation
of AF. The noninvasive measurement of autonomic tone in
humans has been augmented by measures of HRV,282 which
reﬂect changes in the relative autonomic modulation of
heart rate rather than the absolute level of sympathetic or
parasympathetic tone. It appears that the balance
between sympathetic and vagal inﬂuences is as important
as absolute sympathetic or parasympathetic tone as a pre-
dictor of AF. Fluctuations in autonomic tone as measured
by HRV occur prior to the development of AF. Vagal predomi-
nance in the minutes preceding the onset of AF has been
observed in some patients with structurally normal hearts,
while in others there is a shift toward sympathetic predomi-
nance.283,284 Although Coumel285 recognized that certain
patients could be characterized in terms of a vagal or adre-
nergic form of AF, these cases likely represent the extremes
of either inﬂuence. In general, vagally mediated AF occurs
at night or after meals, while adrenergically induced AF
typically occurs during the daytime in patients with
organic heart disease.286 Vagally mediated AF is the more
common form, and in such cases adrenergic blocking drugs
or digitalis sometimes worsens symptoms and anticholiner-
gic agents such as disopyramide are sometimes helpful to
prevent recurrent AF. Classiﬁcation of AF as of either the
vagal or adrenergic form has only limited impact on manage-
ment. For AF of the adrenergic type, beta blockers are the
initial treatment of choice.
6.2. Clinical manifestations
AF has a heterogeneous clinical presentation, occurring in
the presence or absence of detectable heart disease. An
episode of AF may be self-limited or require medical inter-
vention for termination. Over time, the pattern of AF may
be deﬁned in terms of the number of episodes, duration,
frequency, mode of onset, triggers, and response to
therapy, but these features may be impossible to discern
when AF is ﬁrst encountered in an individual patient.
AF may be immediately recognized by sensation of
palpitations or by its hemodynamic or thromboembolic
consequences or follow an asymptomatic period of
unknown duration. Ambulatory ECG recordings and device-
based monitoring have revealed that an individual may
experience periods of both symptomatic and asymptomatic
AF.287–290 Patients in whom the arrhythmia has become per-
manent often notice that palpitation decreases with time
and may become asymptomatic. This is particularly
common among the elderly. Some patients experience
symptoms only during paroxysmal AF or only intermittently
during sustained AF. When present, symptoms of AF vary
with the irregularity and rate of ventricular response,291
underlying functional status, duration of AF, and individual
patient factors.
The initial presentation of AF may be an embolic compli-
cation or exacerbation of HF, but most patients complain of
palpitations, chest pain, dyspnea, fatigue, lightheadedness,
or syncope. Polyuria may be associated with the release of
atrial natriuretic peptide, particularly as episodes of AF
begin or terminate. AF associated with a sustained, rapid
ventricular response can lead to tachycardia-mediated car-
diomyopathy, especially in patients unaware of the
arrhythmia.
Syncope is an uncommon complication of AF that can
occur upon conversion in patients with sinus node dysfunc-
tion or because of rapid ventricular rates in patients with
HCM, in patients with valvular aortic stenosis, or when an
accessory pathway is present.
6.3. Quality of life
Although stroke certainly accounts for much of the func-
tional impairment associated with AF, available data
suggest that quality of life is considerably impaired in
patients with AF compared with age-matched controls.
Sustained sinus rhythm is associated with improved quality
of life and better exercise performance than AF in some
studies but not others.292–296 In the SPAF study cohort,
Ganiats et al.297 found the New York Heart Association func-
tional classiﬁcation, originally developed for HF, an insensi-
tive index of quality of life in patients with AF. In another
study,298 47 of 69 patients (68%) with paroxysmal AF con-
sidered the arrhythmia disruptive of lifestyle, but this per-
ception was not associated with either the frequency or
duration of symptomatic episodes.
7. Clinical evaluation
7.1. Basic evaluation of the patient with atrial
ﬁbrillation
7.1.1. Clinical history and physical examination
The diagnosis of AF is based on history and clinical examin-
ation and conﬁrmed by ECG recording, sometimes in the
form of bedside telemetry or ambulatory Holter recordings.
The initial evaluation of a patient with suspected or proved
AF involves characterizing the pattern of the arrhythmia as
paroxysmal or persistent, determining its cause, and deﬁn-
ing associated cardiac and extracardiac factors pertinent
to the etiology, tolerability, and history of prior manage-
ment (Table 6). A thorough history will result in a well-
planned, focused workup that serves as an effective guide
to therapy.3 The workup of a patient with AF can usually
take place and therapy initiated in a single outpatient
encounter. Delay occurs when the rhythm has not been
speciﬁcally documented and additional monitoring is
necessary.
Typically, AF occurs in patients with underlying
heart disease, such as hypertensive heart disease.33,299
(See Section 6, Causes, Associated Conditions, Clinical
Manifestations, and Quality of Life.) Atherosclerotic or valv-
ular heart diseases are also common substrates, whereas
pulmonary pathology, preexcitation syndromes, and
thyroid disease are less frequent causes.300 Because of
reports of genetic transmission of AF, the family history is
important as well.272,301 Although various environmental
triggers can initiate episodes of AF, this aspect may not
emerge from the history given spontaneously by the
patient and often requires speciﬁc inquiry. Commonly
mentioned triggers include alcohol, sleep deprivation, and
emotional stress, but vagally mediated AF may occur
during sleep or after a large meal and is more likely to
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arise during a period of rest succeeded by a period of stress.
Stimulants such as caffeine or exercise may also precipitate
AF.
The physical examination may suggest AF on the basis of
irregular pulse, irregular jugular venous pulsations, and
variation in the intensity of the ﬁrst heart sound or
absence of a fourth sound heard previously during sinus
rhythm. Examination may also disclose associated valvular
heart disease, myocardial abnormalities, or HF. The ﬁndings
are similar in patients with atrial ﬂutter, except that the
rhythm may be regular and rapid venous oscillations may
occasionally be visible in the jugular pulse.
7.1.2. Investigations
The diagnosis of AF requires ECG documentation by at least
a single-lead recording during the arrhythmia, which may be
facilitated by review of emergency department records,
Holter monitoring, or transtelephonic or telemetric record-
ings. A portable ECG recording tool may help establish the
diagnosis in cases of paroxysmal AF and provide a permanent
ECG record of the arrhythmia. In patients with implanted
pacemakers or deﬁbrillators, the diagnostic and memory
functions may allow accurate and automatic detection of
AF.302 A chest radiograph may detect enlargement of the
cardiac chambers and HF but is valuable mostly to detect
Table 6 Clinical evaluation in patients with AF
Minimum evaluation
1. History and physical examination, to deﬁne
Presence and nature of symptoms associated with AF
Clinical type of AF (ﬁrst episode, paroxysmal, persistent, or permanent)
Onset of the ﬁrst symptomatic attack or date of discovery of AF
Frequency, duration, precipitating factors, and modes of termination of AF
Response to any pharmacological agents that have been administered
Presence of any underlying heart disease or other reversible conditions (e.g., hyperthyroidism or alcohol consumption)
2. Electrocardiogram, to identify
Rhythm (verify AF)
LV hypertrophy
P-wave duration and morphology or ﬁbrillatory waves
Preexcitation
Bundle-branch block
Prior MI
Other atrial arrhythmias
To measure and follow the R-R, QRS, and QT intervals in conjunction with antiarrhythmic drug therapy
3. Transthoracic echocardiogram, to identify
Valvular heart disease
LA and RA size
LV size and function
Peak RV pressure (pulmonary hypertension)
LV hypertrophy
LA thrombus (low sensitivity)
Pericardial disease
4. Blood tests of thyroid, renal, and hepatic function
For a ﬁrst episode of AF, when the ventricular rate is difﬁcult to control
Additional testing
One or several tests may be necessary.
1. Six-minute walk test
If the adequacy of rate control is in question
2. Exercise testing
If the adequacy of rate control is in question (permanent AF)
To reproduce exercise-induced AF
To exclude ischemia before treatment of selected patients with a type IC antiarrhythmic drug
3. Holter monitoring or event recording
If diagnosis of the type of arrhythmia is in question
As a means of evaluating rate control
4. Transesophageal echocardiography
To identify LA thrombus (in the LA appendage)
To guide cardioversion
5. Electrophysiological study
To clarify the mechanism of wide-QRS-complex tachycardia
To identify a predisposing arrhythmia such as atrial ﬂutter or paroxysmal supraventricular tachycardia
To seek sites for curative ablation or AV conduction block/modiﬁcation
6. Chest radiograph, to evaluate
Lung parenchyma, when clinical ﬁndings suggest an abnormality
Pulmonary vasculature, when clinical ﬁndings suggest an abnormality
Type IC refers to the Vaughan Williams classiﬁcation of antiarrhythmic drugs (see Table 19).
AF indicates atrial ﬁbrillation; AV, atrioventricular; LA, left atrial; LV, left ventricular; MI, myocardial infarction; RA, right atrial; RV, right ventricular.
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intrinsic pulmonary pathology and evaluate the pulmonary
vasculature. It is less important than echocardiography for
routine evaluation of patients with AF. As part of the
initial evaluation, all patients with AF should have 2-
dimensional, Doppler echocardiography to assess LA and LV
dimensions and LV wall thickness and function and to
exclude occult valvular or pericardial disease and HCM. LV
systolic and diastolic performance helps guide decisions
regarding antiarrhythmic and antithrombotic therapy.
Thrombus should be sought in the LA but is seldom detected
without TEE.203,303,304
Blood tests are routine but can be abbreviated. It is
important that thyroid, renal, and hepatic function, serum
electrolytes, and the hemogram be measured at least once
in the course of evaluating a patient with AF.305
7.2. Additional investigation of selected patients
with atrial ﬁbrillation
Abnormalities in P-wave duration detected by signal-
averaged ECG during sinus rhythm that reﬂect slow
intra-atrial conduction are associated with an increased
risk of developing AF.133,306–308 The sensitivity and negative
predictive value of signal-averaged P-wave ECG are high,
but speciﬁcity and positive predictive value are low, limiting
the usefulness of this technique.309 Measurement of HRV has
failed to provide useful information for risk stratiﬁcation.309
Both B-type natriuretic peptide (assessed by measuring
BNP or N-terminal pro-BNP), which is produced mainly in
the ventricles, and atrial naturetic peptide (ANP), which is
produced primarily in the atria, are associated with AF.
Plasma levels of both peptides are elevated in patients
with paroxysmal and persistent AF and decrease rapidly
after restoration of sinus rhythm.310–313 Thus, the presence
of AF should be considered when interpreting plasma levels
of these peptides. In the absence of HF, there is an inverse
correlation between LA volume and ANP/BNP levels;251
spontaneous conversion to sinus rhythm is associated with
higher ANP levels during AF and with smaller LA
volumes.311 In long-standing persistent AF, lower plasma
ANP levels may be related to degeneration of atrial myo-
cytes.314 High levels of BNP may be predictive of throm-
boembolism315 and recurrent AF,40,316 but further studies
are needed to evaluate the utility of BNP as a prognostic
marker.
7.2.1. Electrocardiogram monitoring and exercise testing
Prolonged or frequent monitoring may be necessary to
reveal episodes of asymptomatic AF, which may be a cause
of cryptogenic stroke. Ambulatory ECG (e.g., Holter) moni-
toring is also useful to judge the adequacy of rate control.
This technology may provide valuable information to guide
drug dosage for rate control or rhythm management.317
Exercise testing should be performed if myocardial ische-
mia is suspected and prior to initiating type IC anti-
arrhythmic drug therapy. Another reason for exercise
testing is to study the adequacy of rate control across a
full spectrum of activity, not only at rest, in patients with
persistent or permanent AF.
7.2.2. Transesophageal echocardiography
TEE is not part of the standard initial investigation of
patients with AF. By placing a high-frequency ultrasound
transducer close to the heart, however, TEE provides high-
quality images of cardiac structure318 and function.319 It is
the most sensitive and speciﬁc technique to detect sources
and potential mechanisms for cardiogenic embolism.320
The technology has been used to stratify stroke risk in
patients with AF and to guide cardioversion. (See Section
8.1.4, Preventing Thromboembolism.) Several TEE features
have been associated with thromboembolism in patients
with nonvalvular AF, including LA/LAA thrombus, LA/LAA
SEC, reduced LAA ﬂow velocity, and aortic atheromatous
abnormalities.252 Although these features are associated
with cardiogenic embolism,268,321 prospective investigations
are needed to compare these TEE ﬁndings with clinical and
transthoracic echocardiographic predictors of thromboem-
bolism. Detection of LA/LAA thrombus in the setting of
stroke or systemic embolism is convincing evidence of a car-
diogenic mechanism.207
TEE of patients with AF before cardioversion has shown LA
or LAA thrombus in 5% to 15%,304,321–323 but thromboembo-
lism after conversion to sinus rhythm has been reported
even when TEE did not show thrombus.324 These events typi-
cally occur relatively soon after cardioversion in patients
who were not treated with anticoagulation, reinforcing
the need to maintain continuous therapeutic anticoagula-
tion in patients with AF undergoing cardioversion even
when no thrombus is identiﬁed. For patients with AF of
greater than 48-h duration, a TEE-guided strategy or the tra-
ditional strategy of anticoagulation for 4 wk before and 4 wk
after elective cardioversion resulted in similar rates of
thromboembolism (less than 1% during the 8 wk).325
Contrast-enhanced magnetic resonance imaging is an emer-
ging technique for detection of intracardiac thrombi that
appears more sensitive than precordial echocardiography
and comparable to TEE.326
7.2.3. Electrophysiological study
An EP study can be helpful when AF is a consequence of
reentrant tachycardia such as atrial ﬂutter, intra-atrial
reentry, or AV reentry involving an accessory pathway.
Detection of a delta wave on the surface ECG in a patient
with a history of AF or syncope is a ﬁrm indication for EP
study and ablation of the bypass tract. Some patients with
documented atrial ﬂutter also have AF, and ablation of
ﬂutter can eliminate AF, although this is not common and
successful ablation of ﬂutter does not eliminate the possi-
bility of developing AF in the future.327 AF associated with
rapid ventricular rates and wide-complex QRS morphology
may sometimes be mislabeled as ventricular tachycardia,
and an EP study will differentiate the 2 arrhythmias. In
short, EP testing is indicated when ablative therapy of
arrhythmias that trigger AF or ablation of AF is planned.
In patients with AF who are candidates for ablation, an EP
study is critical to deﬁne the targeted site or sites of abla-
tion in the LA and/or right-sided structures. Evolving strat-
egies in the ablation of AF are discussed in Section 8.0.
8. Management
Management of patients with AF involves 3 objectives—rate
control, prevention of thromboembolism, and correction of
the rhythm disturbance, and these are not mutually
exclusive. The initial management decision involves primar-
ily a rate-control or rhythm-control strategy. Under the
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rate-control strategy, the ventricular rate is controlled with
no commitment to restore or maintain sinus rhythm. The
rhythm-control strategy attempts restoration and/or main-
tenance of sinus rhythm. The latter strategy also requires
attention to rate control. Depending on the patient’s
course, the strategy initially chosen may prove unsuccessful
and the alternate strategy is then adopted. Regardless of
whether the rate-control or rhythm-control strategy is
pursued, attention must also be directed to antithrombotic
therapy for prevention of thromboembolism.
At the initial encounter, an overall management strategy
should be discussed with the patient, considering several
factors: (1) type and duration of AF, (2) severity and type
of symptoms, (3) associated cardiovascular disease, (4)
patient age, (5) associated medical conditions, (6) short-
term and long-term treatment goals, and (7) pharmacologi-
cal and nonpharmacological therapeutic options. A patient
with a ﬁrst-documented episode of AF in whom rate
control is achieved does not require hospitalization.
Duration and pattern of atrial ﬁbrillation. As deﬁned in
Section 3, AF may be categorized as paroxysmal (self-
terminating), persistent (requiring electrical or pharmaco-
logical termination), or permanent (cardioversion imposs-
ible or futile). The duration since onset may be known or
unknown in an individual patient depending upon the pre-
sence or absence of speciﬁc symptoms or ECG documen-
tation of the arrhythmia.
Type and severity of symptoms. As described in Section
6.2, few arrhythmias present with such protean manifes-
tations, some of which are subtle. Some patients with AF
become accommodated to a poor state of health and may
feel markedly better once sinus rhythm is restored. In con-
trast, other patients have no or minimal symptoms during
AF and restoration of sinus rhythm would not change their
functional status. Before deciding on whether a patient is
truly asymptomatic, it may be helpful to ask whether the
patient has noticed a decline in activity over time,
especially when there is no other obvious explanation.
Associated cardiovascular Disease. The likelihood that
symptoms may progress is typically related to the presence
of cardiovascular disease. The presence of ventricular hyper-
trophy could, for example, lead to symptoms as diastolic
compliance worsens. Such a patient may not feel different
in sinus rhythmwhen initially evaluated but may face difﬁcul-
ties in the future if left in AF until it becomes difﬁcult to
restore sinus rhythm because of atrial remodeling.
Potential for Changes in Cardiac Function Related to Age.
Before choosing rate control as a long-term strategy, the
clinician should consider how permanent AF is likely to
affect the patient in the future. In a patient with asympto-
matic persistent AF, attempts to restore sinus rhythm may
not be needed. Prospective studies like Rate Control vs.
Electrical cardioversion for persistent atrial ﬁbrillation
(RACE) and Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) showed that patients who
could tolerate rate-controlled AF had outcomes similar to
those randomized to rhythm control. However, these studies
enrolled predominantly older patients (average 70 y), most
of whom had persistent AF and heart disease, and follow-up
extended over just a few years. Thus, the trial data do not
necessarily apply to younger patients without heart disease
or to patients whose dependency upon sinus rhythm is likely
to change appreciably over time. Among the latter may be
patients in HF, who are prone to deteriorate over time if left
in AF. The problem with allowing AF to persist for years is
that it may then be impossible to restore sinus rhythm as a
consequence of electrical and structural remodeling, which
preclude successful restoration or maintenance of sinus
rhythm and favor permanent AF. This makes it important to
ensure that a window of opportunity to maintain sinus
rhythm is not overlooked early in the course of management
of a patient with AF.
8.1. Pharmacological and nonpharmacological
therapeutic options
Drugs and ablation are effective for both rate and rhythm
control, and in special circumstances surgery may be the
preferred option. Regardless of the approach, the need for
anticoagulation is based on stroke risk and not on whether
sinus rhythm is maintained. For rhythm control, drugs are
typically the ﬁrst choice and LA ablation is a second-line
choice, especially in patients with symptomatic lone AF. In
some patients, especially young ones with very symptomatic
AF who need sinus rhythm, radiofrequency ablation may be
preferred over years of drug therapy. Patients with pre-
operative AF undergoing cardiac surgery face a unique
opportunity. While few patients are candidates for a
stand-alone surgical procedure to cure AF using the maze
or LA ablation techniques, these approaches can be an
effective adjunct to coronary bypass or valve repair
surgery to prevent recurrent postoperative AF. Applied in
this way, AF may be eliminated without signiﬁcant
additional risk. Because the LAA is the site of over 95% of
detected thrombi, this structure should be removed from
the circulation when possible during cardiac surgery in
patients at risk of developing postoperative AF, although
this has not been proved to prevent stroke.328
Drugs are the primary treatment for rate control in most
patients with AF. While ablation of the AV conduction
system and permanent pacing (the ‘ablate and pace’ strat-
egy) is an option that often yields remarkable symptomatic
relief, growing concern about the negative effect of long-
term RV pacing makes this a fallback rather than a primary
treatment strategy. LV pacing, on the other hand, may over-
come many of the adverse hemodynamic effects associated
with RV pacing.
8.1.1. Pharmacological therapy
8.1.1.1. Drugs modulating the renin-angiotensin-
aldosterone system. Experimental and clinical studies have
demonstrated that ACE inhibitors and angiotensin receptor
antagonists may decrease the incidence of AF36 (see
Section 8.5, Primary Prevention). ACE inhibitors decrease
atrial pressure, reduce the frequency of atrial premature
beats,329 reduce ﬁbrosis,86 and may lower the relapse rate
after cardioversion39,330,331 in patients with AF. These drugs
can reduce signal-averaged P-wave duration, the number of
deﬁbrillation attempts required to restore sinus rhythm,
and the number of hospital readmissions for AF.332
Withdrawal of ACE-inhibitor medication is associated with
postoperative AF in patients undergoing coronary bypass
surgery,333 and concurrent therapy with ACE-inhibitor and
antiarrhythmic agents enhances maintenance of sinus
rhythm.334
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In patients with persistent AF and normal LV function, the
combination of enalapril or irbesartan plus amiodarone
resulted in lower rates of recurrent AF after electrical con-
version than amiodarone alone.39,331 The role of treatment
with inhibitors of the RAAS in long-term maintenance of
sinus rhythm in patients at risk of developing recurrent AF
requires clariﬁcation in randomized trials before this
approach can be routinely recommended.
8.1.1.2. HMG CoA-reductase inhibitors (statins). Available
evidence supports the efﬁcacy of statin-type cholesterol-
lowering agents in maintaining sinus rhythm in patients
with persistent lone AF. Statins decrease the risk of
recurrences after successful direct-current cardioversion
without affecting the deﬁbrillation threshold.335 The
mechanisms by which these drugs prevent AF recurrence
are poorly understood but include an inhibitory effect on
the progression of CAD, pleiotropic (anti-inﬂammatory and
antioxidant) effects,336,337 and direct antiarrhythmic
effects involving alterations in transmembrane ion
channels.338
8.1.2. Heart rate control versus rhythm control
8.1.2.1. Distinguishing short-term and long-term treatment
goals. The initial and subsequent management of sympto-
matic AF may differ from one patient to another. For
patients with symptomatic AF lasting many weeks, initial
therapy may be anticoagulation and rate control, while
the long-term goal is to restore sinus rhythm. When cardio-
version is contemplated and the duration of AF is unknown
or exceeds 48 h, patients who do not require long-term
anticoagulation may beneﬁt from short-term anticoagula-
tion. If rate control offers inadequate symptomatic relief,
restoration of sinus rhythm becomes a clear long-term
goal. Early cardioversion may be necessary if AF causes
hypotension or worsening HF, making the establishment of
sinus rhythm a combined short- and long-term therapeutic
goal. In contrast, amelioration of symptoms by rate
control in older patients may steer the clinician away from
attempts to restore sinus rhythm. In some circumstances,
when the initiating pathophysiology of AF is reversible, as
for instance in the setting of thyrotoxicosis or after
cardiac surgery, no long-term therapy may be necessary.
8.1.2.2. Clinical trials comparing rate control and rhythm
control. Randomized trials comparing outcomes of rhythm-
versus rate-control strategies in patients with AF are
summarized in Tables 7 and 8. Among these, AFFIRM
(Atrial Fibrillation Follow-up Investigation of Rhythm
Management) found no difference in mortality or stroke
rate between patients assigned to one strategy or the
other. The RACE (Rate Control vs. Electrical cardioversion
for persistent atrial ﬁbrillation) trial found rate control not
inferior to rhythm control for prevention of death and
morbidity. Clinically silent recurrences of AF in
asymptomatic patients treated with antiarrhythmic drugs
may be responsible for thromboembolic events after
withdrawal of anticoagulation. Hence, patients at high risk
for stroke may require anticoagulation regardless of
whether the rate-control or rhythm-control strategy is
chosen, but the AFFIRM trial was not designed to address
this question. While secondary analyses support this
notion,339 the stroke rate in patients assigned to rhythm
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Table 8 General characteristics of rhythm control and rate control trials in patients with AF
Trial Reference Patients
(n)
Mean
Age (y)
Mean length of
follow-up (y)
Inclusion criteria Primary endpoint Patients reaching primary endpoint (n) P
Rate control Rhythm control
PIAF (2000) 294 252 61.0 1.0 Persistent AF (7 to 360 d) Symptomatic improvement 76/125 (60.8%) 70/127 (55.1%) 0.317
RACE (2002) 293 522 68.0 2.3 Persistent AF or ﬂutter for
less than 1 y and 1 to 2
cardioversions over 2 y
and oral anticoagulation
Composite: cardiovascular
death, CHF, severe
bleeding, PM implantation,
thromboembolic events,
severe adverse effects of
antiarrhythmic drugs
44/256 (17.2%) 60/266 (22.6%) 0.11
STAF (2002) 343 200 66.0 1.6 Persistent AF (longer than
4 wk and less than 2 y),
left atrial size greater
than 45 mm, CHF NYHA
II-IV, LVEF less than 45%
Composite: overall
mortality, cerebrovascular
complications, CPR,
embolic events
10/100 (10.0%) 9/100 (9.0%) 0.99
AFFIRM (2002) 296 4060 69.7 3.5 Paroxysmal AF or persistent
AF, age 65 y or older, or
risk of stroke or death
All-cause mortality 310/2027 (25.9%) 356/2033 (26.7%) 0.08
HOT
CAFE´ (2004)
344 205 60.8 1.7 First clinically overt
episode of persistent AF
(7 d or more and less
than 2 y), 50 to 75 y old
Composite: death,
thromboembolic
complications;
intracranial or other major
hemorrhage
1/101 (1.0%) 4/104 (3.9%) Greater
than 0.71
Reprinted with permission from Pelargonio G, Prystowsky EN. Rate versus rhythm control in the management of patients with atrial ﬁbrillation. Nat Clin Pract Cardiovasc Med 2005;2:514–21.346
AF indicates atrial ﬁbrillation; AFFIRM, Atrial Fibrillation Follow-up Investigation of Rhythm Management, CHF, congestive heart failure; CPR, cardiopulmonary resuscitation; HOT CAFE´, How to Treat Chronic Atrial
Fibrillation; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PIAF, Pharmacological Intervention in Atrial Fibrillation; PM, pacemaker; RACE, Rate Control Versus Electrical Cardioversion
for Persistent Atrial Fibrillation, STAF, Strategies of Treatment of Atrial Fibrillation.
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control who stopped warfarin is uncertain, and additional
research is needed to address this important question.
Depending upon symptoms, rate control may be reason-
able initial therapy in older patients with persistent AF
who have hypertension or heart disease. For younger indi-
viduals, especially those with paroxysmal lone AF, rhythm
control may be a better initial approach. Often medications
that exert both antiarrhythmic and rate-controlling effects
are required. Catheter ablation should be considered to
maintain sinus rhythm in selected patients who failed to
respond to antiarrhythmic drug therapy.340
8.1.2.3. Effect on symptoms and quality of life. Information
about the effects of antiarrhythmic and chronotropic
therapies on quality of life is inconsistent.292,294,295 The
AFFIRM,293,296 RACE,293,295 PIAF (Pharmacologic
Intervention in Atrial Fibrillation),342 and STAF (Strategies
of Treatment of Atrial Fibrillation)343 studies found no
differences in quality of life with rhythm control compared
with rate control. Rhythm control in the PIAF and How to
Treat Chronic Atrial Fibrillation (HOT CAFE´)344 studies resul-
ted in better exercise tolerance than rate control, but this
did not translate into improved quality of life. In the
Canadian Trial of Atrial Fibrillation (CTAF) study,347 there
was no difference between amiodarone and sotalol or propa-
fenone as assessed by responses to the Short Form-36 ques-
tionnaire, while a symptom severity scale showed beneﬁt of
amiodarone over the other drugs. In the Sotalol Amiodarone
Atrial Fibrillation Efﬁcacy Trial (SAFE-T),292 restoration and
maintenance of sinus rhythm in patients with AF signiﬁcantly
improved quality of life in certain domains, but amiodarone
was associated with a decrease in mental health function
compared with sotalol or placebo.292 Symptomatic improve-
ment has also been reported after the maze procedure in
patients with AF.348
In a substudy of AFFIRM, there was no signiﬁcant associ-
ation between achieved HR and quality-of-life measure-
ments, New York Heart Association functional class, or
6-min walking distance in patients with AF compared with
less well-controlled patients.345 On the whole, rate- and
rhythm-control strategies do not affect quality of life signiﬁ-
cantly or differently. Even when sinus rhythm can be main-
tained, symptoms of associated cardiovascular conditions
may obscure changes in quality of life related to AF.
Clinicians must exercise judgment, however, in translating
shifts in quality of life in these study populations to the
sense of well-being experienced by individual patients.
Patients with similar health status may experience entirely
different qualitiy of life, and treatment must be tailored
to each individual, depending on the nature, intensity, and
frequency of symptoms, patient preferences, comorbid con-
ditions, and the ongoing response to treatment.
Long-term oral anticoagulant therapy with vitamin K
antagonists involves multiple drug interactions and frequent
blood testing, which inﬂuences quality of life in patients
with AF. Gage et al.349 quantiﬁed this as a mean 1.3%
decrease in utility, a measure of quality of life in quantitat-
ive decision analysis. Some patients (16%) thought that their
quality of life would be greater with aspirin than with oral
anticoagulants, despite its lesser efﬁcacy. Other investi-
gators, using decision analysis to assess patient preferences,
found that 61% of 97 patients preferred anticoagulation to
no treatment, a smaller proportion than that for which
published guidelines recommend treatment.350 In the
future, these comparisons could be inﬂuenced by the devel-
opment of more convenient approaches to antithrombotic
therapy.
8.1.2.4. Effects on heart failure. HF may develop or
deteriorate during either type of treatment for AF due to
progression of underlying cardiac disease, inadequate
control of the ventricular rate at the time of recurrent AF,
or antiarrhythmic drug toxicity. Patients managed with
rate compared with rhythm control did not, however,
differ signiﬁcantly in development or deterioration of HF.
In the AFFIRM study, 2.1% of those in the rate-control
group and 2.7% in the rhythm-control group developed AF
after an average follow-up of 3.5 y. In the RACE study, the
incidence of hospitalization for HF was 3.5% during a
management strategy directed at rate control and 4.5%
with rhythm control, during an average follow-up of 2.3
y. Similarly, there were no differences in the STAF or HOT
CAFE studies. The Atrial Fibrillation and Congestive Heart
Failure (AF-CHF) study53 is currently investigating this
issue in a large number of patients.
8.1.2.5. Effects on thromboembolic complications. The
majority of patients in the AFFIRM and RACE trials had 1 or
more stroke risk factors in addition to AF, and the rhythm-
control strategy did not lower the stroke rate more
effectively than rate control and anticoagulation296,339,351
(see Table 7). One methodological concern is that the
success of rhythm control at maintaining sinus rhythm was
assessed by intermittent ECG recordings, whereas longer-
term monitoring might have identiﬁed patients at lower
thromboembolic risk. Most strokes were diagnosed after
discontinuation of anticoagulation or at subtherapeutic
intensity (International Normalized Ratio [INR] below 2.0).
In addition, while recurrent AF was detected in only about
one-third of those in the rhythm-control groups who
developed stroke, at the time of ischemic stroke, patients
in the rate-control groups typically had AF. Long-term
oral anticoagulation therefore seems appropriate for
most patients with AF who have risk factors for
thromboembolism, regardless of treatment strategy and of
whether AF is documented at any given time.
8.1.2.6. Effects on mortality and hospitalization. In the
AFFIRM study, a trend toward increased overall mortality
was observed in patients treated for rhythm control
compared with rate control after an average of 3.5 y (26.7%
vs. 25.9%, p ¼ 0.08).296 The rhythm-control strategy was
associated with excess mortality among older patients,
those with HF, and those with CAD, but the tendency
persisted after adjustment for these covariates. A substudy
suggested that deleterious effects of antiarrhythmic drugs
(mortality increase of 49%) may have offset the beneﬁts of
sinus rhythm (which was associated with a 53% reduction in
mortality).352 Hospitalization was more frequent in the
rhythm-control arms in all trials, mainly due to admissions
for cardioversion. A substudy of RACE compared
anticoagulated patients in the rhythm-control group who
sustained sinus rhythm with patients in the rate-control
group who had permanent AF and found no beneﬁt of
rhythm control even in this selected subgroup.353 The
implication that adverse drug effects in patients with
underlying heart disease might exert an adverse effect on
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morbidity and mortality that is not overcome by maintaining
sinus rhythm must be interpreted cautiously because the
comparisons of patient subgroups in these secondary
analyses are not based on randomization (Table 9).
8.1.2.7. Implications of the rhythm-control versus rate-
control studies. Theoretically, rhythm control should have
advantages over rate control, yet a trend toward lower
mortality was observed in the rate-control arm of the
AFFIRM study and did not differ in the other trials from
the outcome with the rhythm-control strategy. This might
suggest that attempts to restore sinus rhythm with
presently available antiarrhythmic drugs are obsolete. The
RACE and AFFIRM trials did not address AF in younger,
symptomatic patients with little underlying heart disease,
in whom restoration of sinus rhythm by cardioversion
antiarrhythmic drugs or nonpharmacological interventions
still must be considered a useful therapeutic approach.
One may conclude from these studies that rate control is a
reasonable strategy in elderly patients with minimal
symptoms related to AF. An effective method for
maintaining sinus rhythm with fewer side effects would
address a presently unmet need.
8.1.3. Rate control during atrial ﬁbrillation
Criteria for rate control. In patients with AF, the ventricular
rate may accelerate excessively during exercise even when
it is well controlled at rest. In addition to allowing adequate
time for ventricular ﬁlling and avoiding rate-related ische-
mia, enhancement of intraventricular conduction with rate
reduction may result in improved hemodynamics. It may
be useful to evaluate the heart rate response to submaximal
or maximal exercise or to monitor the rate over an extended
period (e.g., by 24-h Holter recording). In addition, rate
variability during AF provides information about the status
of the autonomic nervous system that may have indepen-
dent prognostic implications.356–359
The deﬁnition of adequate rate control has been based
primarily on short-term hemodynamic beneﬁts and has not
been well studied with respect to regularity or irregularity
of the ventricular response to AF, quality of life, or symp-
toms or development of cardiomyopathy. No standard
method for assessment of heart rate control has been estab-
lished to guide management of patients with AF. Criteria for
rate control vary with patient age but usually involve
achieving ventricular rates between 60 and 80 beats per
minute at rest and between 90 and 115 beats per minute
during moderate exercise. For the AFFIRM trial, adequate
control was deﬁned as an average heart rate up to 80
beats per minute at rest and either an average rate up to
100 beats per minute over at least 18-h ambulatory Holter
monitoring with no rate above 100% of the maximum age-
adjusted predicted exercise heart rate or a maximum
heart rate of 110 beats per minute during a 6-min walk
test.360 In the RACE trial, rate control was deﬁned as less
than 100 beats per minute at rest. Only about 5% of patients
from these large clinical trials required AV ablation to
achieve heart rate control within these limits.
Hemodynamic and clinical consequences of rapid rate.
Patients who are symptomatic with rapid ventricular rates
during AF require prompt medical management, and cardio-
version should be considered if symptomatic hypotension,
angina, or HF is present. A sustained, uncontrolled tachycar-
dia may lead to deterioration of ventricular function (tachy-
cardia-related cardiomyopathy)361 and that improves with
adequate rate control. In the Ablate and Pace Trial (APT),
25% of patients with AF who had an ejection fraction
below 45% displayed a greater than 15% increase in ejection
fraction after ablation.363 Tachycardia-induced cardiomyo-
pathy tends to resolve within 6 mo of rate or rhythm
control; when tachycardia recurs, LV ejection fraction
declines and HF develops over a shorter period, and this is
associated with a relatively poor prognosis.364
8.1.3.1. Pharmacological rate control during atrial
ﬁbrillation.
Recommendations
Class I
(1) Measurement of the heart rate at rest and control of the
rate using pharmacological agents (either a beta blocker
or nondihydropyridine calcium channel antagonist, in
most cases) are recommended for patients with persist-
ent or permanent AF. (Level of Evidence: B)
(2) In the absence of preexcitation, intravenous adminis-
tration of beta blockers (esmolol, metoprolol, or
propranolol) or nondihydropyridine calcium channel
antagonists (verapamil, diltiazem) is recommended to
slow the ventricular response to AF in the acute
setting, exercising caution in patients with hypotension
or HF. (Level of Evidence: B)
Table 9 Comparison of adverse outcomes in rhythm control and rate control trials in patients with AF
Trial Reference Deaths of all causes
(n rate/rhythm)
Deaths from
cardiovascular
causes
Deaths from
noncardiovascular
causes
Stroke Thromboembolic
events
Bleeding
RACE (2002) 293 36 18/18 ND ND 14/21 12/9
PIAF (2000) 294 4 1/1 1a ND ND ND
STAF (2003) 343 12 (8/4) 8/3 0/1 1/5 ND 8/11
AFFIRM (2002) 296 666 (310/356) 167/164 113/165 77/80 ND 107/96
HOT CAFE´ (2004) 344 4 (1/3) 0/2 1/1 0/3 ND 5/8
Reprinted with permission from Pelargonio G, Prystowsky EN. Rate versus rhythm control in the management of patients with atrial ﬁbrillation. Nat Clin
Pract Cardiovasc Med 2005;2:514–21.346
AF indicates atrial ﬁbrillation; AFFIRM, Atrial Fibrillation Follow-up Investigation of Rhythm Management; HOT CAFE´, How to Treat Chronic Atrial
Fibrillation; ND, not determined; PIAF, Pharmacological Intervention in Atrial Fibrillation; RACE, Rate Control Versus Electrical Cardioversion for
Persistent Atrial Fibrillation; STAF, Strategies of Treatment of Atrial Fibrillation.
aTotal number of patients not reported.
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(3) Intravenous administration of digoxin or amiodarone is
recommended to control the heart rate in patients
with AF and HF who do not have an accessory
pathway. (Level of Evidence: B)
(4) In patients who experience symptoms related to AF
during activity, the adequacy of heart rate control
should be assessed during exercise, adjusting pharmaco-
logical treatment as necessary to keep the rate in the
physiological range. (Level of Evidence: C)
(5) Digoxin is effective following oral administration to
control the heart rate at rest in patients with AF and
is indicated for patients with HF, LV dysfunction, or for
sedentary individuals. (Level of Evidence: C)
Class IIa
(1) A combination of digoxin and either a beta blocker or
nondihydropyridine calcium channel antagonist is
reasonable to control the heart rate both at rest and
during exercise in patients with AF. The choice of medi-
cation should be individualized and the dose modulated
to avoid bradycardia. (Level of Evidence: B)
(2) It is reasonable to use ablation of the AV node or acces-
sory pathway to control heart rate when pharmacologi-
cal therapy is insufﬁcient or associated with side
effects. (Level of Evidence: B)
(3)Intravenous amiodarone can be useful to control the heart
rate in patients with AF when other measures are unsuc-
cessful or contraindicated. (Level of Evidence: C)
(4) When electrical cardioversion is not necessary in
patients with AF and an accessory pathway, intravenous
procainamide or ibutilide is a reasonable alternative.
(Level of Evidence: C)
Class IIb
(1) When the ventricular rate cannot be adequately con-
trolled both at rest and during exercise in patients
with AF using a beta blocker, nondihydropyridine
calcium channel antagonist, or digoxin, alone or in com-
bination, oral amiodarone may be administered to
control the heart rate. (Level of Evidence: C)
(2) Intravenous procainamide, disopyramide, ibutilide, or
amiodarone may be considered for hemodynamically
stable patients with AF involving conduction over an
accessory pathway. (Level of Evidence: B)
(3) When the rate cannot be controlled with pharmacologi-
cal agents or tachycardia-mediated cardiomyopathy is
suspected, catheter-directed ablation of the AV node
may be considered in patients with AF to control the
heart rate. (Level of Evidence: C)
Class III
(1) Digitalis should not be used as the sole agent to control
the rate of ventricular response in patients with
paroxysmal AF. (Level of Evidence: B)
(2) Catheter ablation of the AV node should not be
attempted without a prior trial of medication to
control the ventricular rate in patients with AF. (Level
of Evidence: C)
(3) In patients with decompensated HF and AF, intravenous
administration of a nondihydropyridine calcium channel
antagonist may exacerbate hemodynamic compromise
and is not recommended. (Level of Evidence: C)
(4) Intravenous administration of digitalis glycosides or non-
dihydropyridine calcium channel antagonists to patients
with AF and a preexcitation syndrome may paradoxically
accelerate the ventricular response and is not rec-
ommended. (Level of Evidence: C)
The main determinants of ventricular rate during AF are the
intrinsic conduction characteristics and refractoriness of the
AV node and sympathetic and parasympathetic tone. The
functional refractory period of the AV node correlates inver-
sely with ventricular rate during AF, and drugs that prolong
the refractory period are generally effective for rate
control. The efﬁcacy of pharmacological interventions
designed to achieve rate control in patients with AF has
been about 80% in clinical trials.365 There is no evidence
that pharmacological rate control has any adverse inﬂuence
on LV function, but bradycardia and heart block may occur
as an unwanted effect of beta blockers, amiodarone, digi-
talis glycosides, or nondihydropyridine calcium channel
antagonists, particularly in patients with paroxysmal AF,
especially the elderly. When rapid control of the ventricular
response to AF is required or oral administration of medi-
cation is not feasible, medication may be administered
intravenously. Otherwise, in hemodynamically stable
patients with a rapid ventricular response to AF, negative
chronotropic medication may be administered orally
(Table 10). Combinations may be necessary to achieve rate
control in both acute and chronic situations, but proper
therapy requires careful dose titration. Some patients
develop symptomatic bradycardia that requires permanent
pacing. Nonpharmacological therapy should be considered
when pharmacological measures fail.
8.1.3.1.1. Beta blockers. Intravenous beta blockade with
propranolol, atenolol, metoprolol, or esmolol is effective
for control of the rate of ventricular response to AF. These
agents may be particularly useful in states of high adrener-
gic tone (e.g., postoperative AF). After noncardiac surgery,
intravenous esmolol produced more rapid conversion to
sinus rhythm than diltiazem, but rates after 2 and 12 h
were similar with both treatments.366
In 7 of 12 comparisons, beta-adrenergic blockade proved
safe and effective for control of heart rate in patients
with AF and superior to placebo. Nadolol and atenolol
were the most efﬁcacious of the drugs tested. Patients
taking beta blockers may experience slow rates at rest, or
exercise tolerance may be compromised when the rate
response is blunted excessively.367 Sotalol, a nonselective
beta-blocking drug with type III antiarrhythmic activity
used for rhythm control, also provides excellent rate
control in the event of AF recurrence368 and may achieve
lower heart rate than metoprolol during exercise. Atenolol,
metoprolol, and sotalol provide better control of exercise-
induced tachycardia than digoxin.369,370 Carvedilol also
lowers the ventricular rate at rest and during exercise in
such patients and reduces ventricular ectopy.371 With or
without digoxin in the AFFIRM study, beta blockers were
the most effective drug class for rate control, achieving
the speciﬁed heart rate endpoints in 70% of patients com-
pared with 54% with use of calcium channel blockers.360
Beta blockers should be initiated cautiously in patients
with AF and HF who have reduced ejection fraction.372
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Table 10 Intravenous and orally administered pharmacological agents for heart rate control in patients with atrial ﬁbrillation
Drug Class/LOE recommendation Loading dose Onset Maintenance dose Major side effects
Acute setting
Heart rate control in patients without accessory pathway
Esmololab Class I, LOE C 500 mcg/kg IV over 1 min 5 min 60 to 200 mcg/kg/min IV #BP, HB, #HR, asthma, HF
Metoprololb Class I, LOE C 2.5 to 5 mg IV bolus over
2 min; up to 3 doses
5 min NA #BP, HB, #HR, asthma, HF
Propranololb Class I, LOE C 0.15 mg/kg IV 5 min NA #BP, HB, #HR, asthma, HF
Diltiazem Class I, LOE B 0.25 mg/kg IV over 2 min 2 to 7 min 5 to 15 mg/h IV #BP, HB, HF
Verapamil Class I, LOE B 0.075 to 0.15 mg/kg IV
over 2 min
3 to 5 min NA #BP, HB, HF
Heart rate control in patients with accessory pathwayc
Amiodaroned&cjs0952; Class IIa, LOE C 150 mg over 10 min Days 0.5 to 1 mg/min IV #BP, HB, pulmonary toxicity, skin
discoloration, hypothyroidism,
hyperthyroidism, corneal deposits,
optic neuropathy, warfarin interaction,
sinus bradycardia
Heart rate control in patients with heart failure and without accessory pathway
Digoxin Class I, LOE B 0.25 mg IV each 2 h,
up to 1.5 mg
60 min or morec 0.125 to 0.375 mg daily IV or orally Digitalis toxicity, HB, #HR
Amiodaroned Class IIa, LOE C 150 mg over 10 min Days 0.5 to 1 mg/min IV #BP, HB, pulmonary toxicity, skin
discoloration, hypothyroidism,
hyperthyroidism, corneal deposits,
optic neuropathy, warfarin interaction,
sinus bradycardia
Non-acute setting and chronic maintenance therapye
Heart rate control
Metoprololb Class I, LOE C Same as maintenance dose 4 to 6 h 25 to 100 mg twice a day, orally #BP, HB, #HR, asthma, HF
Propranololb Class I, LOE C Same as maintenance dose 60 to 90 min 80 to 240 mg daily in divided doses, orally #BP, HB, #HR, asthma, HF
Diltiazem Class I, LOE B Same as maintenance dose 2 to 4 h 120 to 360 mg daily in divided doses; slow
release available, orally
#BP, HB, HF
Verapamil Class I, LOE B Same as maintenance dose 1 to 2 h 120 to 360 mg daily in divided doses;
slow release available, orally
#BP, HB, HF, digoxin interaction
Heart rate control in patients with heart failure and without accessory pathway
Digoxin Class I, LOE C 0.5 mg by mouth daily 2 days 0.125 to 0.375 mg daily, orally Digitalis toxicity, HB, #HR
Amiodaroned Class IIb, LOE C 800 mg daily for 1 wk, orally
600 mg daily for 1 wk, orally
400 mg daily for 4 to 6 wk, orally
1 to 3 wk 200 mg daily, orally #BP, HB, pulmonary toxicity, skin
discoloration, hypothyroidism,
hyperthyroidism, corneal deposits,
optic neuropathy, warfarin interaction,
sinus bradycardia
aOnset is variable and some effect occurs earlier.
bOnly representative members of the type of beta-adrenergic antagonist drugs are included in the table, but other, similar agents could be used for this indication in appropriate doses. Beta blockers are grouped in an
order preceding the alphabetical listing of drugs.
cConversion to sinus rhythm and catheter ablation of the accessory pathway are generally recommended; pharmacological therapy for rate control may be appropriate in certain patients.
dAmiodarone can be useful to control the heart rate in patients with atrial ﬁbrillation (AF) when other measures are unsuccessful or contraindicated.
eAdequacy of heart rate control should be assessed during physical activity as well as at rest.
&cjs0952; If rhythm cannot be converted or ablated and rate control is needed, intravenous (IV) amiodarone is recommended.
#BP indicates hypotension; #HR, bradycardia; HB, heart block; HF, heart failure; LOE, level of evidence; NA, not applicable.
678
A
C
C
/A
H
A
/ESC
G
uid
elines
Downloaded from https://academic.oup.com/europace/article-abstract/8/9/651/530495
by guest
on 02 April 2018
8.1.3.1.2. Nondihydropyridine calcium channel antagonists.
The nondihydropyridine calcium channel antagonist agents
verapamil and diltiazem are commonly used for treatment
of AF and are the only agents that have been associated
with an improvement in quality of life and exercise toler-
ance. Intravenous bolus injection of either drug is effective
to control the ventricular rate,367,373 although their short
duration of action usually requires continuous intravenous
infusion to maintain rate control. These agents should be
used cautiously or avoided in patients with HF due to systolic
dysfunction because of their negative inotropic effects.
Eight randomized studies comparing calcium channel block-
ers to placebo370 found signiﬁcant decrease in heart rate
with diltiazem. Verapamil decreased heart rate both at
rest (by 8 to 23 beats per minute) and during exercise (by
20 to 34 beats per minute). Direct comparisons of verapamil
and diltiazem have demonstrated similar effectiveness,374
with preserved or improved exercise tolerance in most
patients.374 These agents may be preferred for long-term
use over beta blockers in patients with bronchospasm or
chronic obstructive pulmonary disease.
8.1.3.1.3. Digoxin. Although intravenous digoxin may slow
the ventricular response to AF at rest, there is a delay of
at least 60 min before onset of a therapeutic effect in
most patients, and the peak effect does not develop for
up to 6 h. Digoxin is no more effective than placebo in con-
verting AF to sinus rhythm and may perpetuate AF.375,376 Its
efﬁcacy is reduced in states of high sympathetic tone, a
possible precipitant of paroxysmal AF. In a review of 139 epi-
sodes of paroxysmal AF detected by Holter monitoring,
there was no difference in the ventricular rates of patients
taking digoxin and those not taking this agent.376 Other
investigators, however, have reported that digoxin reduces
the frequency and severity of AF recurrences,30 and the
combination of digoxin and atenolol is effective for rate
control.377 Given the availability of more effective agents,
digoxin is no longer considered ﬁrst-line therapy for rapid
management of AF, except in patients with HF or LV dysfunc-
tion, or perhaps in patients who are so sedentary as to
obviate the need for rate control during activity.
Digoxin exerts only a transient rate-slowing effect in
patients with recent-onset AF,378 perhaps as a result of a
vagotonic effect on the AV node. In contrast to its limited
negative chronotropic effect in patients with paroxysmal
AF, digoxin is moderately effective in those with persistent
AF, particularly when HF is present.362,370 According to a sys-
tematic review, digoxin administered alone slows the heart
rate more than placebo by an average of 4 to 21 beats per
minute at rest, but it does not slow heart rate during exer-
cise in patients with AF.367,370 The most frequent adverse
effects of digoxin are ventricular arrhythmias, atrioventricu-
lar block, and sinus pauses, all of which are dose dependent.
Because of drug interactions, the serum digoxin concen-
tration may rise and toxic effects may be potentiated
when verapamil or antiarrhythmic agents such as propafe-
none or amiodarone are administered concurrently.
8.1.3.1.4. Antiarrhythmic agents. Amiodarone has both
sympatholytic and calcium antagonistic properties,
depresses AV conduction, and is effective for controlling
the ventricular rate in patients with AF. Intravenous amio-
darone is generally well tolerated in critically ill patients
who develop rapid atrial tachyarrhythmias refractory to
conventional treatment, but efﬁcacy has not been sufﬁ-
ciently evaluated in this indication.379 Amiodarone is con-
sidered a suitable alternative agent for heart rate control
when conventional measures are ineffective.379 When con-
ventional measures are ineffective, amiodarone may be con-
sidered as an alternative agent for heart rate control in
patients with AF,379 but this represents an off-label use in
the United States and in some other countries and the
potential beneﬁt must be carefully weighed against the con-
siderable potential toxicity of this drug. Patients given amio-
darone who did not convert from AF to sinus rhythm
experienced substantially lower ventricular rates than
those treated with placebo,370 but important adverse
effects make this agent a second-line therapy for rate
control. In one study, oral amiodarone decreased the ventri-
cular rate without affecting exercise capacity, quality of
life, or AF symptoms.380 High-dose oral amiodarone
loading can worsen hemodynamics in patients with recent
decompensation of HF or hypotension.381 Amiodarone may
cause potentially fatal toxicity, including pulmonary ﬁbrosis,
hepatic injury, and proarrhythmia.
Dofetilide and ibutilide are effective for conversion of
atrial ﬂutter and AF but are not effective for control of
the ventricular rate. Propafenone exerts mild beta-blocking
effects that may slow conduction across the AV node, but
this is seldom sufﬁcient to control the rate in patients with
AF, and AV conduction may accelerate when the atrial
rhythm becomes slower and more regular, so other agents
in addition to propafenone are generally required to main-
tain control of the heart rate when AF recurs.
8.1.3.1.5. Combination therapy. Combinations of drugs may
be required to achieve adequate rate control in some
patients with AF, but care should be taken to avoid bradycar-
dia.370 The addition of other drugs to digoxin is commonly
required to control the rate during exercise. The combi-
nation of digoxin and atenolol produces a synergistic
effect on the AV node,377 and the combination of digoxin
and pindolol provided better control during exercise than
digoxin alone or in combination with verapamil.382 In
general, the combination of digoxin and a beta blocker
appears more effective than the combination of digoxin
with a calcium channel antagonist.377
8.1.3.1.6. Special considerations in patients with the Wolff-
Parkinson-White (WPW) syndrome. Intravenous beta block-
ers, digitalis, adenosine, lidocaine, and nondihydropyridine
calcium channel antagonists, all of which slow conduction
across the AV node, are contraindicated in patients with
the WPW syndrome and tachycardia associated with ventri-
cular preexcitation, because they can facilitate antegrade
conduction along the accessory pathway during AF,3 result-
ing in acceleration of the ventricular rate, hypotension, or
ventricular ﬁbrillation.181 When the arrhythmia is associated
with hemodynamic compromise, however, early direct-
current cardioversion is indicated. In hemodynamically
stable patients with preexcitation, type I antiarrhythmic
agents or amiodarone may be administered intravenously.
Beta blockers and calcium channel blockers are reasonable
for oral chronic use.383
8.1.3.2. Pharmacological therapy to control heart rate in
patients with both atrial ﬁbrillation and atrial ﬂutter. A
patient treated with AV nodal blocking drugs whose
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ventricular rate is well controlled during AF may experience
a rise or fall in rate if he or she develops atrial ﬂutter. This is
also true when antiarrhythmic agents such as propafenone
or ﬂecainide are used to prevent recurrent AF. These
compounds may increase the likelihood of 1:1 AV
conduction during atrial ﬂutter, leading to a very rapid
ventricular response. Thus, when these agents are given
for prophylaxis against recurrent paroxysmal AF or atrial
ﬂutter, AV nodal blocking drugs should be routinely
coadministered. An exception may be patients with
paroxysmal AF who have undergone catheter ablation of
the cavotricuspid isthmus to prevent atrial ﬂutter.
8.1.3.3. Regulation of atrioventricular nodal conduction by
pacing. Because ventricular pacing prolongs the AV nodal
refractory period as a result of concealed retrograde pen-
etration, it eliminates longer ventricular cycles and may
reduce the number of short ventricular cycles related to
rapid AV conduction during AF. Pacing at approximately the
mean ventricular rate during spontaneous AV conduction
can regulate the ventricular rhythm during AF.384 This may
be useful for patients with marked variability in ventricular
rates or for those who develop resting bradycardia
during treatment with medication. In some patients, the
hemodynamic beneﬁt of revascularization may be offset by
asynchronous ventricular activation during RV pacing. At
least 2 multicenter studies examined a ventricular rate
regularization algorithm. In one study, patients with paroxys-
mal AF indicated a preference for the paced regularization
strategy, while patients with permanent AF showed no
preference despite a 29% improvement of irregularity.385 In
another study, ventricular rate regularization did not
improve quality of life in patients with paroxysmal or
permanent AF.386
8.1.3.4. AV nodal ablation. AV nodal ablation in conjunction
with permanent pacemaker implantation provides highly
effective control of the heart rate and improves symptoms
in selected patients with AF.363,387–389 In general, patients
most likely to beneﬁt from this strategy are those with
symptoms or tachycardia-mediated cardiomyopathy
related to rapid ventricular rate during AF that cannot be
controlled adequately with antiarrhythmic or negative
chronotropic medications. Meta-analysis of 21 studies pub-
lished between 1989 and 1998 that included a total of
1181 patients concluded that AV nodal ablation and perma-
nent pacemaker implantation signiﬁcantly improved cardiac
symptoms, quality of life, and healthcare utilization for
patients with symptomatic AF refractory to medical
treatment.389 In the APT, 156 patients with refractory AF
displayed improvements in quality of life, exercise capacity,
and ventricular function over 1 y.363 In a study of 56 patients
with impaired LV function (ejection fraction less than 40%),
the mean ejection fraction improved from 26% plus or minus
8% to 34% plus or minus 13% after AV nodal ablation and
pacemaker implantation and became normal in 16 patients
(29%).390 Patients with persistent LV dysfunction after
ablation were more likely to have structural heart disease
associated with less than 60% survival at 5 y. In small ran-
domized trials involving patients with paroxysmal388 and
persistent387 AF, signiﬁcantly greater proportions experi-
enced improvement in symptoms and quality of life after
AV nodal ablation than with antiarrhythmic medication
therapy. Of 2027 patients randomized to make control in
the AFFIRM study, AV nodal ablation was performed in
5%360 after failure to achieve adequate rate control with a
mean of 2.4 plus or minus 0.7 medications. Another 147
patients required pacemaker implantation because of symp-
tomatic bradycardia. Catheter ablation of inferior atrial
inputs to the AV node slows the ventricular rate during AF
and improves symptoms without pacemaker implan-
tation.391,392 This technique has several limitations,
however, including inadvertent complete AV block and a
tendency of ventricular rate to rise over the 6 mo following
ablation. Two small, randomized trials comparing this type
of AV nodal modiﬁcation with complete AV nodal ablation
and permanent pacemaker implantation demonstrated
better symptom relief with the complete interruption
procedure. Thus, AV nodal modiﬁcation without pacemaker
implantation is only rarely used.
Ablation of the AV inputs in the atrium may improve the
reliability of the junctional escape mechanism.393 This
involves selective ablation of fast and slow AV nodal path-
ways followed, if necessary, by ablation between these
inputs to achieve complete AV block. Complications of AV
nodal ablation include those associated with pacemaker
implantation, ventricular arrhythmias, thromboembolism
associated with interruption of anticoagulation, the rare
occurrence of LV dysfunction, and progression from paroxys-
mal to persistent AF. The 1-y mortality rate after AV nodal
ablation and permanent pacemaker implantation is approxi-
mately 6.3% (95% conﬁdence interval [CI] 5.5% to 7.2%),
including a 2.0% risk of sudden death (95% CI 1.5% to
2.6%). Although a causal relationship between the pro-
cedure and sudden death remains controversial, it has
been suggested that programming the pacemaker to a rela-
tively high nominal rate (90 beats per minute) for the ﬁrst
month after ablation may reduce the risk.394,395
Although the symptomatic beneﬁts of AV nodal ablation
are clear, limitations include the persistent need for anti-
coagulation, loss of AV synchrony, and lifelong pacemaker
dependency. There is also a ﬁnite risk of sudden death due
to torsades de pointes or ventricular ﬁbrillation.396 Patients
with abnormalities of diastolic ventricular compliance who
depend on AV synchrony to maintain cardiac output, such
as those with hypertrophic cardiomyopathy or hypertensive
heart disease, may experience persistent symptoms after AV
nodal ablation and pacemaker implantation. Hence,
patients should be counseled regarding each of these con-
siderations before proceeding with this irreversible
measure.
The adverse hemodynamic effects of RV apical pacing
following AV nodal ablation have been a source of
concern. Compared with RV apical pacing, LV pacing signiﬁ-
cantly improves indices of both LV systolic function
(pressure-volume loop, stroke work, ejection fraction, and
dP/dt) and diastolic ﬁlling.397 Acutely, LV pacing was associ-
ated with a 6% increase in ejection fraction and a 17%
decrease in mitral regurgitation.398 The Post AV Node Abla-
tion Evaluation (PAVE) randomized 184 patients undergoing
AV nodal ablation because of permanent AF to standard RV
apical pacing or biventricular pacing.399 After 6 mo, the
biventricular pacing group walked 25.6 meters farther in
6 min (P ¼ 0.03), had greater peak oxygen consumption,
and had higher scores in 9 of 10 quality-of-life
domains than the RV pacing group. While there was no
difference in LV ejection fraction between the groups at
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baseline, the LV ejection fraction remained stable in the
biventricular pacing group while it declined in the RV
pacing group (46% vs. 41%, respectively; P ¼ 0.03). There
was no signiﬁcant difference in mortality. A subgroup analy-
sis suggested that functional improvements were conﬁned to
patients with LV ejection fraction below 35% before
ablation.
Patients with normal LV function or reversible LV dysfunc-
tion undergoing AV nodal ablation are most likely to beneﬁt
from standard AV nodal ablation and pacemaker implan-
tation. For those with impaired LV function not due to tachy-
cardia, a biventricular pacemaker with or without
deﬁbrillator capability should be considered. Upgrading to
a biventricular device should be considered for patients
with HF and an RV pacing system who have undergone AV
node ablation.400
8.1.4. Preventing thromboembolism
For recommendations regarding antithrombotic therapy in
patients with AF undergoing cardioversion, see Section
8.2.7.
Recommendations
Class I
(1) Antithrombotic therapy to prevent thromboembolism is
recommended for all patients with AF, except those
with lone AF or contraindications. (Level of Evidence: A)
(2) The selection of the antithrombotic agent should be
based upon the absolute risks of stroke and bleeding
and the relative risk and beneﬁt for a given patient.
(Level of Evidence: A)
(3) For patients without mechanical heart valves at high risk
of stroke, chronic oral anticoagulant therapy with a
vitamin K antagonist is recommended in a dose adjusted
to achieve the target intensity INR of 2.0 to 3.0, unless
contraindicated. Factors associated with highest risk
for stroke in patients with AF are prior thromboembo-
lism (stroke, TIA, or systemic embolism) and rheumatic
mitral stenosis. (Level of Evidence: A)
(4) Anticoagulation with a vitamin K antagonist is rec-
ommended for patients with more than 1 moderate
risk factor. Such factors include age 75 y or greater,
hypertension, HF, impaired LV systolic function (ejection
fraction 35% or less or fractional shortening less than
25%), and diabetes mellitus. (Level of Evidence: A)
(5) INR should be determined at least weekly during
initiation of therapy and monthly when anticoagulation
is stable. (Level of Evidence: A)
(6) Aspirin, 81–325 mg daily, is recommended as an alterna-
tive to vitamin K antagonists in low-risk patients or in
those with contraindications to oral anticoagulation.
(Level of Evidence: A)
(7) For patients with AF who have mechanical heart valves,
the target intensity of anticoagulation should be based
on the type of prosthesis, maintaining an INR of at
least 2.5. (Level of Evidence: B)
(8) Antithrombotic therapy is recommended for patients
with atrial ﬂutter as for those with AF. (Level of
Evidence: C)
Class IIa
(1) For primary prevention of thromboembolism in patients
with nonvalvular AF who have just 1 of the following
validated risk factors, antithrombotic therapy with
either aspirin or a vitamin K antagonist is reasonable,
based upon an assessment of the risk of bleeding compli-
cations, ability to safely sustain adjusted chronic antic-
oagulation, and patient preferences: age greater than or
equal to 75 y (especially in female patients), hyperten-
sion, HF, impaired LV function, or diabetes mellitus.
(Level of Evidence: A)
(2) For patients with nonvalvular AF who have 1 or more of
the following less well-validated risk factors, antithrom-
botic therapy with either aspirin or a vitamin K antagonist
is reasonable for prevention of thromboembolism: age 65
to 74 y, female gender, or CAD. The choice of agent
should be based upon the risk of bleeding complications,
ability to safely sustain adjusted chronic anticoagulation,
and patient preferences. (Level of Evidence: B)
(3) It is reasonable to select antithrombotic therapy using
the same criteria irrespective of the pattern (i.e.,
paroxysmal, persistent, or permanent) of AF. (Level of
Evidence: B)
(4) In patients with AF who do not have mechanical
prosthetic heart valves, it is reasonable to interrupt
anticoagulation for up to 1 wk without substituting
heparin for surgical or diagnostic procedures that carry
a risk of bleeding. (Level of Evidence: C)
(5) It is reasonable to reevaluate the need for anticoagula-
tion at regular intervals. (Level of Evidence: C)
Class IIb
(1) In patients 75 y of age and older at increased risk of
bleeding but without frank contraindications to oral
anticoagulant therapy, and in other patients with mod-
erate risk factors for thromboembolism who are unable
to safely tolerate anticoagulation at the standard inten-
sity of INR 2.0 to 3.0, a lower INR target of 2.0 (range 1.6
to 2.5) may be considered for primary prevention of
ischemic stroke and systemic embolism. (Level of Evi-
dence: C)
(2) When surgical procedures require interruption of oral
anticoagulant therapy for longer than 1 wk in high-risk
patients, unfractionated heparin may be administered
or low-molecular-weight heparin given by subcutaneous
injection, although the efﬁcacy of these alternatives in
this situation is uncertain. (Level of Evidence: C)
(3) Following percutaneous coronary intervention or revas-
cularization surgery in patients with AF, low-dose
aspirin (less than 100 mg per d) and/or clopidogrel
(75 mg per d) may be given concurrently with anticoagu-
lation to prevent myocardial ischemic events, but these
strategies have not been thoroughly evaluated and are
associated with an increased risk of bleeding. (Level of
Evidence: C)
(4) In patients undergoing percutaneous coronary interven-
tion, anticoagulation may be interrupted to prevent
bleeding at the site of peripheral arterial puncture,
but the vitamin K antagonist should be resumed as
soon as possible after the procedure and the dose
adjusted to achieve an INR in the therapeutic range.
Aspirin may be given temporarily during the hiatus,
but the maintenance regimen should then consist of
the combination of clopidogrel, 75 mg daily, plus war-
farin (INR 2.0 to 3.0). Clopidogrel should be given for a
minimum of 1 mo after implantation of a bare metal
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stent, at least 3 mo for a sirolimus-eluting stent, at least
6 mo for a paclitaxel-eluting stent, and 12 mo or longer
in selected patients, following which warfarin may be
continued as monotherapy in the absence of a sub-
sequent coronary event. When warfarin is given in com-
bination with clopidogrel or low-dose aspirin, the dose
intensity must be carefully regulated. (Level of Evi-
dence: C)
(5) In patients with AF younger than 60 y without heart
disease or risk factors for thromboembolism (lone AF),
the risk of thromboembolism is low without treatment
and the effectiveness of aspirin for primary prevention
of stroke relative to the risk of bleeding has not been
established. (Level of Evidence: C)
(6) In patients with AF who sustain ischemic stroke or sys-
temic embolism during treatment with low-intensity
anticoagulation (INR 2.0 to 3.0), rather than add an anti-
platelet agent, it may be reasonable to raise the inten-
sity of anticoagulation to a maximum target INR of 3.0 to
3.5. (Level of Evidence: C)
Class III
Long-term anticoagulation with a vitamin K antagonist is
not recommended for primary prevention of stroke in
patients below the age of 60 y without heart disease (lone
AF) or any risk factors for thromboembolism. (Level of Evi-
dence: C)
8.1.4.1. Risk stratiﬁcation
8.1.4.1.1. Epidemiological data. In a small, retrospective,
population-based study in Olmsted County, Minnesota, over
3 decades, the 15-y cumulative stroke rate in people with
lone AF (deﬁned as those younger than 60 y with no clinical
history or echocardiographic signs of cardiopulmonary
disease) was 1.3%.11 Conversely, in the Framingham
Study,28 the age-adjusted stroke rate over a mean follow-
up period of 11 y was 28.2% in those with lone AF, more lib-
erally deﬁned to include patients with a history of hyperten-
sion or cardiomegaly on chest roentgenography, compared
with 6.8% in normal controls.28 In the SPAF study, the annual-
ized rate of ischemic stroke during aspirin treatment was
similar in those with paroxysmal (3.2%) and permanent
(3.3%) AF.401 Those with prior stroke or TIA have a rate of
subsequent stroke of 10% to 12% per year when treated
with aspirin, and these patients beneﬁt substantially from
adjusted-dose oral anticoagulation.402,403 In addition to
prior thromboembolism, HF, hypertension, increasing age,
and diabetes mellitus have consistently emerged as inde-
pendent risk factors for ischemic stroke associated with non-
valvular AF.47,261,264,382,405 Other factors, such as female
gender, systolic blood pressure over 160 mm Hg, and LV dys-
function, have been variably linked to stroke.261,266,406 The
relative risk for ischemic stroke associated with speciﬁc
clinical features, derived from a collaborative analysis of
participants given no antithrombotic therapy in the control
groups of 5 randomized trials, is displayed in Table 11.
In patients with nonvalvular AF, prior stroke or TIA is the
strongest independent predictor of stroke, signiﬁcantly
associated with stroke in all 6 studies in which it was evalu-
ated, with incremental relative risk between 1.9 and 3.7
(averaging approximately 3.0). Attempts to identify patients
with prior stroke or TIA who have relatively low stroke risks
by virtue of the absence of other risk factors did not identify
any reliable predictors.261,407–409 The pathogenic constructs
of stroke in AF are incomplete, but available data indicate
that all patients with prior stroke or TIA are at high risk of
recurrent thromboembolism and require anticoagulation
unless there are ﬁrm contraindications in a given patient.
Efforts to enhance risk stratiﬁcation should remove such
patients from consideration and focus instead on the predic-
tive value of pertinent risk factors and absolute stroke rates
for primary prevention. Patient age is a consistent indepen-
dent predictor of stroke (Figure 8). In 7 studies in which the
variable was assessed, hazard ratios averaged 1.5 per
decade. Nearly half of AF-associated strokes occur in
patients over 75 y, and AF is the most frequent cause of dis-
abling stroke in elderly women.21,405,406 Older people are
also at increased risk for anticoagulant-related bleeding410
and are less likely to be treated with oral anticoagulation,
even in situations for which it has been proved efﬁcacious,
in part because of concern about the risk of bleeding.411
Special consideration of these older patients is therefore a
critical aspect of effective stroke prophylaxis.405
Female gender has emerged as an independent predictor
of stroke in 3 cohort studies of patients with AF but not in
several others.47,268,404 The relative increase was 1.6 in
the largest study of the ATRIA cohort.262 In the SPAF analyses
of aspirin-treated patients, gender interacted with age such
that women over 75 y old were at particularly high risk, but
this interaction was not apparent in the AnTicoagulation and
Risk factors In Atrial ﬁbrillation (ATRIA) cohort.262,412
Similarly, hypertension is a consistent, powerful predictor
of stroke, with a history of hypertension independently pre-
dictive in 5 studies (median relative risk approximately 2.0)
and systolic blood pressure signiﬁcant in 2 others (mean rela-
tive risk approximately 2.0). A history of hypertension and
systolic blood pressure over 160 mm Hg were independently
predictive of stroke in the SPAF aspirin-treated cohorts.
Diabetes was a signiﬁcant independent predictor in 4
studies, associated with an average relative risk of 1.8,
but not in 2 other studies. The strength of diabetes as a
predictor may be greater in lower-risk patients with AF,
prompting speculation that it may be associated with non-
cardioembolic strokes. Diabetes is a less powerful indepen-
dent predictor than prior stroke/TIA, hypertension, or age,
but analysis of the type, duration, or control of diabetes
has not been undertaken to reﬁne its predictive value for
thromboembolism in patients with AF. The reduction in
stroke among warfarin-treated patients with diabetes was
below average in 2 studies.413,414
Table 11 Risk factors for ischemic stroke and systemic
embolism in patients with nonvalvular atrial ﬁbrillation
Risk factors Relative risk
Previous stroke or TIA 2.5
Diabetes mellitus 1.7
History of hypertension 1.6
Heart failure 1.4
Advanced age (continuous, per decade) 1.4
Data derived from collaborative analysis of 5 untreated control groups
in primary prevention trials.47 As a group, patients with nonvalvular atrial
ﬁbrillation (AF) carry about a 6-fold increased risk of thromboembolism
compared with patients in sinus rhythm. Relative risk refers to compari-
son of patients with AF to patients without these risk factors.
TIA indicates transient ischemic attack.
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In 2 studies, CAD was a univariate predictor of stroke in
otherwise low-risk patients47,415; it has not been shown to
have independent predictive value for stroke in patients
with AF.
Clinical HF has not been conclusively shown to have inde-
pendent predictive value for stroke in any study of AF
patients. In the SPAF I and II studies,412 recent (within
3 mo) HF or impaired LV systolic function (deﬁned as M-
mode echocardiographic fractional shortening less than
25%) was a signiﬁcant independent predictor, as was LV
systolic dysfunction by 2-dimensional echocardiography
in placebo-treated patients in some studies266 but not in
others.261,268 Clinical diagnosis of HF may be difﬁcult in
elderly patients with AF, and misclassiﬁcation could blunt
the power of association. In short, while it seems logical
based on pathophysiological concepts and echocardio-
graphic correlates that HF should be an independent predic-
tor of stroke in patients with nonvalvular AF, available data
do not provide strong support.
8.1.4.1.2. Echocardiography and risk stratiﬁcation. Echo-
cardiography is valuable to deﬁne the origin of AF (e.g.,
detecting rheumatic mitral valve disease or HCM) and may
add information useful in stratifying thromboembolic risk.
Among high-risk AF patients, impaired LV systolic function
on transthoracic echocardiography, thrombus, dense SEC
or reduced velocity of blood ﬂow in the LAA, and complex
atheromatous plaque in the thoracic aorta on TEE have
been associated with thromboembolism, and oral anticoagu-
lation effectively lowers the risk of stroke in AF patients
with these features. LA diameter and ﬁbrocalciﬁc endocar-
dial abnormalities have been less consistently associated
with thromboembolism. Whether the absence of these echo-
cardiographic abnormalities identiﬁes a low-risk group of
patients who could safely avoid anticoagulation has not
been established, limiting the value of echocardiography
as a prime determinant of the need for chronic anticoagula-
tion in patients with AF.
Transthoracic echocardiography. Correlations in placebo-
assigned participants in randomized trials of antithrombotic
therapy provide information about the independent predic-
tive value of transthoracic echocardiography for throm-
boembolic events in patients with nonvalvular AF.265,416
Meta-analysis of 3 trials found moderate to severe LV
dysfunction to be the only independent echocardiographic
predictor of stroke in patients with AF after adjustment
for clinical features; the diameter of the LA was less
useful.266
Secondary analyses of aspirin-assigned patients in multi-
center trials yield variable results regarding the role of
transthoracic echocardiography for predicting thromboem-
bolic risk.54,203 In the SPAF I and II studies, LV fractional
shortening less than 25% (estimated by M-mode echo-
cardiography) was the only independent echocardiographic
predictor of stroke. Among 2012 aspirin-assigned patients
in the SPAF trials (including 290 in SPAF-III assigned to a
relatively ineffective ﬁxed-dose combination of aspirin
plus warfarin), no transthoracic echocardiographic par-
ameter independently predicted thromboembolism when
clinical risk factors were considered. Similarly, no indepen-
dent predictors of thromboembolism were identiﬁed by
transthoracic echocardiography and TEE at entry in the
Embolism in the Left Atrial Thrombi (ELAT) study of 409
patients with nonvalvular AF taking aspirin, 160 mg daily.268
Transesophageal echocardiography. TEE is a sensitive and
speciﬁc technique for detection of LA and LAA thrombus, far
surpassing transthoracic echocardiography.203 This modality
also permits superior evaluation for other causes of cardio-
genic embolism,320 as well as a means of measuring LAA
function.319 Several TEE features have been associated
with thromboembolism, including thrombus, reduced ﬂow
velocity, and SEC in the LA or LAA and atheromatous
disease of the aorta.252,417
Detection of LA/LAA thrombus stands as a contraindica-
tion to elective cardioversion of AF. Unfortunately, the
absence of a detectable thrombus does not preclude
stroke after cardioversion in the absence of anticoagulation
therapy.324,418 A TEE-guided strategy for elective cardio-
version of AF yielded comparable outcomes for thromboem-
bolism and death comparedwith conventional anticoagulation
for 3 wk before and 4 wk after cardioversion.320
8.1.4.1.3. Therapeutic implications. The efﬁcacy and safety
of oral anticoagulation and platelet inhibitor therapy with
aspirin for prevention of stroke in patients with AF have
been well characterized.420 The selection of appropriate
antithrombotic therapy is discussed below in the context
of thromboembolic risk (see Section 8.1.6, Pharmacological
Agents to Maintain Sinus Rhythm, and Section 8.1.7, Out-of-
Hospital Initiation of Antiarrhythmic Drugs in Patients With
Atrial Fibrillation). Patients with AF who have low rates of
stroke when treated with aspirin may not gain sufﬁcient
beneﬁt from anticoagulation to outweigh the attendant
risks and the need for close medical monitoring.421,422 Esti-
mating the risk of stroke for individual AF patients is crucial
for the decision to provide anticoagulation therapy to indi-
vidual patients with AF,54 but the threshold risk that war-
rants anticoagulation is controversial. Patients with a
stroke risk of 2% per year or less do not beneﬁt substantially
from oral anticoagulation, which would require treating 100
or more patients for 1 y to prevent a single stroke.420 For
high-risk AF patients with stroke rates of 6% per year or
greater, the comparable number needed-to-treat is 25 or
fewer, strongly favoring anticoagulation. Opinion remains
divided about routine anticoagulation for patients at inter-
mediate stroke risk (annual rate 3% to 5%).
Figure 8 Stroke rates in relation to age among patients in
untreated control groups of randomized trials of antithrombotic
therapy. Data are from the Atrial Fibrillation Investigators. Risk
factors for stroke and efﬁcacy of antithrombotic therapy in atrial
ﬁbrillation. Analysis of pooled data from ﬁve randomized controlled
trials. Arch Intern Med 1994;154:1449–57.47
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To stratify the risk of ischemic stroke in patients with AF,
several clinical schemes have been proposed based on ana-
lyses of prospectively monitored cohorts of participants in
clinical trials in which antithrombotic therapy was con-
trolled.391,421,423 One set of criteria (Atrial Fibrillation Inves-
tigators [AFI]) is based on multivariate pooled analysis of
1593 participants assigned to the control or placebo groups
of 5 randomized primary prevention trials in which 106
ischemic strokes occurred over a mean follow-up of 1.4 y.
47 Patients were divided into 2 strata, distinguishing low-
risk patients from those at intermediate or high risk.
Although echocardiographic features were not considered
initially, a subsequent analysis of 3 of the trials identiﬁed
abnormal LV systolic function as an independent predictor
of stroke.421 The SPAF study criteria were based on multi-
variate analysis of 854 patients assigned to aspirin and fol-
lowed for a mean of 2.3 y, during which 68 ischemic
strokes were observed. These criteria were subsequently
used to select a low-risk cohort for treatment with aspirin
in the SPAF III study. Over a mean follow-up of 2 y, the rate
of ischemic stroke was 2.0% per year (95% CI 1.5% to 2.8%)
and the rate of disabling ischemic stroke was 0.8% per year
(95% CI 0.5% to 1.3%). Patients with a history of hypertension
had a higher rate of thromboembolism (3.6% per year) than
those without hypertension (1.1% per year; p less than
0.001). Other criteria have been developed by expert con-
sensus423,424 based on consideration of the foregoing
schemes to classify patients into low-, intermediate-, and
high-risk groups. Still others have employed recursive parti-
tioning and other techniques to identify low-risk patients.
Nine schemes that included more than 30 stroke events
have been promulgated based on multivariate analysis of
clinical and/or echocardiographic predictors. Three were
derived from overlapping patient cohorts, while 6 were
derived from entirely independent cohorts.47,261,266,412,415
Of the 6 studies with distinct patient cohorts, 2 involved
participants in randomized trials, 2 were based on clinical
case series, one was a population-based epidemiological
study, and the other was a hospital-based case-control
study. The largest study262 was limited to analysis of
female gender as an independent predictor.
A multivariate analysis from the Framingham Heart Study
examined risk factors for stroke among 705 patients with
recently detected AF, excluding those who had sustained
ischemic stroke, TIA, or death within 30 d of diagnosis.425
The only signiﬁcant predictors of ischemic stroke were age
(RR ¼ 1.3 per decade), female gender (RR ¼ 1.9), prior
stroke or TIA (RR ¼ 1.9), and diabetes mellitus (RR ¼ 1.8),
consistent with earlier studies. Systolic blood pressure
became a signiﬁcant predictor of stroke when warfarin
was included in a time-dependent Cox proportional
hazards model. With a scoring system based on age,
gender, systolic hypertension, diabetes, and prior stroke or
TIA, the proportion of patients classiﬁed as low risk varied
from 14.3% to 30.6% depending upon whether stroke rate
thresholds were less than 1.5% per year or less than 2% per
year. Observed stroke rates were 1.1% to 1.5% per year
based on 88 validated events. In the future, it may be poss-
ible to consider other characteristics that may contribute to
stroke risk, including genetic abnormalities of hemostatic
factors and endothelial dysfunction, but none have yet
been identiﬁed that have sufﬁcient predictive value for
clinical use in risk stratiﬁcation.230,413
Another stroke risk classiﬁcation scheme, known as
CHADS2 (Cardiac Failure, Hypertension, Age, Diabetes,
Stroke [Doubled]) integrates elements from several of the
foregoing schemes. The CHADS2 risk index is based on a
point system in which 2 points are assigned for a history of
stroke or TIA and 1 point each is assigned for age over 75 y,
a history of hypertension, diabetes, or recent HF
(Table 12).415,426 The predictive value of this scoring
system was evaluated in 1733 Medicare beneﬁciaries with
nonvalvular AF between the ages of 65 and 95 y who were
not given warfarin at hospital discharge. Although high
scores were associated with an increased stroke rate in
this elderly cohort, few patients had a score of 5 or more
or a score of 0. In the same cohort, the modiﬁed AFI
scheme had high-risk (prior stroke or TIA, hypertension, or
diabetes) and moderate-risk (age greater than 65 y without
other high-risk features) categories, corresponding to
stroke rates of 5.4% per year (95% CI 4.2% to 6.5% per
year) for high-risk and 2.2% per year (95% CI 1.1% to 3.5%
per year) for moderate-risk patients. Patients with high-
risk features according to the SPAF criteria (prior stroke or
TIA, women older than 75 y, or recent HF) had a stroke
rate of 5.7% per year (95% CI 4.4% to 7.0% per year); moder-
ate-risk patients (history of hypertension with no other high-
risk features) had a rate of 3.3% per year (95% CI 1.7% to 5.2%
per year); and low-risk patients (without risk factors) had a
stroke rate of 1.5% per year (95% CI 0.5% to 2.8% per year).
Although the schemes for stratiﬁcation of stroke risk
identify patients who beneﬁt most and least from anticoagu-
lation, the threshold for use of anticoagulation is controver-
sial. Opinion is particularly divided about anticoagulation for
those at intermediate risk (stroke rate 3% to 5% per year).
Table 12 Stroke risk in patients with nonvalvular af not treated
with anticoagulation according to the CHADS2 index
CHADS2 risk criteria Score
Prior stroke or TIA 2
Age .75 y 1
Hypertension 1
Diabetes mellitus 1
Heart failure 1
Patients (N ¼ 1733) Adjusted stroke
rate (%/y)a (95% CI)
CHADS2
score
120 1.9 (1.2 to 3.0) 0
463 2.8 (2.0 to 3.8) 1
523 4.0 (3.1 to 5.1) 2
337 5.9 (4.6 to 7.3) 3
220 8.5 (6.3 to 11.1) 4
65 12.5 (8.2 to 17.5) 5
5 18.2 (10.5 to 27.4) 6
Data are from van Walraven WC, Hart RG, Wells GA, et al. A clinical
prediction rule to identify patients with atrial ﬁbrillation and a low risk
for stroke while taking aspirin. Arch Intern Med 2003;163:936–43415;
and Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classi-
ﬁcation schemes for predicting stroke: results from the National Registry
of Atrial Fibrillation. JAMA 2001; 285:2864–70.426
AF indicates atrial ﬁbrillation; CHADS2, Cardiac Failure, Hypertension,
Age, Diabetes, and Stroke (Doubled); CI, conﬁdence interval; TIA, transi-
ent ischemic attack.
aThe adjusted stroke rate was derived from multivariate analysis
assuming no aspirin usage.
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Some advocate the routine use of anticoagulation for those
with stroke rates in this range,427 whereas others favor
selective anticoagulation of patients at intermediate risk,
with weight given to individual bleeding risks and patient
preferences.54,428 The threshold of beneﬁt at which AF
patients choose anticoagulation varies; some at intermedi-
ate risk elect anticoagulation, whereas others do not.429
Our recommendations for antithrombotic therapy in
patients with AF are summarized in Table 13.
Atrial ﬂutter is uncommon as a chronic arrhythmia, and
the risk of thromboembolism is not as well established as it
is for AF but is generally estimated as higher than that for
patients with sinus rhythm and less than that for those
with persistent or permanent AF. On the basis of multivariate
analysis, Wood et al.430 reported hypertension as the only
signiﬁcant correlate of previous thromboembolism for
patients with chronic atrial ﬂutter. From a review of 8 y of
retrospective data from 749 988 hospitalized older patients,
including 17 413 with atrial ﬂutter and 337 428 with AF, 3 of 4
patients with atrial ﬂutter also had or developed AF. The
overall stroke risk ratio for patients with atrial ﬂutter was
1.406, and for those with AF, it was 1.642 compared with
the control group. Coexisting HF, rheumatic heart disease,
and hypertension predicted an episode of AF in patients
with atrial ﬂutter. Risk ratios for patients with these comor-
bid conditions were 1.243, 1.464, and 1.333, respectively.431
Although the overall thromboembolic risk associated with
atrial ﬂutter may be somewhat lower than with AF, it seems
prudent to estimate risk by the use of similar stratiﬁcation
criteria for both arrhythmias until more robust data
become available (Tables 13 and 14).
8.1.4.2. Antithrombotic strategies for prevention of
ischemic stroke and systemic embolism. Before 1990,
antithrombotic therapy for prevention of ischemic stroke
and systemic embolism in patients with AF was limited
mainly to those with rheumatic heart disease or prosthetic
heart valves.21 Anticoagulation was also accepted therapy
for patients who had sustained ischemic stroke to prevent
recurrence but was often delayed to avoid hemorrhagic
transformation. Some advocated anticoagulation of patients
with thyrotoxicosis or other conditions associated with car-
diomyopathy. Since then, 24 randomized trials involving
patients with nonvalvular AF have been published, including
20 012 participants with an average follow-up of 1.6 y, a
total exposure of about 32 800 patient-y (Table 15). In
these studies, patient age averaged 71 y; 36% were
women. Most trials originated in Europe (14 trials, 7273
participants) or North America (7 trials, 8349 participants).
Most studied oral vitamin K inhibitors or aspirin in varying
dosages/intensities, but other anticoagulants (low-molecu-
lar-weight heparin, ximelagatran) and other antiplatelet
agents (dipyridamole, indobufen, trifulsal) have also been
tested. Nine trials had double-blind designs for antiplate-
let57,403,432–435 or anticoagulation436–438 comparisons.
8.1.4.2.1. Anticoagulation with vitamin K antagonist
agents. Five large randomized trials published between
1989 and 1992 evaluated oral anticoagulation mainly for
primary prevention of thromboembolism in patients with
nonvalvular AF57,428,432,436,437 (Figure 9, Table 15). A sixth
trial focused on secondary prevention among patients who
had survived nondisabling stroke or TIA.403 Meta-analysis
according to the principle of intention to treat showed
that adjusted-dose oral anticoagulation is highly efﬁcacious
for prevention of all stroke (both ischemic and hemorrha-
gic), with a risk reduction of 62% (95% CI 48% to 72%)
versus placebo420 (Figure 9). This reduction was similar for
both primary and secondary prevention and for both dis-
abling and nondisabling strokes. By on-treatment analysis
(excluding patients not undergoing oral anticoagulation at
the time of stroke), the preventive efﬁcacy of oral anticoa-
gulation exceeded 80%. Four of these trials were placebo
controlled; of the 2 that were double blinded with regard
to anticoagulation,437 one was stopped early because of
external evidence that oral anticoagulation was superior
to placebo, and the other included no female subjects. In
3 of the trials, oral anticoagulant dosing was regulated
according to the prothrombin time ratio; 2 used INR target
ranges of 2.5 to 4.0 and 2.0 to 3.0. These trials are summar-
ized in Table 15. The duration of follow-up was generally
between 1 and 2 y; the longest was 2.2 y, whereas in clinical
practice, the need for antithrombotic therapy in patients
with AF typically extends over much longer periods.
All reported trials excluded patients considered at
high risk of bleeding. Patient age and the intensity of antic-
oagulation are the most powerful predictors of major bleed-
ing.449–454 Trial participants, at an average age of 69 y, were
Table 13 Antithrombotic therapy for patients with atrial ﬁbrillation
Risk Category Recommended therapy
No risk factors Aspirin, 81 to 325 mg daily
One moderate-risk factor Aspirin, 81 to 325 mg daily, or warfarin
(INR 2.0 to 3.0, target 2.5)
Any high-risk factor or more than
1 moderate-risk factor
Warfarin (INR 2.0 to 3.0, target 2.5)a
Less validated or weaker risk factors Moderate-risk factors High-risk factors
Female gender Age greater than or equal to 75 y Previous stroke, TIA or embolism
Age 65 to 74 y Hypertension Mitral stenosis
Coronary artery disease Heart failure Prosthetic heart valvea
Thyrotoxicosis LV ejection fraction 35% or less
Diabetes mellitus
INR indicates international normalized ratio; LV, left ventricular; TIA, transient ischemic attack.
aIf mechanical valve, target international normalized ratio (INR) greater than 2.5.
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carefully selected and managed, however, and it is unclear
whether the relatively low observed rates of major hemor-
rhage also apply to patients with AF in clinical practice,
who have a mean age of about 75 y and less closely regu-
lated anticoagulation therapy.19,431,455
The target intensity of anticoagulation involves a balance
between prevention of ischemic stroke and avoidance of
hemorrhagic complications (Figure 10). Targeting the
lowest adequate intensity of anticoagulation to minimize
the risk of bleeding is particularly important for elderly AF
Table 14 Risk-based approach to antithrombotic therapy in patients with atrial ﬁbrillation
Patient features Antithrombotic therapy Class of recommendation
Age less than 60 y, no heart disease (lone AF) Aspirin (81 to 325 mg per day) or no therapy I
Age less than 60 y, heart disease but no risk factorsa Aspirin (81 to 325 mg per day) I
Age 60 to 74 y, no risk factorsa Aspirin (81 to 325 mg per day) I
Age 65 to 74 y with diabetes mellitus or CAD Oral anticoagulation (INR 2.0 to 3.0) I
Age 75 y or older, women Oral anticoagulation (INR 2.0 to 3.0) I
Age 75 y or older, men, no other risk factors Oral anticoagulation (INR 2.0 to 3.0) or aspirin
(81 to 325 mg per day)
I
Age 65 or older, heart failure Oral anticoagulation (INR 2.0 to 3.0) I
LV ejection fraction less than 35% or fractional
shortening less than 25%, and hypertension
Oral anticoagulation (INR 2.0 to 3.0) I
Rheumatic heart disease (mitral stenosis) Oral anticoagulation (INR 2.0 to 3.0) I
Prosthetic heart valves Oral anticoagulation (INR 2.0 to 3.0 or higher) I
Prior thromboembolism Oral anticoagulation (INR 2.0 to 3.0 or higher) I
Persistent atrial thrombus on TEE Oral anticoagulation (INR 2.0 to 3.0 or higher) IIa
AF indicates atrial ﬁbrillation; CAD, coronary artery disease; INR, international normalized ratio; TEE, transesophageal echocardiography.
aRisk factors for thromboembolism include heart failure (HF), left ventricular (LV) ejection fraction less than 35%, and history of hypertension.
Table 15 Randomized trials of antithrombotic therapy in patients with nonvalvular AF
Trials Reference Year published No. of patients interventions
Large published trials
Copenhagen Atrial Fibrillation, Aspirin,
Anticoagulation I (AFASAK I)
432 1989 1007 VKA, ASA, placebo
Copenhagen Atrial Fibrillation, Aspirin,
Anticoagulation II (AFASAK II)
439 1998 677 VKA, ASA, LDAþ ASA, LDA
Stroke Prevention in Atrial Fibrillation I (SPAF I) 57 1991 1330 VKA, ASA, placebo
Stroke Prevention in Atrial Fibrillation II (SPAF II) 440 1994 1100 VKA, ASA
Stroke Prevention in Atrial Fibrillation III (SPAF III) 402 1996 1044 VKA, LDAþ ASA
Boston Area Anticoagulation Trial for Atrial
Fibrillation (BAATAF)
428 1990 420 VKA, control
Canadian Atrial Fibrillation Anticoagulation (CAFA) 436 1991 378 VKA, placebo
Stroke Prevention in Nonrheumatic Atrial
Fibrillation (SPINAF)
437 1992 571 VKA, placebo
European Atrial Fibrillation Trial (EAFT) 403 1993 1007 VKA, ASA, placebo
Studio Italiano Fibrillazione Atriale (SIFA) 441 1997 916 VKA, indobufen
Minidose Warfarin in Nonrheumatic Atrial Fibrillation 442 1998 303 VKA, LDA
Prevention of Arterial Thromboembolism in
Atrial Fibrillation (PATAF)
443 1999 729 VKA, LDA, ASA
Stroke Prevention using an Oral Direct
Thrombin Inhibitor In Patients with Atrial
Fibrillation (SPORTIF-III)
477 2003 3407 DTI, VKA
Stroke Prevention using an Oral
Direct Thrombin Inhibitor
In Patients With Atrial Fibrillation (SPORTIF-V)
438 2005 3922 DTI, VKA
National Study for Prevention of Embolism in Atrial
Fibrillation (NASPEAF)
445 2004 1209 VKA, triﬂusal, VKAþ triﬂusal
Small or pilot trials
Harenberg et al. 446 1993 75 LMW heparin, control
Low-dose Aspirin, Stroke, Atrial Fibrillation (LASAF) 447 1996 285 ASA, placebo
Subgroups with AF in other trials
European Stroke Prevention Study II (ESPS II) 404 1997 429 ASA, dipyridamole, placebo
Adapted with permission from Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial ﬁbrillation:
a meta-analysis. Ann Intern Med 1999;131:492–501.420
AF, atrial ﬁbrillation; ASA, aspirin; DTI, direct thrombin inhibitor; LDA, low-dose aspirin; LMW, low-molecular-weight; VKA, vitamin K antagonist.
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patients. Maximum protection against ischemic stroke in AF
is probably achieved at an INR range of 2.0 to 3.0,456
whereas an INR range of 1.6 to 2.5 is associated with incom-
plete efﬁcacy, estimated at approximately 80% of that
achieved with higher-intensity anticoagulation.432,449 Two
randomized trials with a target INR of 1.4 to 2.8 (estimated
mean achieved INR 2.0 to 2.1) found the largest relative risk
reductions for ischemic stroke. A trial in which AF patients
with prior stroke or TIA were randomly assigned to target
INR ranges of 2.2 to 3.5 versus 1.5 to 2.1 found a greater
rate of major hemorrhage with the higher intensity.450 For
patients with nonvalvular AF, an INR of 1.6 to 3.0 is efﬁca-
cious and relatively safe. For primary prevention in most
AF patients under age 75 y and for secondary prevention,
an INR of 2.5 (target range 2.0 to 3.0) is recommended. A
target INR of 2.0 (target range 1.6 to 2.5) seems reasonable
for primary prevention in patients older than 75 y who are
considered at high risk of bleeding. In clinical trials, INRs
achieved during follow-up were more often below than
above the target range. Low-intensity anticoagulation
requires special efforts to minimize time spent below the
target range, during which stroke protection is sharply
reduced. The major bleeding rate for 5 randomized clinical
trials was 1.2% per year202 (Figure 11).
Despite anticoagulation of more elderly patients with AF,
rates of intracerebral hemorrhage are considerably lower
than in the past, typically between 0.1% and 0.6% in contem-
porary reports. This may reﬂect lower anticoagulation inten-
sity, more careful dose regulation, or better control of
hypertension.438,457 In 2 time-dependent INR analyses of
anticoagulation in elderly AF cohorts, intracranial bleeding
increased with INR values over 3.5 to 4.0, and there was
no increment with values between 2.0 and 3.0 compared
with lower INR levels.454,456 Pooled results of randomized
trials and a large cohort comparison, however, suggest a
doubling of intracranial hemorrhages with mean INR values
between 2.0 and 2.5.458 Other than dose intensity, advanced
age, and hypertension, factors associated with higher rates
of intracerebral hemorrhage during anticoagulant therapy
include associated cerebrovascular disease and possibly con-
comitant antiplatelet therapy, tobacco or alcohol consump-
tion, ethnicity, genotype, and certain vascular abnormalities
detected by brain imaging, such as amyloid angiopathy, leu-
koaraiosis, or microbleeds.457 No stratiﬁcation scheme for
prediction of intracerebral hemorrhage during anticoagulant
therapy has been prospectively evaluated.
8.1.4.2.2. Aspirin for antithrombotic therapy in patients
with atrial ﬁbrillation. Aspirin offers only modest protection
against stroke for patients with AF46,57,403,432,439,440,443,447,448
(Figure 12). Meta-analysis of 5 randomized trials showed a
stroke reduction of 19% (95% CI 2% to 34%).420 The effect
of aspirin on stroke in these trials was less consistent than
that of oral anticoagulation,420,459 but differences in
patient features may have inﬂuenced aspirin efﬁcacy. For
example, aspirin reduced stroke occurrence by 33% in
primary prevention studies (in which the stroke rate with
placebo averaged 5% per year) versus 11% for secondary pre-
vention trials (in which the stroke rate with placebo aver-
aged 14% per year).420 Aspirin may be more efﬁcacious for
AF patients with hypertension or diabetes459 and for
reduction of noncardioembolic versus cardioembolic
ischemic strokes in AF patients.200 Cardioembolic strokes
are, on average, more disabling than noncardioembolic
strokes.250 Aspirin appears to prevent nondisabling strokes
more than disabling strokes.420 Thus, the greater the risk
of disabling cardioembolic stroke in a population of patients
with AF, the less protection is afforded by aspirin.250
Additional information about event rates on aspirin or no
antithrombotic therapy can be extracted from contempor-
ary databases such as the ATRIA cohort of 13 428 ambulatory
patients with AF enrolled in the Kaiser Permanente Medical
Care Program in North Carolina during the period 1996
through 1999.262,456,458,461 In the 11 526 patients without
Figure 10 Adjusted odds ratios for ischemic stroke and intracra-
nial bleeding in relation to intensity of anticoagulation. Modiﬁed
with permission from Hylek EM, Singer DE. Risk factors for intracra-
nial hemorrhage in outpatients taking warfarin. Ann Intern Med
1994;120:897–902.451 Data from Ode´n A, Fahle´n M and Hart RG.
Optimal INR for prevention of stroke and death in atrial ﬁbrillation:
a critical appraisal. Thromb Res 2006;117:493–9.452
Figure 9 Effects on all stroke (ischemic and hemorrhagic) of thera-
pies for patients with atrial ﬁbrillation. Adjusted-dose warfarin
compared with placebo (six random trials). Adapted with permission
from Hart RG, Benavente O, McBride R, et al. Antithrombotic
therapy to prevent stroke in patients with atrial ﬁbrillation: a
meta-analysis. Ann Intern Med 1999;131:492–501.420 AFASAK indi-
cates Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation;
BAATAF, Boston Area Anticoagulation Trial for Atrial Fibrillation;
CAFA, Canadian Atrial Fibrillation Anticoagulation; CI, conﬁdence
interval; EAFT, European Atrial Fibrillation Trial; SPAF, Stroke
Prevention in Atrial Fibrillation; SPINAF, Stroke Prevention in
Nonrheumatic Atrial Fibrillation.
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apparent contraindications to anticoagulation,458 6320
patients were treated with warfarin. Among the 5089
patients not treated with warfarin, the absolute rate of
thromboembolism was 2.0% per year.461 There was a
history of stroke or TIA in only 4% of the patients not
treated with anticoagulation, making this mainly a primary
prevention cohort.458 During a mean follow-up of 2.2 y
(median 2.35 y), 249 thromboembolic events (231 ischemic
strokes and 18 systemic embolic events outside the central
nervous system) occurred among the patients who were
not anticoagulated (2.0% per year [95% CI 1.8% to 2.3%]).
From a nested case-control study of 294 patients, it was
estimated that about 45% were using aspirin. When those
from the larger cohort with contraindications to warfarin
(who were older and more often had prior stroke or TIA)
were included, the rate of thromboembolism was 2.5% per
year.
While the use of administrative and claims-based data
from a managed care organization may have been prone to
underdetection of stroke events, these rates were not very
different from those in other reported populations. By com-
parison, among 1853 patients without prior thromboembolic
events assigned to aspirin in the SPAF I, II, and III trials, the
rate of ischemic stroke was 2.7% per year.261 In the AFI
cohort of 2732 patients from 6 randomized trials (about
half from the SPAF trials), without prior stroke or TIA, the
Figure 11 Annual rates of major hemorrhage during anticoagulation in primary prevention trials involving patients with nonvalvular atrial
ﬁbrillation. The mean age of participants was 69 years. Major hemorrhage was variously deﬁned but typically involved bleeding severe enough
to require hospitalization, transfusion or surgical intervention, involved a critical anatomical site, or was permanently disabling or fatal. Data
adapted from Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial ﬁbrillation: a
meta-analysis. Ann Intern Med 1999;131:492–501.420 AFASAK indicates Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation; BAATAF,
Boston Area Anticoagulation Trial for Atrial Fibrillation; CAFA, Canadian Atrial Fibrillation Anticoagulation; SPAF, Stroke Prevention in
Atrial Fibrillation; SPINAF, Stroke Prevention in Nonrheumatic Atrial Fibrillation.
Figure 12 Effects on all stroke (ischemic and hemorrhagic) of therapies for patients with atrial ﬁbrillation: warfarin compared with aspirin
and aspirin compared with placebo. Modiﬁed with permission from Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to
prevent stroke in patients with atrial ﬁbrillation: a meta-analysis. Ann Intern Med 1999;131:492–501.420 AFASAK indicates Copenhagen Atrial
Fibrillation, Aspirin, Anticoagulation; CI, conﬁdence interval; EAFT, European Atrial Fibrillation Trial; ESPS, European Stroke Prevention
Study; LASAF, Low-dose Aspirin, Stroke, Atrial Fibrillation; UK-TIA, The United Kingdom transient ischaemic attack aspirin trial; PATAF,
Prevention of Arterial Thromboembolism in Atrial Fibrillation; SPAF, Stroke Prevention in Atrial Fibrillation; SPINAF, Stroke Prevention in
Nonrheumatic Atrial Fibrillation.
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rate of ischemic stroke was 2.1% per year with aspirin
therapy. Among 210 patients in the population-based Cardi-
ovascular Health Study (mean age 74 y) followed without
anticoagulation, the stroke rate was 2.6% per year.462
When stratiﬁed according to the CHADS2 stroke risk
scheme,426 patients in the ATRIA cohort with a single
stroke risk factor (32% of the cohort) who were not anticoa-
gulated had a rate of stroke and systemic embolism of 1.5%
per year (95% CI 1.2% to 1.9%).458 Of 670 patients treated
with aspirin in 6 clinical trials, the stroke rate was 2.2%
per year for those with a CHADS2 score of 1 (95% CI 1.6%
to 3.1% per year).463
In summary, adjusted-dose oral anticoagulation is more
efﬁcacious than aspirin for prevention of stroke in patients
with AF, as suggested by indirect comparisons and by a 33%
risk reduction (95% CI 13% to 49%) in a meta-analysis of 5
trials.420 Randomized trials involving high-risk AF patients
(stroke rates greater than 6% per year) show larger relative
risk reductions by adjusted-dose oral anticoagulation rela-
tive to aspirin (Figure 12), whereas the relative risk
reductions are consistently smaller in trials of AF patients
with lower stroke rates. Accordingly, oral anticoagulation
may be most beneﬁcial for AF patients at higher intrinsic
thromboembolic risk, offering only modest reductions over
aspirin in both the relative risk and absolute rates of
stroke for patients at low risk. Individual risk varies over
time, so the need for anticoagulation must be reevaluated
periodically in all patients with AF.
8.1.4.2.3. Other antiplatelet agents for antithrombotic
therapy in patients with atrial ﬁbrillation. Anticoagulation
with oral vitamin K antagonists has been compared with
platelet cyclooxygenase inhibitors other than aspirin in 2
trials involving 1395 participants. In the Italian Studio Italiano
Fibrillazione Atriale (SIFA) study,441 indobufen, 100 to 200 mg
twice daily, was compared with warfarin (INR 2.0 to 3.5) in
916 patients with recent cerebral ischemic events. Incidences
of the combined endpoint of nonfatal stroke, intracerebral
bleeding, pulmonary or systemic embolism, MI, and vascular
death were not signiﬁcantly different between treatment
groups, but more ischemic strokes occurred in the indobufen
group18 than in the warfarin group.10 In the primary preven-
tion cohort of the Spanish National Study for Prevention of
Embolism in Atrial Fibrillation (NASPEAF) trial,445 the rate
of the composite of thromboembolism plus cardiovascular
death was lower with acenocoumarol than with triﬂusal.
There was no signiﬁcant difference in rates of ischemic
stroke and systemic embolism. Neither indobufen nor trifusal
is widely available; these agents have not been compared
with aspirin for efﬁcacy and safety, nor do they offer advan-
tages over anticoagulation with a vitamin K antagonist in
patients with AF at high risk of thromboembolism.
In the Atrial Fibrillation Clopidogrel Trial with Irbesartan
for Prevention of Vascular Events (ACTIVE-W), which was
stopped on the recommendation of the Data Safety and
Monitoring Board before planned follow-up was completed,
the combination of the thienopyridine antiplatelet agent
clopidogrel (75 mg daily) plus aspirin (75 to 100 mg daily)
proved inferior to warfarin (target INR 2.0 to 3.0) in patients
with an average of 2 stroke risk factors in addition to
AF.464 Additional studies are ongoing to assess the impact
of this therapy for patients unable or unwilling to take
warfarin.
8.1.4.2.4. Combining anticoagulant and platelet-inhibitor
therapy. Combinations of oral anticoagulants plus antiplate-
let agents to reduce the risk of hemorrhage by allowing
lower intensities of anticoagulation or to augment efﬁcacy
for selected patients at particularly high risk of thromboem-
bolism, such as those with prior stroke, have been evaluated
in several trials. Such a strategy has been successful in redu-
cing the risk of thromboembolism in patients with mechan-
ical heart valves.465 Still another objective of combination
therapy is to enhance protection against ischemic cardiac
events in patients with AF who have established coronary
atherosclerosis or diabetes. In 2 trials, SPAF III and Copenha-
gen Atrial FIbrillation, Aspirin, and Anticoagulation (AFASAK)
2, the combination of low-dose oral anticoagulation (INR less
than 1.5) with aspirin added little protection against stroke
compared with aspirin alone in patients with AF.402,439
In 2 other trials, substantially higher intensities of anti-
coagulation combined with platelet inhibitor agents were
evaluated in patients with AF. The French Fluindione-
Aspirin Combination in High Risk Patients With AF (FFAACS)
study compared the oral anticoagulant ﬂuindione (target
INR 2.0 to 2.6) plus placebo or in combination with
aspirin, 100 mg daily, versus ﬂuindione alone in patients at
high risk of stroke. The trial was stopped with only 157
patients enrolled (mean follow-up 0.84 y) because of exces-
sive hemorrhage in the group receiving the combination
therapy.433
In the larger Spanish National Study for Primary Preven-
tion of Embolism in Nonrheumatic Atrial Fibrillation
(NASPEAF) study, patients were stratiﬁed into a high-risk
group (n ¼ 495) with AF and rheumatic mitral stenosis or
AF and a history of stroke, TIA, or systemic embolism, and
a lower-risk group (n ¼ 714) with AF and age greater than
60 y, hypertension, or HF.445 The higher-risk patients were
randomized to anticoagulation with acenocoumrarol
(target INR 2.0 to 3.0) or to acenocoumarol (INR 1.4 to
2.4) combined with the platelet cyclooxygenase inhibitor
triﬂusal (600 mg daily). The lower-risk patients were ran-
domized to triﬂusal alone, acenocoumarol alone (INR 2.0
to 3.0), or the combination of triﬂusal plus acenocoumarol
(INR 1.25 to 2.0). The achieved anticoagulation intensities
in the anticoagulation and combination therapy arms were
closer to one another than intended, however (mean INR
2.5 with acenocoumarol alone in both risk strata versus
1.96 and 2.18 for the combination arms in the lower- and
higher-risk groups during median follow-up of 2.6 and 2.9
y, respectively). The primary outcome was a composite of
thromboembolism plus cardiovascular death (sudden death
or death due to thromboembolism, stroke, bleeding, or HF
but not MI). Patients in both risk categories had a lower
risk of primary events with the combination therapy than
with acenocoumarol alone. These observations suggest
that a combination of platelet inhibitor and anticoagulant
therapy might be effective and relatively protective if tar-
geted INR levels are closer to the standard range, but the
superiority of combination therapy over monotherapy with
a vitamin K antagonist for prevention of ischemic stroke
and MI has not been convincingly established.
Combining aspirin with an oral anticoagulant at higher
intensities may accentuate intracranial hemorrhage, par-
ticularly in elderly AF patients.466 In a retrospective analysis
of 10 093 patients with AF after hospital discharge (mean
age 77 y), platelet inhibitor medication was associated
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with a higher rate of intracerebral hemorrhage (relative risk
3.0, 95% CI 1.6% to 5.5%),467 but 2 case-control studies
yielded conﬂicting results.454,468
The superior efﬁcacy of anticoagulation over aspirin for
prevention of recurrent stroke in patients with AF was
demonstrated in the European Atrial Fibrillation Trial.403
Therefore, unless a clear contraindication exists, AF
patients with a recent stroke or TIA should be treated with
long-term anticoagulation rather than antiplatelet therapy.
There is no evidence that combining anticoagulation with
an antiplatelet agent reduces the risk of stroke compared
with anticoagulant therapy alone. Hence, pending further
data for AF patients who sustain cardioembolic events
while receiving low-intensity anticoagulation, anticoagula-
tion intensity should be increased to a maximum target
INR of 3.0 to 3.5 rather than routinely adding antiplatelet
agents.
Several studies have evaluated anticoagulation in combi-
nation with aspirin for prevention of ischemic cardiac
events in patients with CAD. From these it may be possible
to draw inferences regarding management of antithrombotic
therapy in patients who have both CAD and AF. A meta-
analysis of 31 randomized trials of oral anticoagulant
therapy published between 1960 and 1999 involving patients
with CAD treated for at least 3 mo and stratiﬁed by the
intensities of anticoagulation and aspirin therapy came to
the following conclusions.469 High-intensity (INR 2.8 to 4.8)
and moderate-intensity (INR 2.0 to 3.0) oral anticoagulation
regimens reduced rates of MI and stroke but increased the
risk of bleeding 6.0- to 7.7-fold. Combining aspirin with
low-intensity anticoagulation (INR less than 2.0) was not
superior to aspirin alone. While the combination of mode-
rate- to high-intensity oral anticoagulation plus aspirin
appeared promising compared with aspirin alone, the
combination was associated with increased bleeding.
From the results of more contemporary trials involving
long-term treatment of patients with acute myocardial
ischemia470–473 and the Combined Hemotherapy and
Mortality Prevention Study (CHAMP),474 it appears that
high-intensity oral anticoagulation (INR 3.0 to 4.0) is more
effective than aspirin but increases the risk of bleeding.
The combination of aspirin and moderate-intensity warfarin
(INR 2.0 to 3.0) is more effective than aspirin alone but is
associated with a greater risk of bleeding. The combination
of aspirin and moderate-intensity warfarin (INR 2.0 to 3.0) is
as effective as high-intensity warfarin and associated with a
similar risk of bleeding. The contemporary trials, however,
have not addressed the effectiveness of moderate-intensity
warfarin (INR 2.0 to 3.0) alone. In the absence of direct
evidence, it cannot be assumed that moderate-intensity
warfarin is superior to aspirin in preventing death or rein-
farction. The choice for long-term management of patients
with CAD and AF therefore involves aspirin alone, aspirin
plus moderate-intensity warfarin (INR 2.0 to 3.0), or war-
farin alone (INR 2.0 to 3.0). For those with risk factors for
stroke, the latter 2 regimens are more effective than
aspirin alone but are associated with more bleeding and
inconvenience. Further, without close INR control, the com-
bination regimen may be associated with a greater risk of
bleeding. For most patients with AF who have stable CAD,
warfarin anticoagulation alone (target INR 2.0 to 3.0)
should provide satisfactory antithrombotic prophylaxis
against both cerebral and myocardial ischemic events.
The importance of platelet-inhibitor drugs for prevention
of recurrent myocardial ischemia is enhanced in patients
undergoing percutaneous coronary intervention, but no ade-
quate studies have been published that speciﬁcally address
this issue in patients who also require chronic anticoagula-
tion because of AF. It is the consensus of the authors of
these guidelines that the most important agent for the
maintenance of coronary and stent patency is the thienopyr-
idine derivative clopidogrel and that the addition of aspirin
to the chronic anticoagulant regimen contributes more risk
than beneﬁt. Although it is usually necessary to interrupt
or reduce anticoagulation to prevent bleeding at the site
of peripheral arterial puncture, the vitamin K antagonist
should be resumed as soon as possible after the procedure
and the dose adjusted to achieve an INR in the therapeutic
range. Aspirin may be given temporarily during the hiatus,
but the maintenance regimen should then consist of the
combination of clopidogrel, 75 mg daily, plus warfarin (INR
2.0 to 3.0) for 9 to 12 mo, following which warfarin may
be continued as monotherapy in the absence of a sub-
sequent coronary event.
8.1.4.2.5. Emerging and investigational antithrombotic
agents. While clearly efﬁcacious against stroke in patients
with AF, warfarin carries a substantial risk of hemorrhage,
a narrow therapeutic margin necessitating frequent moni-
toring of the INR level, and interactions with numerous
drugs and foods that may cause a need for dose adjust-
ments. These limitations result in undertreatment of a
considerable proportion of the AF population at risk,
particularly the elderly, for whom numerous concomitant
medications are typically prescribed,455,475 engendering a
quest for safer, more convenient alternatives.
Because of its central role in thrombogenesis, thrombin
(factor IIa) represents an attractive target for speciﬁc inhi-
bition. Direct thrombin inhibitors bind to the active site of
thrombin and prevent it from cleaving ﬁbrinogen to form
ﬁbrin. These compounds also suppress thrombin-mediated
activation of platelets and coagulation factors V, VIII, XI,
and XIII. Ximelagatran is administered orally and converted
after absorption to the active direct thrombin inhibitor mel-
agatran. The compound appears to have stable pharmacoki-
netics independent of the hepatic P450 enzyme system and a
low potential for food or drug interactions.476 Two long-term
phase III studies compared ximelagatran with warfarin in
patients with AF, SPORTIF (Stroke Prevention using an Oral
Thrombin Inhibitor in patients with atrial Fibrillation)-III
and -V, with a combined population of more than 7000.444
In these trials, ximelagatran was administered without
dose titration or coagulation monitoring and was compared
with warfarin (INR 2.0 to 3.0) for the primary endpoint of
all stroke (ischemic and hemorrhagic) and systemic
embolism.
SPORTIF-III involved an open-label design444 and careful
regulation of dosing among patients assigned to warfarin,
with INR values within the therapeutic range for 66% of
the duration of exposure. The relative risk reduction of
29% and absolute risk reduction of 0.7% per year according
to intention-to-treat conﬁrmed the noninferiority of ximela-
gatran to warfarin. By on-treatment analysis, the relative
risk reduction with ximelagatran was 41% (p ¼ 0.018).
There was no signiﬁcant difference between treatments in
rates of hemorrhagic stroke, fatal bleeding, or other major
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bleeding, but when minor hemorrhages are considered as
well, ximelagatran caused signiﬁcantly less bleeding
(25.5% vs. 29.5% per year, p ¼ 0.007).
The results of the SPORTIF-V trial, in which treatment was
administered in a double-blind manner, were similar to
those of SPORTIF-III.438 The primary event rates were 1.6%
per year with ximelagatran and 1.2% per year with warfarin
(absolute difference 0.45% per year, 95% CI 0.13% to 1.03%
per year, p less than 0.001 for the noninferiority hypothesis),
and there was no difference between treatment groups in
rates of major bleeding, but as in the SPORTIF-III study,
total bleeding (major plus minor) was lower with
ximelagatran.
In both the SPORTIF-III and V trials, serum alanine amino-
transferase levels rose to greater than 3 times the upper
limit of normal in about 6% of patients treated with ximela-
gatran. Hence, despite evidence of efﬁcacy comparable to
carefully adjusted warfarin and some advantage in terms
of bleeding risk, ximelagatran will not be marketed for clini-
cal use as an anticoagulant, mainly because of concerns
about hepatic toxicity.478 Trials of a variety of investiga-
tional oral anticoagulant compounds that directly inhibit
thrombin, antagonize factor Xa, or inactivate prothrombin
are ongoing or planned, but there are no currently available
alternatives to vitamin K antagonists.
8.1.4.2.6. Interruption of anticoagulation for diagnostic or
therapeutic procedures. From time to time, it may be
necessary to interrupt oral anticoagulant therapy in prep-
aration for elective surgical procedures. In patients with
mechanical prosthetic heart valves, it is generally appropriate
to substitute unfractionated or low-molecular-weight heparin
to prevent thrombosis.479,480 In patients with AF who do not
have mechanical valves, however, based on extrapolation
from the annual rate of thromboembolism in patients with
nonvalvular AF, it is the consensus of the Writing Committee
that anticoagulation may be interrupted for a period of up
to 1 wk for surgical or diagnostic procedures that carry a
risk of bleeding without substituting heparin. In high-risk
patients (particularly those with prior stroke, TIA, or systemic
embolism) or when a series of procedures requires interrup-
tion of oral anticoagulant therapy for longer periods, unfrac-
tionated or low-molecular-weight heparin may be
administered intravenously or subcutaneously.
The use of low-molecular-weight heparin instead of unfrac-
tionated heparin in patients with AF is based largely on extra-
polation from venous thromboembolic disease states and
from limited observational studies.481 In general, low-
molecular-weight heparins have several pharmacological
advantages over unfractionated heparin. These include a
longer half-life, more predictable bioavailability (greater
than 90% after subcutaneous injection), predictable clear-
ance (enabling once- or twice-daily subcutaneous adminis-
tration), and a predictable antithrombotic response based
on body weight, which permits ﬁxed-dose treatment
without laboratory monitoring except under special circum-
stances such as obesity, renal insufﬁciency, or pregnancy.482
Treatment with low-molecular-weight heparin is associated
with a lower risk of heparin-induced thrombocytopenia than
unfractionated heparin.483 The favorable properties of low-
molecular-weight heparins may simplify the treatment of AF
in acute situations and shorten or eliminate the need for hos-
pitalization to initiate anticoagulation. Self-administration of
low-molecular-weight heparins out of hospital by patients
with AF undergoing elective cardioversion is a promising
approach that may result in cost savings.484
8.1.4.3. Nonpharmacological approaches to prevention of
thromboembolism. An emerging option for patients with
AF who cannot safely undergo anticoagulation, which is
not yet sufﬁciently investigated to allow general clinical ap-
plication, is obliteration of the LAA to remove a principal
nidus of thrombus formation.485,486 In addition to direct
surgical amputation or truncation of appendage, several
methods are under development to achieve this with
intravascular catheters or transpericardial approaches.487
The efﬁcacy of these techniques is presumably related to
the completeness and permanence of elimination of blood
ﬂow into and out of the LAA. This has been demonstrated
by TEE at the time of intervention, but the durability of
the effect has not been conﬁrmed by subsequent examin-
ations over several years. Whether mechanical measures
intended to prevent embolism from thrombotic material in
the LAA will prove to be comparably effective and safer
than anticoagulation for some patients remains to be estab-
lished.488 These must presently be considered investiga-
tional, and indications for this type of intervention have
not been convincingly established.
8.1.5. Cardioversion of atrial ﬁbrillation
Recommendations
Recommendations for Pharmacological Cardioversion of
Atrial Fibrillation
Class I
Administration of ﬂecainide, dofetilide, propafenone, or
ibutilide is recommended for pharmacological cardioversion
of AF. (Level of Evidence: A)
Class IIa
(1) Administration of amiodarone is a reasonable option
for pharmacological cardioversion of AF. (Level of Evi-
dence: A)
(2) A single oral bolus dose of propafenone or ﬂecainide
(‘pill-in-the-pocket’) can be administered to terminate
persistent AF outside the hospital once treatment has
proved safe in hospital for selected patients without
sinus or AV node dysfunction, bundle-branch block, QT-
interval prolongation, the Brugada syndrome, or struc-
tural heart disease. Before antiarrhythmic medication
is initiated, a beta blocker or nondihydropyridine
calcium channel antagonist should be given to prevent
rapid AV conduction in the event atrial ﬂutter occurs.
(Level of Evidence: C)
(3) Administration of amiodarone can be beneﬁcial on an
outpatient basis in patients with paroxysmal or persist-
ent AF when rapid restoration of sinus rhythm is not
deemed necessary. (Level of Evidence: C)
Class IIb
Administration of quinidine or procainamide might be con-
sidered for pharmacological cardioversion of AF, but the use-
fulness of these agents is not well established. (Level of
Evidence: C)
Class III
(1) Digoxin and sotalol may be harmful when used for
pharmacological cardioversion of AF and are not rec-
ommended. (Level of Evidence: A)
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(2) Quinidine, procainamide, disopyramide, and dofetilide
should not be started out of hospital for conversion of
AF to sinus rhythm. (Level of Evidence: B)
8.1.5.1. Basis for cardioversion of atrial ﬁbrillation.
Cardioversion may be performed electively to restore sinus
rhythm in patients with persistent AF. The need for
cardioversion may be immediate when the arrhythmia is
the main factor responsible for acute HF, hypotension, or
worsening of angina pectoris in a patient with CAD.
Nevertheless, cardioversion carries a risk of
thromboembolism unless anticoagulation prophylaxis is
initiated before the procedure, and this risk is greatest
when the arrhythmia has been present for longer than 48 h.
8.1.5.2. Methods of cardioversion. Cardioversion may be
achieved by means of drugs or electrical shocks. Drugs
were commonly used before direct-current cardioversion
became a standard procedure. The development of new
drugs has increased the popularity of pharmacological
cardioversion, but the disadvantages include the risk of
drug-induced torsades de pointes or other serious arrhyth-
mias. Moreover, pharmacological cardioversion is less effec-
tive than direct-current cardioversion when biphasic shocks
are used. The disadvantage of electrical cardioversion is
that it requires conscious sedation or anesthesia, which
pharmacological cardioversion does not.
There is no evidence that the risk of thromboembolism or
stroke differs between pharmacological and electrical
methods of cardioversion. The recommendations for anticoa-
gulation are therefore the same for both methods, as outlined
in Section 8.1.4 (Preventing Thromboembolism). Cardiover-
sion in patients with AF following recent heart surgery or MI
is addressed later (see Section 8.4, Special Considerations).
8.1.5.3. Pharmacological cardioversion. The quality of evi-
dence available to gauge the effectiveness of pharmacologi-
cal cardioversion is limited by small samples, lack of
standard inclusion criteria (many studies include both
patients with AF and those with atrial ﬂutter), variable inter-
vals from drug administration to assessment of outcome, and
arbitrary dose selection. Although pharmacological and
direct-current cardioversion have not been compared
directly, pharmacological approaches appear simpler but
are less efﬁcacious. The major risk is related to the toxicity
of antiarrhythmic drugs. In developing these guidelines,
placebo-controlled trials of pharmacological cardioversion
in which drugs were administered over short periods of
time speciﬁcally to restore sinus rhythm have been empha-
sized. Trials in which the control group was given another
antiarrhythmic drug have, however, been considered as well.
Pharmacological cardioversion seems most effective
when initiated within 7 d after the onset of an episode
of AF.489–492 A majority of these patients have a ﬁrst-
documented episode of AF or an unknown pattern of AF at
the time of treatment. (See Section 3, Classiﬁcation.) A
large proportion of patients with recent-onset AF experi-
ence spontaneous cardioversion within 24 to 48 h.493–495
Spontaneous conversion is less frequent in patients with AF
of longer than 7-d duration, and the efﬁcacy of pharmaco-
logical cardioversion is markedly reduced in these patients
as well. Pharmacological cardioversion may accelerate res-
toration of sinus rhythm in patients with recent-onset AF,
but the advantage over placebo is modest after 24 to 48 h,
and drug therapy is much less effective in patients with per-
sistent AF. Some drugs have a delayed onset of action, and
conversion may not occur for several days after initiation
of treatment.496 Drug treatment abbreviated the interval
to cardioversion compared with placebo in some studies
without affecting the proportion of patients who remained
in sinus rhythm after 24 h.494 A potential interaction of anti-
arrhythmic drugs with vitamin K antagonist oral anticoagu-
lants, increasing or decreasing the anticoagulant effect, is
an issue whenever these drugs are added or withdrawn
from the treatment regimen. The problem is ampliﬁed
when anticoagulation is initiated in preparation for elective
cardioversion. Addition of an antiarrhythmic drug to
enhance the likelihood that sinus rhythm will be restored
and maintained may perturb the intensity of anticoagulation
beyond the intended therapeutic range, raising the risk of
bleeding or thromboembolic complications.
A summary of recommendations concerning the use of
pharmacological agents and recommended doses is pre-
sented in Tables 16–18. Algorithms for pharmacological
management of AF are given in Figures 13–16. Throughout
this document, reference is made to the Vaughan Williams
classiﬁcation of antiarrhythmic drugs,497 modiﬁed to
include drugs that became available after the original classi-
ﬁcation was developed (Table 19). Considerations speciﬁc to
individual agents are summarized below. Within each cat-
egory, drugs are listed alphabetically. The antiarrhythmic
drugs listed have been approved by federal regulatory
agencies in the United States and/or Europe for clinical
use, but their use for the treatment of AF has not been
approved in all cases. Furthermore, not all agents are
approved for use in all countries. The recommendations
given in this document are based on published data and do
not necessarily adhere to the regulations and labeling
requirements of government agencies.
8.1.5.4. Agents with proven efﬁcacy for cardioversion of
atrial ﬁbrillation
8.1.5.4.1. Amiodarone. Data on amiodarone are confusing
because the drug may be given intravenously or orally and
the effects vary with the route of administration. Five
meta-analyses of trials compared amiodarone to placebo
or other drugs for conversion of recent-onset AF.546–549
One concluded that intravenous amiodarone was no more
effective than placebo,550 while another found amiodarone
effective but associated with adverse reactions.546 Another
meta-analysis found amiodarone more effective than
placebo after 6 to 8 h and at 24 h but not at 1 to 2 h.547
Amiodarone was inferior to type IC drugs for up to 8 h, but
there was no difference at 24 h, indicating delayed conver-
sion with amiodarone. In another meta-analysis of 21 trials
involving heterogeneous populations, the relative likelihood
of achieving sinus rhythm over a 4-wk period with oral/intra-
venous amiodarone was 4.33 in patients with AF of longer
than 48-h duration and 1.40 in those with AF of less than
48-h duration.548 In a meta-analysis of 18 trials, the efﬁcacy
of amiodarone ranged from 34% to 69% with bolus (3 to
7 mg/kg body weight) regimens and 55% to 95% when the
bolus was followed by a continuous infusion (900 to
3000 mg daily).550 Predictors of successful conversion were
shorter duration of AF, smaller LA size, and higher amiodar-
one dose. Amiodarone was not superior to other anti-
arrhythmic drugs for conversion of recent-onset AF but
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was relatively safe in patients with structural heart disease,
including those with LV dysfunction for whom administration
of class IC drugs is contraindicated. In addition, limited
information suggests that amiodarone is equally effective
for conversion of AF or atrial ﬂutter. Because safety data
are limited, randomized trials are needed to determine
the beneﬁt of amiodarone for conversion of recent-onset
AF in speciﬁc patient populations.
In the SAFE-T trial involving 665 patients with persistent
AF, conversion occurred in 27% of patients after 28 d of
treatment with amiodarone, compared with 24% with
sotalol and 0.8% with placebo.292 Although the speed of
response may differ during sustained oral therapy, amiodar-
one, propafenone, and sotalol seemed equally effective in
converting persistent AF to sinus rhythm. Apart from intra-
venous drug therapy for conversion early after onset of AF
(within 24 h), antiarrhythmic drug agents may also be
given over a longer period of time in an effort to achieve
cardioversion after a longer period of AF. Under these
circumstances, administration of oral amiodarone is associ-
ated with a conversion rate between 15% and 40% over
28 d.292,529,533,551 In a comparative study, amiodarone and
propafenone were associated with similar rates (40%) of con-
verting persistent AF averaging 5 mo in duration.551 Remark-
ably, all cases in which conversion followed administration
of amiodarone occurred after 7 d, with responses continuing
to 28 d, whereas conversion occurred more rapidly with pro-
pafenone (between 1 and 14 d).
Adverse effects of amiodarone include bradycardia, hypo-
tension, visual disturbances, thyroid abnormalities, nausea,
and constipation after oral administration and phlebitis
after peripheral intravenous administration. Serious toxicity
has been reported, including death due to bradycardia
ending in cardiac arrest.496,504,516,527–534,537,551
8.1.5.4.2. Dofetilide. Oral dofetilide is more effective than
placebo for cardioversion of AF that has persisted longer
than 1 wk, but available studies have not further stratiﬁed
Table 17 Recommendations for pharmacological cardioversion of atrial ﬁbrillation present for more than 7 d
Druga Route of administration Recommendation
class
Level of
evidence
References
Agents with proven efﬁcacy
Dofetilide Oral I A 498–503
Amiodarone Oral or intravenous IIa A 496, 504, 516, 527–534
Ibutilide Intravenous IIa A 510–515
Less effective or incompletely
studied agents
Disopyramide Intravenous IIb B 544
Flecainide Oral IIb B 489–491, 493, 504–509
Procainamide Intravenous IIb C 510, 512, 536, 557
Propafenone Oral or intravenous IIb B 494, 495, 505, 509, 516–526
Quinidine Oral IIb B 489, 494, 524, 529, 537–539, 698
Should not be administered
Digoxin Oral or intravenous III B 375, 494, 505, 526, 530, 542
Sotalol Oral or intravenous III B 513, 538–540, 543
aThe doses of medications used in these studies may not be the same as those recommended by the manufacturers. Drugs are listed alphabetically within
each category by class and level of evidence.
Table 16 Recommendations for pharmacological cardioversion of atrial ﬁbrillation of up to 7-d duration
Druga Route of
administration
Class of
recommendation
Level of
evidence
References
Agents with proven efﬁcacy
Dofetilide Oral I A 498–503
Flecainide Oral or intravenous I A 489–491, 493, 504–509
Ibutilide Intravenous I A 510–515
Propafenone Oral or intravenous I A 491, 494, 495, 505, 509, 516–526, 557
Amiodarone Oral or intravenous IIa A 496, 504, 516, 527–534
Less effective or incompletely
studied agents
Disopyramide Intravenous IIb B 544
Procainamide Intravenous IIb B 510, 512, 536
Quinidine Oral IIb B 489, 494, 524, 529, 537–539, 698
Should not be administered
Digoxin Oral or intravenous III A 375, 494, 505, 526, 530, 542
Sotalol Oral or intravenous III A 513, 538–540, 543
aThe doses of medications used in these studies may not be the same as those recommended by the manufacturers. Drugs are listed alphabetically within
each category of recommendation and level of evidence.
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Table 18 Recommended doses of drugs proven effective for pharmacological cardioversion of atrial ﬁbrillation
Druga Route of
administration
Dosageb Potential adverse effects References
Amiodarone Oral Inpatient: 1.2 to 1.8 g per day in divided dose until 10 g total, then 200 to
400 mg per day maintenance or 30 mg/kg as single dose
Hypotension, bradycardia, QT
prolongation, torsades de pointes (rare),
GI upset, constipation, phlebitis (IV)
496, 504, 516, 527–534,
537, 545
Outpatient: 600 to 800 mg per day divided dose until 10 g total,
then 200 to 400 mg per day maintenance
Intravenous/oral 5 to 7 mg/kg over 30 to 60 min, then 1.2 to 1.8 g per day continuous IVor in
divided oral doses until 10 g total, then 200 to 400 mg per day
maintenance
Dofetilide Oral Creatinine Clearance (mL/min) Dose (mcg BID)
More than 60 500 QT prolongation, torsades de pointes;
adjust dose for renal function,
body size, and age
498–503
40 to 60 250
20 to 40 125
Less than 20 Contraindicated
Flecainide Oral 200 to 300 mgc Hypotension, atrial ﬂutter with high
ventricular rate
489–491, 493, 504, 505,
507–509Intravenous 1.5 to 3.0 mg/kg over 10 to 20 minc
Ibutilide Intravenous 1 mg over 10 min; repeat 1 mg when necessary QT prolongation, torsades de pointes 510–515
Propafenone Oral 600 mg Hypotension, atrial ﬂutter with high
ventricular rate
491, 494, 495, 505, 506,
509, 516–526, 557Intravenous 1.5 to 2.0 mg/kg over 10 to 20 minc
Quinidined Oral 0.75 to 1.5 g in divided doses over 6 to 12 h, usually with a
rate-slowing drug
QT prolongation, torsades de pointes,
GI upset, hypotension
489, 494, 524, 529,
537–539
AF indicates atrial ﬁbrillation; BID, twice a day; GI, gastrointestinal; IV, intravenous.
aDrugs are listed alphabetically.
bDosages given in the table may differ from those recommended by the manufacturers.
cInsufﬁcient data are available on which to base speciﬁc recommendations for the use of one loading regimen over another for patients with ischemic heart disease or impaired left ventricular function, and these drugs
should be used cautiously or not at all in such patients.
dThe use of quinidine loading to achieve pharmacological conversion of atrial ﬁbrillation is controversial, and safer methods are available with the alternative agents listed in the table. Quinidine should be used with
caution.
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patients on the basis of the duration of the arrhythmia.
Dofetilide appears more effective for cardioversion of
atrial ﬂutter than of AF. A response may take days or
weeks when the drug is given orally. The intravenous form
is investigational.498–502
8.1.5.4.3. Flecainide. Flecainide administered orally or
intravenously was effective for cardioversion of recent-
onset AF in placebo-controlled trials. In 7 studies, the
success of a single oral loading dose (300 mg) for cardiover-
sion of recent-onset AF ranged from 57% to 68% at 2 to 4 h
and 75% to 91% at 8 h after drug administration.552 Single
oral loading and intravenous loading regimens of ﬂecainide
were equally efﬁcacious, but a response usually occurs
within 3 h after oral administration and 1 h after intravenous
administration. Arrhythmias, including atrial ﬂutter with
rapid ventricular rates and bradycardia after conversion,
are relatively frequent adverse effects. Transient hypoten-
sion and mild neurological side effects may also occur.
Overall, adverse reactions are slightly more frequent with
ﬂecainide than with propafenone, and these drugs should
be avoided in patients with underlying organic heart
disease involving abnormal ventricular function.489–
491,493,504,505,507–509
8.1.5.4.4. Ibutilide. In placebo-controlled trials, intrave-
nous ibutilide has proved effective for cardioversion within
a few weeks after onset of AF. Available data are insufﬁcient
to establish its efﬁcacy for conversion of persistent AF of
longer duration. Ibutilide may be used in patients who fail
to convert following treatment with propafenone553 or in
those in whom the arrhythmia recurs during treatment
with propafenone or ﬂecainide.554 The risk of torsades de
pointes was about 1% in these studies, lower than the
approximate 4% incidence observed during ibutilide mono-
therapy.555 Presumably, this is related to the protective
effect of sodium channel blockade with type IC drugs.554 Ibu-
tilide is more effective for conversion of atrial ﬂutter than of
AF. An effect may be expected within 1 h after adminis-
tration. In clinical practice, there is a 4% risk of torsades
de pointes ventricular tachycardia and appropriate resusci-
tation equipment must therefore be immediately available.
Women are more susceptible than men to this complication
(5.6% vs. 3% in a meta-analysis).555 Ibutilide should be
avoided in patients with very low ejection fractions or HF
because of the higher risk of ventricular proarrhythmia.556
Serum concentrations of potassium and magnesium should
be measured before administration of ibutilide, and patients
should be monitored for at least 4 h afterward. Hypotension
is an infrequent adverse response.510–515
8.1.5.4.5. Propafenone. Placebo-controlled trials have veri-
ﬁed that propafenone, given orally or intravenously, is effec-
tive for pharmacological cardioversion of recent-onset AF.
The effect occurs between 2 and 6 h after oral adminis-
tration and earlier after intravenous injection, so that
when compared with the intravenous regimen, oral propafe-
none resulted in fewer conversions in the ﬁrst 2 h. In 12
placebo-controlled trials, the success rate of oral propafe-
none (600 mg) for cardioversion of recent-onset AF ranged
from 56% to 83%.557 Oral propafenone was as efﬁcacious as
ﬂecainide but superior to oral amiodarone and quinidine
plus digoxin.494,558 Limited data suggest reduced efﬁcacy
in patients with persistent AF, in conversion of atrial
ﬂutter, and in patients with structural heart disease.
Adverse effects are uncommon but include rapid atrial
ﬂutter, ventricular tachycardia, intraventricular conduction
disturbances, hypotension, and bradycardia at conversion.
Available data on the use of various regimens of propafe-
none loading in patients with organic heart disease are
scant. This agent should be used cautiously or not at all
for conversion of AF in such cases and should be avoided
in patients with HF or severe obstructive lung
disease.491,495,505,506,509,516–526,557
8.1.5.5. Less effective or incompletely studied agents for
cardioversion of atrial ﬁbrillation
8.1.5.5.1. Quinidine. Quinidine is used less frequently than
other pharmacological agents, due to the perception that it
is less efﬁcacious and has more frequent side effects, although
direct comparative studies are lacking. Quinidine is usually
administered after digoxin or verapamil has been given to
control the ventricular response rate. Potential adverse
effects include QT-interval prolongation that may precede
torsades de pointes, nausea, diarrhea, fever, hepatic
Figure 14 Pharmacological management of patients with recur-
rent paroxysmal atrial ﬁbrillation (AF). See Figure 15. AAD indi-
cates antiarrhythmic drug.
Figure 13 Pharmacological management of patients with newly
discovered atrial ﬁbrillation (AF). See Figure 15. HF indicates
heart failure.
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dysfunction, thrombocytopenia, and hemolytic anemia.
During the initiation of quinidine therapy, hypotension and
acceleration of the ventricular response to AF may occur on
a vagolytic basis. A clinical response may be expected 2 to
6 h after administration.489,491,494,524,529,537–539,545
8.1.5.5.2. Procainamide. Intravenous procainamide has
been used extensively for conversion within 24 h of onset
of AF, and several studies suggest that it may be superior
to placebo.510,512,536 Procainamide appears less useful than
some other drugs and has not been tested adequately in
Figure 15 Antiarrhythmic drug therapy to maintain sinus rhythm in patients with recurrent paroxysmal or persistent atrial ﬁbrillation.
Within each box, drugs are listed alphabetically and not in order of suggested use. The vertical ﬂow indicates order of preference under
each condition. The seriousness of heart disease proceeds from left to right, and selection of therapy in patients with multiple conditions
depends on the most serious condition present. See Section 8.3.3.3 for details. LVH indicates left ventricular hypertrophy.
Figure 16 Pharmacological management of patients with recurrent persistent or permanent atrial ﬁbrillation (AF). Initiate drug therapy
before cardioversion to reduce the likelihood of early recurrence of AF. See Figure 15. AAD indicates antiarrhythmic drug.
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patients with persistent AF. Hypotension is the major
adverse effect after intravenous administration.
8.1.5.5.3. Beta blockers. When given intravenously, the
short-acting beta blocker esmolol may have modest efﬁcacy
for pharmacological cardioversion of recent-onset AF, but
this has not been established by comparison with placebo.
Conversion is probably mediated through slowing of the ven-
tricular rate. It is not useful in patients with persistent AF,
and there are no data comparing its relative efﬁcacy for
atrial ﬂutter and AF. A response may be expected within
1 h after initiation of intravenous infusion. Hypotension
and bronchospasm are the major adverse effects of
esmolol and other beta blockers.492,559
8.1.5.5.4. Nondihydropyridine calcium channel antagonists
(verapamil and diltiazem). The nondihydropyridine calcium
channel antagonists verapamil and diltiazem have not
been found effective for pharmacological cardioversion of
recent-onset or persistent AF, but they act rapidly to
control the rate of ventricular response.373,491,492,532 The
negative inotropic effects of nondihydropine calcium
channel blockers might result in hypotension; caution
should be used in patients with HF.
8.1.5.5.5. Digoxin. Digitalis glycosides are generally not
more effective than placebo for conversion of recent-onset
AF to sinus rhythm. Digoxin may prolong the duration of epi-
sodes of paroxysmal AF in some patients,375 and it has not
been evaluated adequately in patients with persistent AF
except to achieve rate control. Digoxin has few adverse
effects after acute administration in therapeutic doses,
aside from AV block and increased ventricular ectopy, but
all manifestations of digitalis toxicity are dose
related.375,378,494,505,526,530,540,542
8.1.5.5.6. Disopyramide. Disopyramide has not been tested
adequately for conversion of AF but may be effective when
administered intravenously. Adverse effects include dryness
of mucous membranes, especially in the mouth, consti-
pation, urinary retention, and depression of LV contractility.
The last reaction makes it a relatively unattractive option
for pharmacological conversion of AF.
8.1.5.5.7. Sotalol. In contrast to its relative efﬁcacy for
maintenance of sinus rhythm, sotalol has no proved efﬁcacy
for pharmacological cardioversion of recent-onset or persist-
ent AF when given either orally or intravenously. It does,
however, control the heart rate.513,538–540,543 In patients
who tolerate AF relatively well, a wait-and-see approach
using oral sotalol is an appropriate option. Side effects
consist mainly of QT prolongation associated with torsades
de pointes.
8.1.6. Pharmacological agents to maintain sinus rhythm
8.1.6.1. Agents with proven efﬁcacy to maintain sinus
rhythm. Thirty-six controlled trials evaluating 7 anti-
arrhythmic drugs for the maintenance of sinus rhythm in
patients with paroxysmal or persistent AF, 14 controlled
trials of drug prophylaxis involving patients with paroxysmal
AF, and 22 trials of drug prophylaxis for maintenance of
sinus rhythm in patients with persistent AF were identiﬁed.
Comparative data are not sufﬁcient to permit subclassiﬁca-
tion by drug or etiology. Individual drugs, listed alphabeti-
cally, are described below, and doses for maintenance of
sinus rhythm are given in Table 20. It should be noted that
any membrane-active agent may cause proarrhythmia.
8.1.6.1.1. Amiodarone. Available evidence suggests that
amiodarone is more effective than either class I drugs,
sotalol, or placebo in the long-term maintenance of sinus
rhythm in patients with paroxysmal or persistent AF refrac-
tory to other drugs.560–574 However, amiodarone is associ-
ated with a relatively high incidence of potentially severe
extracardiac toxic effects, making it a second-line or last-
resort agent in many cases. The use of low-dose amiodarone
(200 mg daily or less) may be effective and associated with
fewer side effects537,561,565,566 than higher-dose regimens.
In patients with LVH, HF, CAD, and/or previous MI, amiodar-
one is associated with a low risk of proarrhythmia, making it
an appropriate initial choice to prevent recurrent AF in
these situations. Use of amiodarone for AF is associated
with the added beneﬁt of effective rate control, frequently
eliminating the need for other drugs to control the ventricu-
lar rate.
A majority of the 403 patients in the CTAF study561 had
ﬁrst-time paroxysmal (46%) or persistent (54%) AF of less
than 6-mo duration. AF was considered persistent when
more than half the previous episodes had required cardio-
version, implying that many of the cases designated as
persistent AF actually had spontaneously terminating parox-
ysmal AF. Amiodarone maintained sinus rhythm more
successfully than propafenone or sotalol (69% vs. 39%) over
a 16-mo follow-up period. The reduced recurrence of AF
was associated with improved quality of life, fewer AF-
related procedures, and lower cost.347 Nevertheless, 18%
of patients stopped amiodarone because of side effects
after a mean of 468 d, compared with 11% of patients
assigned to sotalol or propafenone.
Table 19 Vaughan Williams classiﬁcation of antiarrhythmic
drugs
Type IA
Disopyramide
Procainamide
Quinidine
Type IB
Lidocaine
Mexiletine
Type IC
Flecainide
Propafenone
Type II
Beta blockers (e.g., propranolol)
Type III
Amiodarone
Bretylium
Dofetilide
Ibutilide
Sotalol
Type IV
Nondihydropyridine calcium channel antagonists (verapamil
and diltiazem)
Table includes compounds introduced after publication of the original
classiﬁcation.
Modiﬁed with permission from Vaughan Williams EM. A classiﬁcation of
antiarrhythmic actions reassessed after a decade of new drugs. J Clin
Pharmacol 1984;24:129–47.497 & 1984 by Sage Publications Inc.
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Of 222 patients randomized to either amiodarone or class I
agents in the AFFIRM study, 62% treated with amiodarone
remained in sinus rhythm at 1 y compared with 23% on
class I agents. In 256 patients randomized between amiodar-
one and sotalol, 60% versus 38% sustained sinus rhythm.570 In
patients with paroxysmal AF, amiodarone was more effective
than propafenone575 and sotalol,562 but this advantage was
offset by a higher incidence of side effects.562 In patients
who develop recurrent AF during long-term therapy with
oral amiodarone, intravenous amiodarone exerted an
additional therapeutic effect to terminate recurrences.576
Amiodarone increases the success rate of electric cardio-
version and prevents relapses by suppressing atrial ectopy in
patients with persistent AF.577–579
Experimentally, amiodarone, but not dofetilide or ﬂecai-
nide, reverses pacing-induced atrial remodeling and inhibits
the inducibility and stability of AF.580 To date, only a few
randomized studies have been performed with amiodarone
after cardioversion in patients with persistent AF. Amiodar-
one was tested as a ﬁrst-line agent in a study of patients
postcardioversion537 stratiﬁed according to age, duration
of AF, mitral valve disease, and cardiac surgery. After 6
mo, amiodarone was more effective (83% of patients
remaining in sinus rhythm) than quinidine (43%). Amiodar-
one was associated with fewer side effects than quinidine
over 6 mo, but side effects often occur after more prolonged
treatment with amiodarone. In a crossover study of 32
patients who had persistent AF for more than 3 wk random-
ized to amiodarone or quinidine537 when pharmacological
conversion did not occur with quinidine (direct-current car-
dioversion was not used), amiodarone was better tolerated
and far more effective in achieving restoration and long-
term maintenance of sinus rhythm. After 9 mo, 18 of 27
(67%) amiodarone-treated patients were in sinus rhythm
versus 2 of 17 (12%) taking quinidine.
The double-blind, placebo-controlled SAFE-T trial292
involved 665 patients with persistent AF, of whom 267
received amiodarone, 261 received sotalol, and 137
received placebo. After a run-in period of 28 d allowing
for a full antiarrhythmic effect, spontaneous conversion
occurred in 27% of those given amiodarone, 24% on sotalol,
and 0.8% on placebo. Among patients who did not
experience conversion pharmacologically, direct-current
shocks subsequently failed in 28%, 26.5%, and 32% of
patients in the 3 treatment groups, respectively. This indi-
cates that sotalol and amiodarone, when given on a
chronic basis, are equally effective in converting persistent
AF to sinus rhythm (see Section 8.1.5.4, Agents With Proven
Efﬁcacy for Cardioversion of Atrial Fibrillation). The median
times to recurrence of AF were signiﬁcantly longer with
amiodarone (487 d) than with sotalol (74 d) or placebo (6
d). In patients with ischemic heart disease, the median
time to AF recurrence did not differ between amiodarone
(569 d) and sotalol (428 d). There were no signiﬁcant differ-
ences in major adverse events, but the duration of amiodar-
one therapy may have been insufﬁcient to expose toxicity.
Although amiodarone is more effective than sotalol,
sotalol was equally effective in patients with CAD, for
whom it is preferred because of lower toxicity.
One uncontrolled study involved 89 patients with persist-
ent AF in whom previous treatments had failed; actuarially,
53% were in sinus rhythm after 3 y of amiodarone therapy.566
In another study563 of 110 patients with refractory AF (57
with paroxysmal AF) or atrial ﬂutter in whom a median of
2 class I agents had failed, amiodarone (268 plus or minus
100 mg daily) was associated with recurrence in 9% of
patients with persistent AF and 40% of those with
paroxysmal AF over 5 y. Several other uncontrolled studies
also support the use of amiodarone as an agent of last
resort.564,568,581,582 In one, a dose of 200 mg daily appeared
effective in patients for whom cardioversion had failed;
52% underwent repeated cardioversion with success for
12 mo.531
8.1.6.1.2. Beta blockers. Beta blockers are generally not
considered primary therapy for maintenance of sinus
rhythm in patients with AF and structural heart disease.
Various beta blockers have shown moderate but consistent
efﬁcacy to prevent AF recurrence or reduce the frequency
of paroxysmal AF, comparable to conventional anti-
arrhythmic drugs.583–586 One placebo-controlled study583 of
394 patients with persistent AF found a lower risk of early
recurrence after cardioversion and slower ventricular
response with sustained-release metoprolol than
Table 20 Typical doses of drugs used to maintain sinus rhythm in patients with atrial ﬁbrillationa
Drugb Daily Dosage Potential Adverse Effects
Amiodaronec 100 to 400 mg Photosensitivity, pulmonary toxicity, polyneuropathy, GI upset,
bradycardia, torsades de pointes (rare), hepatic toxicity, thyroid
dysfunction, eye complications
Disopyramide 400 to 750 mg Torsades de pointes, HF, glaucoma, urinary retention, dry mouth
Dofetilided 500 to 1000 mcg Torsades de pointes
Flecainide 200 to 300 mg Ventricular tachycardia, HF, conversion to atrial ﬂutter with
rapid conduction through the AV node
Propafenone 450 to 900 mg Ventricular tachycardia, HF, conversion to atrial ﬂutter with
rapid conduction through the AV node
Sotalold 160 to 320 mg Torsades de pointes, HF, bradycardia, exacerbation of chronic
obstructive or bronchospastic lung disease
AF indicates atrial ﬁbrillation; AV, atrioventricular; GI, gastrointestinal; HF, heart failure.
aDrugs and doses given here have been determined by consensus on the basis of published studies.
bDrugs are listed alphabetically.
cA loading dose of 600 mg per day is usually given for one month or 1000 mg per day for 1 week.
dDose should be adjusted for renal function and QT-interval response during in-hospital initiation phase.
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placebo.583 Two studies found atenolol587 and bisoprolol584
as effective as sotalol and better than placebo in reducing
the frequency and duration of paroxysmal AF and in redu-
cing the probability of relapse after cardioversion, but
proarrhythmic events occurred more often during treatment
with sotalol. In patients with persistent AF, carvedilol and
bisoprolol initiated after cardioversion produced similar
reductions in relapse over the course of 1 y.585 These
results conﬁrm a previous observational study in which
beta blockers reduced the risk of developing AF during an
average follow-up of 3.2 y.25 Beta blockers have the advan-
tage of controlling the ventricular rate when AF recurs and
reduce or abolish associated symptoms, but unawareness
of recurrent AF may have disadvantages. These agents
may be effective in postoperative patients but potentially
aggravate vagally mediated AF.
8.1.6.1.3. Dofetilide. Two large-scale, double-blind, ran-
domized studies support the efﬁcacy of dofetilide for pre-
vention of AF or atrial ﬂutter.503 Results from the
Symptomatic Atrial Fibrillation Investigative Research on
Dofetilide (SAFIRE-D) study found dofetilide associated
with conversion to sinus rhythm,503 most (87%) within 30 h
after treatment was initiated. In SAFIRE-D,503 dofetilide
(500 mcg daily) exhibited 58% efﬁcacy in maintaining sinus
rhythm 1 y after cardioversion compared with only 25% in
the placebo group. In the Distensibility Improvement And
Remodeling in Diastolic Heart Failure (DIAMOND)588 study
of patients with compromised LV function, sinus rhythm
was maintained in 79% of the dofetilide group compared
with 42% of the placebo group. The incidence of torsades
de pointes was 0.8%. Four of 5 such events occurred in the
ﬁrst 3 d. To reduce the risk of early proarrhythmia, dofeti-
lide must be initiated in the hospital at a dose titrated to
renal function and the QT interval.
8.1.6.1.4. Disopyramide. Several small, randomized studies
support the efﬁcacy of disopyramide to prevent recurrent AF
after direct-current cardioversion. One study comparing
propafenone and disopyramide showed equal efﬁcacy, but
propafenone was better tolerated.589 Treatment with diso-
pyramide for more than 3 mo after cardioversion was associ-
ated with an excellent long-term outcome in an
uncontrolled study: 98 of 106 patients were free of recur-
rent AF, and 67% remained in sinus rhythm after a mean of
6.7 y. Although the duration of AF was more than 12 mo in
most patients, few had signiﬁcant underlying cardiac
disease other than previously treated thyrotoxicosis. It is
not clear, therefore, whether disopyramide was the critical
factor in suppressing AF.544 Disopyramide has negative ino-
tropic and negative dromotropic effects that may cause HF
or AV block.544,589–592 Disopyramide may be considered
ﬁrst-line therapy in vagally induced AF, and its negative ino-
tropic effects may be desirable in patients with HCM associ-
ated with dynamic outﬂow tract obstruction.593
8.1.6.1.5. Flecainide. Two placebo-controlled studies594,595
found ﬂecainide effective in postponing the ﬁrst recurrence
of AF and the overall time spent in AF; and in other random-
ized studies596,597 efﬁcacy was comparable to quinidine with
fewer side effects. Several uncontrolled studies598–600 found
that ﬂecainide delayed recurrence. Severe ventricular
proarrhythmia or sudden death was not observed at a
mean dose of 199 mg daily among patients with little or no
structural heart disease. Side effects in 5 patients (9%)
were predominantly related to negative dromotropism,
with or without syncope. Flecainide (200 mg daily) was
superior to long-acting quinidine (1100 mg daily) in prevent-
ing recurrent AF after cardioversion and associated with
fewer side effects, but one patient died a month after
entry, presumably due to proarrhythmia.600
8.1.6.1.6. Propafenone. The United Kingdom Paroxysmal
Supraventricular Tachycardia (UK PSVT) study was a large,
randomized, placebo-controlled trial of propafenone in
which transtelephonic monitoring was used to detect
relapses to AF.601 The primary endpoint was time to ﬁrst
recurrence or adverse event. A dose of 300 mg twice daily
was effective and 300 mg 3 times daily even more effective,
but the higher dose was associated with more frequent side
effects. In a small, placebo-controlled study,602 propafe-
none, compared with placebo, reduced days in AF from 51%
to 27%. Propafenone was more effective than quinidine in
another randomized comparison.603 In an open-label random-
ized study involving 100 patients with AF (with balanced pro-
portions of paroxysmal and persistent AF), propafenone and
sotalol were equally effective in maintaining sinus rhythm
(30% vs. 37% of patients in sinus rhythm at 12 mo, respect-
ively).604 The pattern of AF (paroxysmal or persistent), LA
size, and previous response to drug therapy did not predict
efﬁcacy, but statistical power for this secondary analysis
was limited. Other uncontrolled studies, usually involving
selected patients refractory to other antiarrhythmic drugs,
also support the efﬁcacy of propafenone.605–609
In a randomized study, propafenone and disopyramide
appeared equally effective in preventing postcardioversion
AF, but propafenone was better tolerated.589 A few observa-
tional studies involving mixed cohorts of patients with par-
oxysmal and persistent AF found propafenone effective in
terms of maintenance of sinus rhythm and reduction of
arrhythmia-related complaints.608
In 2 placebo-controlled studies on patients with sympto-
matic AF,610,611 a sustained-release formulation of propafe-
none (225, 325, and 425 mg twice daily) delayed the ﬁrst
symptomatic recurrence and reduced the ventricular rate
at the time of relapse.
Like other highly effective class IC drugs, propafenone
should not be used in patients with ischemic heart disease
or LV dysfunction due to the high risk for proarrhythmic
effects. Close follow-up is necessary to avoid adverse
effects due to the development of ischemia or HF.
8.1.6.1.7. Sotalol. Sotalol is not effective for conversion of AF
to sinus rhythm, but itmay be used to prevent AF. Twoplacebo-
controlled studies612,613 involving patients in sinus rhythm and
at least one documented prior episode of AF found sotalol safe
and effective at doses ranging from 80 to 160 mg twice daily.
Patients considered at risk of proarrhythmia, HF, or AV conduc-
tion disturbances were excluded; whether any of the partici-
pants had undergone previous direct-current cardioversion
was not reported.561,612 The effects of the reverse use depen-
dence of sotalol and proarrhythmic risk may be greater after
conversion to slower rates in sinus rhythm than during AF
with a rapid ventricular response.
In another study,604 sotalol and propafenone seemed
equally effective for maintenance of sinus rhythm in patients
with AF. In the CTAF study, sotalol and propafenone (given
separately) were less effective than amiodarone as assessed
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by the number of patients without documented recurrence of
AF. The difference between outcomes with these drugs was
less marked when the number of patients continuing treat-
ment without side effects was considered. In an uncontrolled
study of a stepped-care approach beginning with propafe-
none and, after failure, then sotalol, paroxysmal AF occurred
in nearly 50% of patients, but only 27% of those with persist-
ent AF converted to sinus rhythm at 6 mo.609
Sotalol was as effective as and better tolerated than slow-
release quinidine sulfate for preventing recurrent AF in a mul-
ticenter study.614 Moreover, sotalol was more effective in sup-
pressing symptoms in patients who relapsed into AF, probably
because it induced a slower ventricular rate. In patients with
recurrent AF, propafenone was as effective as sotalol in main-
taining sinus rhythm 1 y after cardioversion. Recurrences
occurred later and were less symptomatic with either drug
than with placebo.615 Several studies found sotalol and the
combination of quinidine and verapamil equally effective
after cardioversion of AF, although ventricular arrhythmias
(including torsades de pointes)weremore frequentwith quini-
dine.538,615 Sotalol should be avoided in patients with asthma,
HF, renal insufﬁciency, or QT interval prolongation.
8.1.6.2. Drugs with unproven efﬁcacy or no longer
recommended
8.1.6.2.1. Digoxin. Available evidence does not support a
role for digitalis in suppressing recurrent AF in most
patients. The lack of an AV blocking effect during sympath-
etic stimulation results in poor rate control with digoxin,
and hence it does not usually reduce symptoms associated
with recurrent paroxysmal AF.30
8.1.6.2.2. Procainamide. No adequate studies of procaina-
mide are available. Long-term treatment is frequently
associated with development of antinuclear antibodies and
is occasionally associated with arthralgia or agranulocytosis.
8.1.6.2.3. Quinidine. Quinidine has not been evaluated
extensively in patients with paroxysmal AF but appears
approximately as effective as class IC drugs.596,597,616 In
one study,603 quinidine was less effective than propafenone
(22% of patients free from AF with quinidine vs. 50% with
propafenone). Side effects are more prominent than with
other antiarrhythmic drugs, and proarrhythmia is a particu-
lar concern. A meta-analysis of 6 trials found quinidine
superior to no treatment to maintain sinus rhythm after car-
dioversion of AF (50% vs. 25% of patients, respectively, over
1 y). However, total mortality was signiﬁcantly higher among
patients given quinidine (12 of 413 patients; 2.9%) than
among those not given quinidine (3 of 387 patients;
0.8%).609 In a registry analysis,616 6 of 570 patients less
than 65 y old died shortly after restoration of sinus rhythm
while taking quinidine. Up to 30% of patients taking quini-
dine experience intolerable side effects, most commonly
diarrhea. Other investigators614 found sotalol and quinidine
equally effective for maintaining sinus rhythm after direct-
current cardioversion of AF. Sotalol, but not quinidine,
reduced heart rate in patients with recurrent AF, and
there were fewer symptoms with sotalol.535,592,614,617–624
In 2 European multicenter studies, the combination of qui-
nidine plus verapamil was as effective as or superior to
sotalol in preventing recurrences of paroxysmal and persist-
ent AF. In the Suppression Of Paroxysmal Atrial Tachyarrhyth-
mias (SOPAT) trial,625 1033 patients (mean age 60 y, 62%
male) with frequent episodes of symptomatic paroxysmal
AF either received high-dose quinidine (480 mg per day)
plus verapamil (240 mg per day; 263 patients), low-dose qui-
nidine (320 mg per day) plus verapamil (160 mg per day; 255
patients), sotalol (320 mg per day; 264 patients), or placebo
(251 patients). Each of the active treatments was statisti-
cally superior to placebo and not different from one
another with respect to time to ﬁrst recurrence or drug dis-
continuation. The symptomatic AF burden also improved
(3.4%, 4.5%, 2.9%, and 6.1% of days for each treatment
group, respectively). Four deaths, 13 episodes of syncope,
and 1 episode of ventricular tachycardia were documented,
with 1 death and occurrence of VT related to quinidine plus
verapamil. Sotalol and the quinidine-verapamil combination
were associated with more severe side effects.
The Prevention of Atrial Fibrillation After Cardioversion
(PAFAC) trial287 compared the efﬁcacy and safety of the
combination of quinidine plus verapamil (377 patients),
sotalol (383 patients), and placebo (88 patients) in patients
with persistent AF or following direct-current cardioversion,
with daily transtelephonic monitoring for detection of recur-
rent AF. AF recurrence or death occurred in 572 patients
(67%), and AF recurrence became persistent in 348 (41%).
Over 1 y, recurrence rates were 83% with placebo, 67%
with sotalol, and 65% with the combination of quinidine
plus verapamil, the last mentioned statistically superior to
placebo but not different from sotalol. Persistent AF
occurred in 77%, 49%, and 38%, respectively, with the quini-
dine-verapamil combination superior to placebo and to
sotalol. About 70% of AF recurrences were asymptomatic.
Adverse events were comparable on sotalol and quinidine/
verapamil, except that torsades de pointes was conﬁned
to the sotalol group. Therefore, the combination of quini-
dine plus verapamil appeared useful to prevent recurrent
AF after cardioversion of persistent AF.
8.1.6.2.4. Verapamil and diltiazem. There is no evidence to
support the antiarrhythmic efﬁcacy of calcium channel
antagonist drugs in patients with paroxysmal AF, but they
reduce heart rate during an attack such that symptoms
may disappear despite recurrent AF. In one study, diltiazem
reduced the number of AF episodes occurring in a 3-mo
period by approximately 50%.626
8.1.7. Out-of-hospital initiation of antiarrhythmic drugs
in patients with atrial ﬁbrillation
A frequent issue related to pharmacological cardioversion of
AF is whether to initiate antiarrhythmic drug therapy in hos-
pital or on an outpatient basis. The major concern is the
potential for serious adverse effects, including torsades de
pointes (Table 21). With the exception of those involving
low-dose oral amiodarone,533 virtually all studies of pharma-
cological cardioversion have involved hospitalized patients.
However, one study627 provided a clinically useful approach
with out-of-hospital patient-controlled conversion using
class IC drugs (see Tables 6–8).
The ‘pill-in-the-pocket’ strategy consists of the self-
administration of a single oral dose of drug shortly after
the onset of symptomatic AF to improve quality of life,
decrease hospital admission, and reduce cost.628 Rec-
ommendations for out-of-hospital initiation or intermittent
use of antiarrhythmic drugs differ for patients with paroxys-
mal and persistent AF. In patients with paroxysmal AF, the
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aims are to terminate an episode or to prevent recurrence.
In patients with persistent AF, the aims are to achieve
pharmacological cardioversion of AF, obviating the need
for direct-current cardioversion, or to enhance the success
of direct-current cardioversion by lowering the deﬁbrillation
threshold and prevent early recurrence of AF.
In patients with lone AF without structural heart disease,
class IC drugs may be initiated on an outpatient basis. For
other selected patients without sinus or AV node dysfunc-
tion, bundle-branch block, QT-interval prolongation, the
Brugada syndrome, or structural heart disease, ‘pill-in-the-
pocket’ administration of propafenone and ﬂecainide
outside the hospital becomes an option once treatment
has proved safe in hospital given the relative safety (lack
of organ toxicity and low estimated incidence of proarrhyth-
mia).181,557,629–631 Before these agents are initiated,
however, a beta blocker or nondihydropyridine calcium
channel antagonist is generally recommended to prevent
rapid AV conduction in the event of atrial ﬂutter.632–636
Unless AV node conduction is impaired, a short-acting beta
blocker or nondihydropyridine calcium channel antagonist
should be given at least 30 min before administration of a
type IC antiarrhythmic agent to terminate an acute
episode of AF, or the AV nodal blocking agents should be pre-
scribed as continuous background therapy. Sudden death
related to idiopathic ventricular ﬁbrillation may occur in
patients with the Brugada syndrome following adminis-
tration of class I antiarrhythmic drugs even in patients
with structurally normal hearts.637,638 Because termination
of paroxysmal AF may be associated with bradycardia due
to sinus node or AV node dysfunction, an initial conversion
trial should be undertaken in hospital before a patient is
declared ﬁt for outpatient ‘pill-in-the-pocket’ use of ﬂecai-
nide or propafenone for conversion of subsequent recur-
rences of AF. Table 22 lists other factors associated with
proarrhythmic toxicity, including proarrhythmic effects,
which vary according to the electrophysiological properties
of the various drugs. For class IC agents, risk factors for
proarrhythmia include female gender.
Few prospective data are available on the relative safety
of initiating antiarrhythmic drug therapy in the outpatient
versus inpatient setting, and the decision to initiate
therapy out of hospital should be carefully individualized.
The efﬁcacy and safety of self-administered oral loading of
ﬂecainide and propafenone in terminating recent-onset AF
outside of hospital were analyzed in 268 patients with
minimal heart disease with hemodynamically well-tolerated
recent-onset AF.627 Fifty-eight patients (22%) were excluded
because of treatment failure or side effects. Using resol-
ution of palpitations within 6 h after drug ingestion as the
criterion of efﬁcacy, treatment was successful in 534 epi-
sodes (94%), during 15-mo follow-up, with conversion
occurring over a mean of 2 h. Compared with conventional
care, the numbers of emergency department visits and hos-
pitalizations were signiﬁcantly reduced. Among patients
with recurrences, treatment was effective in 84%, and
adverse effects were reported by 7% of patients. Despite
efﬁcacy, 5% of patients dropped out of the study because
of multiple recurrences, side effects (mostly nausea), or
anxiety. Thus, the ‘pill-in-the-pocket’ approach appears
feasible and safe for selected patients with AF, but the
safety of this approach without previous inpatient
evaluation remains uncertain.
As long as the baseline uncorrected QT interval is less than
450 ms, serum electrolytes are normal, and risk factors
associated with class III drug-related proarrhythmia are con-
sidered (Table 23), sotalol may be initiated in outpatients
with little or no heart disease. It is safest to start sotalol
when the patient is in sinus rhythm. Amiodarone can also
usually be given safely on an outpatient basis, even in
patients with persistent AF, because it causes minimal
depression of myocardial function and has low proarrhyth-
mic potential,566 but in-hospital loading may be necessary
for earlier restoration of sinus rhythm in patients with HF
or other forms of hemodynamic compromise related to AF.
Loading regimens typically call for administration of
600 mg daily for 4 wk566 or 1 g daily for 1 wk,531 followed
by lower maintenance doses. Amiodarone, class IA or IC
agents, or sotalol can be associated with bradycardia requir-
ing permanent pacemaker implantation639; this is more
frequent with amiodarone, and amiodarone-associated bra-
dycardia is more common in women than in men. Quinidine,
procainamide, and disopyramide should not be started out
of hospital. Currently, out-of-hospital initiation of dofetilide
is not permitted. Transtelephonic monitoring or other
methods of ECG surveillance may be used to monitor
cardiac rhythm and conduction as pharmacological anti-
arrhythmic therapy is initiated in patients with AF. Speciﬁ-
cally, the PR interval (when ﬂecainide, propafenone,
sotalol, or amiodarone are used), QRS duration (with ﬂecai-
nide or propafenone), and QT interval (with dofetilide,
sotalol, or amiodarone) should be measured. As a general
rule, antiarrhythmic drugs should be started at a relatively
low dose and titrated based on response, and the ECG
Table 21 Types of proarrhythmia during treatment
with various antiarrhythmic drugs for AF or atrial ﬂutter
according to the vaughan williams classiﬁcation
Ventricular proarrhythmia
Torsades de pointes (VW types IA and III drugsa)
Sustained monomorphic ventricular tachycardia
(usually VW type IC drugs)
Sustained polymorphic ventricular tachycardia/VF
without long QT (VW types IA, IC, and III drugs)
Atrial proarrhythmia
Provocation of recurrence
(probably VW types IA, IC, and III drugs)
Conversion of AF to ﬂutter (usually VW type IC drugs)
Increase of deﬁbrillation threshold
(a potential problem with VW type IC drugs)
Abnormalities of conduction or impulse formation
Acceleration of ventricular rate during AF
(VW types IA and IC drugs)
Accelerated conduction over accessory pathway
(digoxin, intravenous verapamil, or diltiazemb)
Sinus node dysfunction, atrioventricular block
(almost all drugs)
Vaughan Williams (VW) classiﬁcation of antiarrhythmic drugs
from Vaughan Williams EM. A classiﬁcation of antiarrhythmic
actions reassessed after a decade of new drugs. J Clin
Pharmacol 1984;24:129–47.
AF indicates atrial ﬁbrillation; VF, ventricular ﬁbrillation.
aThis complication is rare with amiodarone.
bAlthough the potential for beta blockers to potentiate con-
duction across the accessory pathway is controversial, caution
should also be exercised for the use of these agents in patients
with AF associated with preexcitation.
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should be reassessed after each dose change. The heart rate
should be monitored at approximately weekly intervals by
checking the pulse rate, using an event recorder, or
reading ECG tracings obtained at the ofﬁce. The dose of
other medication for rate control should be reduced when
the rate slows after initiation of amiodarone and stopped
if the rate slows excessively. Concomitant drug therapies
(see Table 19) should be monitored closely, and both the
patient and the physician should be alert to possible dele-
terious interactions. The doses of digoxin and warfarin, in
particular, should usually be reduced upon initiation of
amiodarone in anticipation of the rises in serum digoxin
levels and INR that typically occur.
8.1.8. Drugs under development
To overcome the limited efﬁcacy and considerable toxicity
of available drugs for maintaining sinus rhythm, selective
blockers of atrial ion channels and nonselective ion
channel blockers are under development. Use of nonantiar-
rhythmic drugs, such as inhibitors of the renin-angiotensin
system, n-3 polyunsaturated fatty acids, and statins, which
might modify the underlying atrial remodeling, have not
been extensively investigated for this purpose.640–645
8.1.8.1. Atrioselective agents. The ﬁnding that the ultra-
rapid delayed rectiﬁer (IKur) exists in atrial but not
ventricular tissue opened the possibility that atrioselective
Table 22 Factors predisposing to drug-induced ventricular proarrhythmia
VW types IA and III agents VW type IC agents
Long QT interval (QTc greater than or equal to 460 ms) Wide QRS duration (more than 120 ms)
Long QT interval syndrome Concomitant VT
Structural heart disease, substantial LVH Structural heart disease
Depressed LV functiona Depressed LV functiona
Hypokalemia/hypomagnesemiaa
Female gender
Renal dysfunctiona
Bradycardiaa Rapid ventricular response ratea
1. (Drug-induced) sinus node disease or AV block 1. During exercise
2. (Drug-induced) conversion of AF to sinus rhythm 2. During rapid AV conduction
3. Ectopy producing short-long R-R sequences
Rapid dose increase Rapid dose increase
High dose (sotalol, dofetilide), drug accumulationa High dose, drug accumulationa
Addition of drugsa Addition of drugsa
1. Diuretics 1. Negative inotropic drugs
2. Other QT-prolonging antiarrhythmic drugs
3. Nonantiarrhythmic drugs listed in http://www.torsades.org/
Previous proarrhythmia
After initiation of drug
Excessive QT lengthening Excessive (more than 150%) QRS widening
AF indicates atrial ﬁbrillation; AV, atrioventricular; LV, left ventricular; LVH, left ventricular hypertrophy; QTc, corrected QT
interval; VT, ventricular tachycardia.
Vaughan Williams (VW) classiﬁcation of antiarrhythmic drugs from Vaughan Williams EM. A classiﬁcation of antiarrhythmic
actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129–47.497
aSomeof these factorsmay develop later after initiation of drug treatment. See Section 8.3.3.3 in the full-text guidelines for details.
Table 23 Pharmacological treatment before cardioversion in patients with persistent AF: Effects of various antiarrhythmic drugs on
immediate recurrence, outcome of transthoracic direct-current shock, or both
Efﬁcacy Enhance conversion by DC
shock and prevent IRAFa
Recommendation
class
Level of
evidence
Suppress SRAF and maintenance
therapy class
Known Amiodarone IIa B All drugs in recommendation class I
(except ibutilide) plus beta
blockers
Flecainide
Ibutilide
Propafenone
Sotalol
Uncertain/unknown Beta blockers IIb C Diltiazem
Diltiazem Dofetilide
Disopyramide Verapamil
Dofetilide
Procainamide
Verapamil
aAll drugs (except beta blockers and amiodarone) should be initiated in the hospital. Drugs are listed alphabetically within each class of recommendation.
AF indicates atrial ﬁbrillation; DC, direct-current; IRAF, immediate recurrence of atrial ﬁbrillation; SRAF, subacute recurrence of atrial ﬁbrillation.
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drugs without ventricular proarrhythmic toxicity could be
developed for treatment of patients with AF.643,646 IKur
blockers (NIP-142, RSD1235, AVE0118) prolong atrial
refractoriness (left more than right) with no effect on
ventricular repolarization and show strong atrial
antiarrhythmic efﬁcacy.642,644,645,647 AVE0118 is an IKur and
Ito blocker that, unlike dofetilide, increases refractoriness
in electrically remodeled atria, prolongs atrial wavelength,
and converts persistent AF to sinus rhythm without
disturbing intra-atrial conduction velocity or prolonging
the QT interval.648
8.1.8.2. Nonselective ion channel-blocking drugs. Azimilide
and dronedarone block multiple potassium, sodium, and
calcium currents and prolong the cardiac action potential
without reverse use-dependence.641–643,645
Azimilide has a long elimination half-life (114 h), allowing
for once-daily administration. In patients with paroxysmal
SVT enrolled in 4 clinical trials, azimilide at doses of 100
and 125 mg daily prolonged time to recurrence of AF and
atrial ﬂutter647,649 and reduced symptoms associated with
recurrence.650 Patients with ischemic heart disease and HF
displayed greater efﬁcacy than those without structural
heart disease. In a placebo-controlled trial involving 3717
survivors of MI with LV systolic dysfunction,651 azimilide,
100 mg daily, was associated with a 1-y mortality rate
similar to placebo. Fewer patients in the azimilide group
developed AF or new or worsening HF than those given
placebo,651 and more patients in the azimilide group con-
verted from AF to sinus rhythm.652 The major adverse
effects of azimilide were severe neutropenia (less than
500 cells per microliter) in 0.9% and torsades de pointes in
0.5% of treated patients.651
Dronedarone is a noniodinated amiodarone deriva-
tive.653,654 In a randomized, placebo-controlled study invol-
ving 204 patients undergoing cardioversion of persistent
AF,655 dronedarone (800 mg daily) delayed ﬁrst recurrence
from 5.3 to 60 d. Higher doses (1200 and 1600 mg daily)
were no more effective and associated with gastrointestinal
side effects (diarrhea, nausea, and vomiting). To date,
neither organ toxicity nor proarrhythmia has been reported.
In 2 placebo-controlled trials, European Trial in Atrial
Fibrillation or Flutter Patients Receiving Dronedarone for
Maintenance of Sinus Rhythm (EURIDIS)656 and American-
Australian Trial with Dronedarone in Atrial Fibrillation or
Flutter Patients for Maintenance of Sinus Rhythm
(ADONIS),657 dronedarone prolonged the time to ﬁrst docu-
mented AF/atrial ﬂutter recurrence and helped control
the ventricular rate.
Tedisamil, an antianginal agent, blocks several potassium
channels and causes a reverse rate-dependent QT-interval
prolongation. Tedisamil (0.4 and 0.6 mg/kg) was superior
to placebo for rapid conversion (within 35 min) of recent-
onset AF or atrial ﬂutter.658 The main side effects were
pain at the injection site and ventricular tachycardia.
8.2. Direct-current cardioversion of atrial
ﬁbrillation and ﬂutter
Recommendations
Class I
(1) When a rapid ventricular response does not respond
promptly to pharmacological measures for patients
with AF with ongoing myocardial ischemia, symptomatic
hypotension, angina, or HF, immediate R-wave synchro-
nized direct-current cardioversion is recommended.
(Level of Evidence: C)
(2) Immediate direct-current cardioversion is recommended
for patients with AF involving preexcitation when very
rapid tachycardia or hemodynamic instability occurs.
(Level of Evidence: B)
(3) Cardioversion is recommended in patients without
hemodynamic instability when symptoms of AF are unac-
ceptable to the patient. In case of early relapse of AF
after cardioversion, repeated direct-current cardiover-
sion attempts may be made following administration of
antiarrhythmic medication. (Level of Evidence: C)
Class IIa
(1) Direct-current cardioversion can be useful to restore
sinus rhythm as part of a long-term management strat-
egy for patients with AF. (Level of Evidence: B)
(2) Patient preference is a reasonable consideration in the
selection of infrequently repeated cardioversions for
the management of symptomatic or recurrent AF.
(Level of Evidence: C)
Class III
(1) Frequent repetition of direct-current cardioversion is
not recommended for patients who have relatively
short periods of sinus rhythm between relapses of AF
after multiple cardioversion procedures despite
prophylactic antiarrhythmic drug therapy. (Level of
Evidence: C)
(2) Electrical cardioversion is contraindicated in patients with
digitalis toxicity or hypokalemia. (Level of Evidence: C)
8.2.1. Terminology
Direct-current cardioversion involves delivery of an electri-
cal shock synchronized with the intrinsic activity of the
heart by sensing the R wave of the ECG to ensure that elec-
trical stimulation does not occur during the vulnerable
phase of the cardiac cycle.659 Direct-current cardioversion
is used to normalize all abnormal cardiac rhythms except
ventricular ﬁbrillation. The term deﬁbrillation implies an
asynchronous discharge, which is appropriate for correction
of ventricular ﬁbrillation because R-wave synchronization is
not feasible, but not for AF.
8.2.2. Technical aspects
Successful cardioversion of AF depends on the underlying
heart disease and the current density delivered to the
atrial myocardium. Current may be delivered through exter-
nal chest wall electrodes or through an internal cardiac
electrode. Although the latter technique has been con-
sidered superior to external countershocks in obese patients
and in patients with obstructive lung disease, it has not been
widely applied. The frequency of recurrent AF does not
differ between the 2 methods.355,660–664
The current density delivered to the heart by transthor-
acic electrodes depends on the deﬁbrillator capacitor
voltage, output waveform, size and position of the elec-
trode paddles, and thoracic impedance. For a given paddle
surface area, current density decreases with increasing
impedance, related to the thickness and composition of
the paddles, contact medium between electrodes and
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skin, distance between paddles, body size, respiratory
phase, number of shocks, and interval between shocks.665
Use of electrolyte-impregnated pads can minimize the
electrical resistance between electrode and skin. Pulmonary
tissue between paddles and the heart inhibits conduction, so
shocks delivered during expiration or chest compression
deliver higher energy to the heart. Large paddles lower
impedance but may make current density in cardiac tissue
insufﬁcient; conversely, undersized paddles may cause
injury due to excess current density. Animal experiments
have shown that the optimum diameter approximates the
cross-sectional area of the heart. There are no ﬁrm data
regarding the best paddle size for cardioversion of AF, but
a diameter of 8 to 12 cm665 is generally recommended.
Because the combination of high impedance and low
energy reduces the success of cardioversion, measurement
of impedance has been proposed to shorten the procedure
and improve outcomes.666,667 Kerber et al.668 reported
better efﬁcacy by automatically increasing energy delivery
when the impedance exceeded 70 ohms.
The output waveform also inﬂuences energy delivery
during direct-current cardioversion. In a randomized trial,
77 patients treated with sinusoidal monophasic shocks had
a cumulative success rate of 79% compared with 94% in 88
subjects cardioverted with rectilinear biphasic shocks, and
the latter required less energy. In addition to rectilinear
biphasic shocks, independent correlates of successful con-
version were thoracic impedance and the duration of
AF.669 For cardioversion of AF, a biphasic shock waveform
has greater efﬁcacy, requires fewer shocks and lower deliv-
ered energy, and results in less dermal injury than a mono-
phasic shock waveform, and represents the present
standard for cardioversion of AF.670
In their original description of cardioversion, Lown
et al.659,671 recommended an anterior-posterior electrode
conﬁguration over anterior-anterior positioning, but others
disagree.665,672,673 Anterior-posterior positioning allows
current to reach a sufﬁcient mass of atrial myocardium to
achieve cardioversion of AF when the pathology involves
both atria (as in patients with atrial septal defects or cardi-
omyopathy). A drawback of this conﬁguration is the amount
of pulmonary tissue separating the anterior paddle and the
heart, particularly in patients with emphysema. Placing
the anterior electrode to the left of the sternum reduces
electrode separation. The paddles should be placed directly
against the chest wall, under rather than over the breast
tissue. Other paddle positions result in less current ﬂow
through crucial parts of the heart.665 In a randomized
study involving 301 subjects undergoing elective external
cardioversion, the energy required was lower and the
overall success (adding the outcome of low-energy shocks
to that of high-energy shocks) was greater with the
anterior-posterior conﬁguration (87%) than with the
anterior-lateral alignment (76%).674 Animal experiments
show a wide margin of safety between the energy required
for cardioversion of AF and that associated with myocardial
depression.675,676 Even without apparent myocardial
damage, transient ST-segment elevation may appear on
the ECG after cardioversion677,678 and blood levels of cre-
atine kinase may rise. Serum troponin-T and troponin-I
levels did not rise signiﬁcantly in a study of 72 cardioversion
attempts with average energy over 400 J (range 50 to 1280
J).679 In 10% of the patients, creatine kinase-MB levels rose
beyond levels attributable to skeletal muscle trauma, and
this was related to energy delivered. Microscopic myocardial
damage related to direct-current cardioversion has not been
conﬁrmed and is probably clinically insigniﬁcant.
8.2.3. Procedural aspects
Cardioversion should be performed with the patient under
adequate general anesthesia in a fasting state. Short-acting
anesthetic drugs or agents that produce conscious sedation
are preferred to enable rapid recovery after the procedure;
overnight hospitalization is seldom required.680 The electric
shock should be synchronized with the QRS complex, trig-
gered by monitoring the R wave with an appropriately
selected ECG lead that also clearly displays atrial activation
to facilitate assessment of outcome. The initial energy may
be low for cardioversion of atrial ﬂutter, but higher energy
is required for AF. The energy output has traditionally been
increased successively in increments of 100 J to a maximum
of 400 J, but some physicians begin with higher energies to
reduce the number of shocks and thus the total energy deliv-
ered. To avoid myocardial damage, some have suggested that
the interval between consecutive shocks should be at least
1 min.681 In 64 patients randomly assigned to initial monopha-
sic waveform energies of 100, 200, or 360 J, high initial
energy was signiﬁcantly more effective than low levels
(immediate success rates 14% with 100 J, 39% with 200 J,
and 95% with 360 J, respectively), resulting in fewer shocks
and less cumulative energy when 360 J was delivered
initially.682 These data indicate that an initial shock of 100
J with monophasic waveform is often too low for direct-
current cardioversion of AF; hence, an initial energy of 200
J or greater is recommended. A similar recommendation to
start with 200 J applies to biphasic waveforms, particularly
when cardioverting patients with AF of long duration.683
External cardioversion of AF with a rectilinear biphasic wave-
form (99.1% of 1877 procedures in 1361 patients) was more
effective than a monophasic sinusoidal waveform (92.4% of
2818 procedures in 2025 patients; p less than 0.001), but
comparable for patients with atrial ﬂutter (99.2% and
99.8%, respectively). The median successful energy level
was 100 J with the biphasic waveform compared with 200 J
with the monophasic waveform.684
8.2.4. Direct-current cardioversion in patients with
implanted pacemakers and deﬁbrillators
When appropriate precautions are taken, cardioversion of
AF is safe in patients with implanted pacemaker or deﬁbril-
lator devices. Pacemaker generators and deﬁbrillators are
designed with circuits protected against sudden external
electrical discharges, but programmed data may be
altered by current surges. Electricity conducted along an
implanted electrode may cause endocardial injury and
lead to a temporary or permanent increase in stimulation
threshold, resulting in loss of ventricular capture. To
ensure appropriate function, the implanted device should
be interrogated and, if necessary, reprogrammed before
and after cardioversion. Devices are typically implanted
anteriorly, so the paddles used for external cardioversion
should be positioned as distantly as possible, preferably in
the anterior-posterior conﬁguration. The risk of exit block
is greatest when one paddle is positioned near the impulse
generator and the other over the cardiac apex, and lower
with the anterior-posterior electrode conﬁguration and
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with bipolar electrode systems.685,686 Low-energy internal
cardioversion does not interfere with pacemaker function
in patients with electrodes positioned in the RA, coronary
sinus, or left pulmonary artery.687
8.2.5. Risks and complications of direct-current
cardioversion of atrial ﬁbrillation
The risks of direct-current cardioversion are mainly related
to thromboembolism and arrhythmias. Thromboembolic
events have been reported in 1% to 7% of patients not
given prophylactic anticoagulation before cardioversion of
AF.688,689 Prophylactic antithrombotic therapy is discussed
below. (See Section 8.2.7, Prevention of Thromboembolism
in Patients With Atrial Fibrillation Undergoing Cardioversion.)
Various benign arrhythmias, especially ventricular and
supraventricular premature beats, bradycardia, and short
periods of sinus arrest, may arise after cardioversion and
commonly subside spontaneously.690 More dangerous
arrhythmias, such as ventricular tachycardia and ﬁbrillation,
may arise in the face of hypokalemia, digitalis intoxication,
or improper synchronization.691,692 Serum potassium levels
should be in the normal range for safe, effective cardiover-
sion. Magnesium supplementation does not enhance cardio-
version.693 Cardioversion is contraindicated in cases of
digitalis toxicity because resulting ventricular tachyarrhyth-
mia may be difﬁcult to terminate. A serum digitalis level in
the therapeutic range does not exclude clinical toxicity but
is not generally associated with malignant ventricular
arrhythmias during cardioversion,694 so it is not routinely
necessary to interrupt digoxin before elective cardioversion
of AF. It is important, however, to exclude clinical and ECG
signs of digitalis excess and delay cardioversion until a
toxic state has been corrected, which usually requires with-
drawal of digoxin for longer than 24 h.
In patients with long-standing AF, cardioversion commonly
unmasks underlying sinus node dysfunction. A slow ventricu-
lar response to AF in the absence of drugs that slow conduc-
tion across the AV node may indicate an intrinsic conduction
defect. The patient should be evaluated before cardiover-
sion with this in mind so a transvenous or transcutaneous
pacemaker can be used prophylactically.695
8.2.6. Pharmacological enhancement of direct-current
cardioversion
Recommendations
Class IIa
(1) Pretreatment with amiodarone, ﬂecainide, ibutilide,
propafenone, or sotalol can be useful to enhance the
success of direct-current cardioversion and prevent
recurrent atrial ﬁbrillation. (Level of Evidence: B)
(2) In patients who relapse to AF after successful cardiover-
sion, it can be useful to repeat the procedure following
prophylactic administration of antiarrhythmic medi-
cation. (Level of Evidence: C)
Class IIb
(1) For patients with persistent AF, administration of beta
blockers, disopyramide, diltiazem, dofetilide, procaina-
mide, or verapamil may be considered, although the
efﬁcacy of these agents to enhance the success of
direct-current cardioversion or to prevent early recur-
rence of AF is uncertain. (Level of Evidence: C)
(2) Out-of-hospital initiation of antiarrhythmic medications
may be considered in patients without heart disease to
enhance the success of cardioversion of AF. (Level of
Evidence: C)
(3) Out-of-hospital administration of antiarrhythmic medi-
cations may be considered to enhance the success of
cardioversion of AF in patients with certain forms of
heart disease once the safety of the drug has been
veriﬁed for the patient. (Level of Evidence: C)
Although most recurrences of AF occur within the ﬁrst
month after direct-current cardioversion, research with
internal atrial cardioversion696 and postconversion studies
using transthoracic shocks697 have established several pat-
terns of AF recurrence (Figure 17). In some cases, direct-
current countershock fails to elicit even a single isolated
sinus or ectopic atrial beat, tantamount to a high atrial deﬁ-
brillation threshold. In others, AF recurs within a few
minutes after a period of sinus rhythm,698,699 and recurrence
after cardioversion is sometimes delayed for days or
weeks.697 Complete shock failure and immediate recurrence
occur in approximately 25% of patients undergoing direct-
current cardioversion of AF, and subacute recurrences
occur within 2 wk in almost an equal proportion.698
Restoration and maintenance of sinus rhythm are less
likely when AF has been present for longer than 1 y than
in patients with AF of shorter duration. The variation in
immediate success rates for direct-current cardioversion
from 70% to 99% in the literature617,682,684,700,701 is partly
explained by differences in patient characteristics and the
waveform used but also depends upon the deﬁnition of
success, because the interval at which the result is evalu-
ated ranges from moments to several days. Over time, the
proportion of AF caused by rheumatic heart disease has
declined, the average age of the AF population has
increased,700–702 and the incidences of lone AF have
Figure 17 Hypothetical illustration of cardioversion failure. Three
types of recurrences after electrical cardioversion of persistent
atrial ﬁbrillation (AF) are shown. The efﬁcacy of drugs varies in
enhancement of shock conversion and suppression of recurrences.
Modiﬁed with permission from van Gelder IC, Tuinenburg AE,
Schoonderwoerd BS, et al. Pharmacologic versus direct-current
electrical cardioversion of atrial ﬂutter and ﬁbrillation. Am J
Cardiol 1999;84:147R–51R, with permission from Excerpta Medica
Inc.704 ECV indicates external cardioversion; IRAF, immediate recur-
rence of AF deﬁned as the ﬁrst recurrence of AF after cardioversion;
SR, sinus rhythm.
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remained constant, making it difﬁcult to compare the
outcome of cardioversion across various studies.
In a large consecutive series of patients undergoing cardi-
oversion of AF published in 1991, 24% were classiﬁed as
having ischemic heart disease, 24% with rheumatic valvular
disease, 15% with lone AF, 11% with hypertension, 10% with
cardiomyopathy, 8% with nonrheumatic valvular disease, 6%
with congenital heart disease, and 2% with hyperthyroid-
ism.700 Seventy percent were in sinus rhythm 24 h after
cardioversion. Multivariate analysis found a short duration
of AF, atrial ﬂutter, and younger age to be independent pre-
dictors of success, whereas LA enlargement, underlying
organic heart disease, and cardiomegaly were associated
with HF. A decade later, a study of 166 consecutive patients
followed after ﬁrst direct-current cardioversion found that
short duration of AF, smaller LA size, and treatment with
beta blockers, verapamil, or diltiazem were clinical predic-
tors of both initial success and maintenance of sinus
rhythm.703 In another series of 100 patients, the primary
success rate assessed 3 d after cardioversion was 86%,701
increasing to 94% when the procedure was repeated during
treatment with quinidine or disopyramide. Only 23% of
patients remained in sinus rhythm after 1 y, however, and
16% remained after 2 y. In those who relapsed to AF, repeated
cardioversion after administration of antiarrhythmic medi-
cation resulted in sinus rhythm in 40% and 33% after 1 and
2 y, respectively. For patients who relapsed again, a third
cardioversion resulted in sinus rhythm in 54% after 1 y and
41% after 2 y. Thus, sinus rhythm can be restored in a sub-
stantial proportion of patients by direct-current cardiover-
sion, but the rate of relapse is high without concomitant
antiarrhythmic drug therapy704 (Figure 17).
When given in conjunction with direct-current cardiover-
sion, the primary aims of antiarrhythmic medication therapy
are to increase the likelihood of success (e.g., by lowering
the cardioversion threshold) and to prevent recurrent AF.
Enhanced efﬁcacy may involve multiple mechanisms, such
as decreasing the energy required to achieve cardioversion,
prolonging atrial refractory periods, and suppressing atrial
ectopy that may cause early recurrence of AF.580,705 Anti-
arrhythmic medications may be initiated out of hospital or
in hospital immediately prior to direct-current cardiover-
sion. (See Section 8.1.7, Out-of-Hospital Initiation of Anti-
arrhythmic Drugs in Patients With Atrial Fibrillation.) The
risks of pharmacological treatment include the possibility
of paradoxically increasing the deﬁbrillation threshold, as
described with ﬂecainide,600 accelerating the ventricular
rate when class IA or IC drugs are given without an AV
nodal blocking agent,632–636,706 and inducing ventricular
arrhythmias (see Table 21).
Prophylactic drug therapy to prevent early recurrence of
AF should be considered individually for each patient.
Patients with lone AF of relatively short duration are less
prone to early recurrence of AF than are those with heart
disease and longer AF duration, who therefore stand to
gain more from prophylactic administration of anti-
arrhythmic medication. Pretreatment with pharmacological
agents is most appropriate in patients who fail to respond to
direct-current cardioversion and in those who develop
immediate or subacute recurrence of AF. In patients with
late recurrence and those undergoing initial cardioversion
of persistent AF, pretreatment is optional. Antiarrhythmic
drug therapy is recommended in conjunction with a
second cardioversion attempt, particularly when early
relapse has occurred. Additional cardioversion, beyond a
second attempt, is of limited value and should be reserved
for carefully selected patients. Infrequently repeated cardi-
oversions may be acceptable in patients who are highly
symptomatic upon relapse to AF.
Speciﬁc Pharmacological Agents for Prevention of Recur-
rent AF in Patients Undergoing Electrical Cardioversion
8.2.6.1. Amiodarone. In patients with persistent AF, treat-
ment with amiodarone for 6 wk before and after cardiover-
sion increased the conversion rate and the likelihood of
maintaining sinus rhythm and reduced supraventricular
ectopic activity that may trigger recurrent AF.579 Prophylac-
tic treatment with amiodarone was also effective when an
initial attempt at direct-current cardioversion had
failed.531,569 In patients with persistent AF randomly assigned
to treatment with carvedilol, amiodarone, or placebo for 4
wk before direct-current cardioversion, the 2 drugs yielded
similar cardioversion rates, but amiodarone proved superior
at maintaining sinus rhythm after conversion.707
8.2.6.2. Beta-adrenergic antagonists. Although beta
blockers are unlikely to enhance the success of
cardioversion or to suppress immediate or late recurrence
of AF, they may reduce subacute recurrences.583
8.2.6.3. Nondihydropyridine calcium channel antagonists.
Therapy with calcium-channel antagonists prior to electrical
cardioversion of AF has yielded contradictory results.
Several studies found that verapamil708,709 reduced immedi-
ate or early recurrences of AF. On the other hand, verapamil
and diltiazem may increase AF duration, shorten refractori-
ness, and increase the spatial dispersion of refractoriness
leading to more sustained AF.710,711 In patients with persistent
AF, the addition of verapamil to class I or class II drugs can
prevent immediate recurrence after cardioversion,712 and
prophylaxis against subacute recurrence was enhanced
when this combination was given for 3 d before and after car-
dioversion.713,714 Verapamil also reduced AF recurrence when
a second cardioversion was performed after early recurrence
of AF.714 In a comparative study,715 amiodarone and diltiazem
were more effective than digoxin for prevention of early
recurrence, whereas at 1 mo the recurrence rate was lower
with amiodarone (28%) than with diltiazem (56%) or digoxin
(78%). In patients with persistent AF, treatment with verapa-
mil 1 mo before and after direct-current cardioversion did not
improve the outcome of cardioversion.716
8.2.6.4. Quinidine. A loading dose of quinidine (1200 mg
orally 24 h before direct-current cardioversion) signiﬁcantly
reduced the number of shocks and the energy required in
patients with persistent AF. Quinidine prevented immediate
recurrence in 25 cases, whereas recurrence developed in 7
of 25 controls.698 When quinidine (600 to 800 mg 3 times
daily for 2 d) failed to convert the rhythm, there was no
difference in deﬁbrillation threshold between patients ran-
domized to continue or withdraw the drug.617
8.2.6.5. Type IC antiarrhythmic agents. In-hospital
treatment with oral propafenone started 2 d before direct-
current cardioversion decreases early recurrence of AF
after shock, thus allowing more patients to be discharged
from the hospital with sinus rhythm. Compared with
placebo, propafenone did not inﬂuence either the mean
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deﬁbrillation threshold or the rate of conversion (shock
efﬁcacy 84% vs. 82%, respectively) but suppressed
immediate recurrences (within 10 min), and 74% versus 53%
of patients were in sinus rhythm after 2 d.522 In patients
with persistent AF, pretreatment with intravenous
ﬂecainide had no signiﬁcant effect on the success of
direct-current cardioversion.717
8.2.6.6. Type III Antiarrhythmic agents. Controlled studies
are needed to determine the most effective treatment of
immediate and subacute recurrences of AF. Type III anti-
arrhythmic drugs may suppress subacute recurrences less
effectively than late recurrences of AF (Table 23). Available
data suggest that starting pharmacological therapy and
establishing therapeutic plasma drug concentrations
before direct-current cardioversion enhance immediate
success and suppress early recurrences. After cardioversion
to sinus rhythm, patients receiving drugs that prolong the
QT interval should be monitored in the hospital for 24 to
48 h to evaluate the effects of heart rate slowing and
allow for prompt intervention in the event torsades de
pointes develops.
In randomized studies of direct-current cardioversion,
patients pretreated with ibutilide were more often con-
verted to sinus rhythm than untreated controls, and those
in whom cardioversion initially failed could more often be
converted when the procedure was repeated after treat-
ment with ibutilide.556,718 Ibutilide was more effective
than verapamil in preventing immediate recurrence of AF.705
8.2.7. Prevention of thromboembolism in patients with
atrial ﬁbrillation undergoing cardioversion
Recommendations
Class I
(1) For patients with AF of 48-h duration or longer, or when
the duration of AF is unknown, anticoagulation (INR 2.0
to 3.0) is recommended for at least 3 wk prior to and 4
wk after cardioversion, regardless of the method (elec-
trical or pharmacological) used to restore sinus rhythm.
(Level of Evidence: B)
(2) For patients with AF of more than 48-h duration requir-
ing immediate cardioversion because of hemodynamic
instability, heparin should be administered concurrently
(unless contraindicated) by an initial intravenous bolus
injection followed by a continuous infusion in a dose
adjusted to prolong the activated partial thromboplastin
time to 1.5 to 2 times the reference control value.
Thereafter, oral anticoagulation (INR 2.0 to 3.0) should
be provided for at least 4 wk, as for patients undergoing
elective cardioversion. Limited data support subcu-
taneous administration of low-molecular-weight
heparin in this indication. (Level of Evidence: C)
(3) For patients with AF of less than 48-h duration associ-
ated with hemodynamic instability (angina pectoris,
MI, shock, or pulmonary edema), cardioversion should
be performed immediately without delay for prior
initiation of anticoagulation. (Level of Evidence: C)
Class IIa
(1) During the ﬁrst 48 h after onset of AF, the need for antic-
oagulation before and after cardioversion may be based
on the patient’s risk of thromboembolism. (Level of
Evidence: C)
(2) As an alternative to anticoagulation prior to cardiover-
sion of AF, it is reasonable to perform TEE in search of
thrombus in the LA or LAA. (Level of Evidence: B) 2a.
For patients with no identiﬁable thrombus, cardiover-
sion is reasonable immediately after anticoagulation
with unfractionated heparin (e.g., initiate by intrave-
nous bolus injection and an infusion continued at a
dose adjusted to prolong the activated partial thrombo-
plastin time to 1.5 to 2 times the control value until oral
anticoagulation has been established with a vitamin K
antagonist (e.g., warfarin), as evidenced by an INR
equal to or greater than 2.0.). (Level of Evidence: B)
Thereafter, oral anticoagulation (INR 2.0 to 3.0) is
reasonable for a total anticoagulation period of at
least 4 wk, as for patients undergoing elective cardio-
version. (Level of Evidence: B)
Limited data are available to support the subcutaneous
administration of a low-molecular-weight heparin in
this indication. (Level of Evidence: C) 2b. For patients
in whom thrombus is identiﬁed by TEE, oral anticoagula-
tion (INR 2.0 to 3.0) is reasonable for at least 3 wk prior
to and 4 wk after restoration of sinus rhythm, and a
longer period of anticoagulation may be appropriate
even after apparently successful cardioversion,
because the risk of thromboembolism often remains
elevated in such cases. (Level of Evidence: C)
(3) For patients with atrial ﬂutter undergoing cardioversion,
anticoagulation can be beneﬁcial according to the
recommendations as for patients with AF. (Level of
Evidence: C)
Randomized studies of antithrombotic therapy are lacking
for patients undergoing cardioversion of AF or atrial ﬂutter,
but in case-control series, the risk of thromboembolism was
between 1% and 5%.689,719 The risk was near the low end of
this spectrum when anticoagulation (INR 2.0 to 3.0) was
given for 3 to 4 wk before and after conversion.54,181,695 It
is now common practice to administer anticoagulant drugs
when preparing patients with AF of more than 2-d duration
for cardioversion. Manning et al.304 suggested that TEE
might be used to identify patients without LAA thrombus
who do not require anticoagulation, but a subsequent inves-
tigation324 and meta-analysis found this approach to be
unreliable.720
If most AF-associated strokes result from embolism of
stasis-induced thrombus from the LAA, then restoration
and maintenance of atrial contraction should logically
reduce thromboembolic risk. LV function can also improve
after cardioversion,721 potentially lowering embolic risk
and improving cerebral hemodynamics.722 There is no evi-
dence, however, that cardioversion followed by prolonged
maintenance of sinus rhythm effectively reduces throm-
boembolism in AF patients. Conversion of AF to sinus
rhythm results in transient mechanical dysfunction of the
LA and LAA417 known as ‘stunning,’ which can occur after
spontaneous, pharmacological,723,724 or electrical724–726
conversion of AF or after radiofrequency catheter ablation
of atrial ﬂutter226 and which may be associated with
SEC.417 Recovery of mechanical function may be delayed
for several weeks, depending in part on the duration of AF
before conversion.191,727,728 This could explain why some
patients without demonstrable LA thrombus on TEE before
cardioversion subsequently experience thromboembolic
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events.324 Presumably, thrombus forms during the period of
stunning and is expelled after the return of mechanical func-
tion, explaining the clustering of thromboembolic events
during the ﬁrst 10 d after cardioversion.212
Patients with AF or atrial ﬂutter in whom LAA thrombus is
identiﬁed by TEE are at high risk of thromboembolism and
should be anticoagulated for at least 3 wk prior to and 4
wk after pharmacological or direct-current cardioversion.
In a multicenter study, 1222 patients with either AF persist-
ing longer than 2 d or atrial ﬂutter and previous AF729 were
randomized to a TEE-guided or conventional strategy. In the
group undergoing TEE, cardioversion was postponed when
thrombus was identiﬁed, and warfarin was administered
for 3 wk before TEE was repeated to conﬁrm resolution of
thrombus. Anticoagulation with heparin was used brieﬂy
before cardioversion and with warfarin for 4 wk after cardi-
oversion. The other group received anticoagulation for 3 wk
before and 4 wk after cardioversion without intercurrent
TEE. Both approaches were associated with comparably
low risks of stroke (0.81% with the TEE approach and
0.50% with the conventional approach) after 8 wk, there
were no differences in the proportion of patients achieving
successful cardioversion, and the risk of major bleeding
did not differ signiﬁcantly. The clinical beneﬁt of the TEE-
guided approach was limited to saving time before
cardioversion.
Anticoagulation is recommended for 3 wk prior to and 4
wk after cardioversion for patients with AF of unknown dur-
ation or with AF for more than 48 h. Although LA thrombus
and systemic embolism have been documented in patients
with AF of shorter duration, the need for anticoagulation
is less clear. When acute AF produces hemodynamic insta-
bility in the form of angina pectoris, MI, shock, or pulmonary
edema, immediate cardioversion should not be delayed
to deliver therapeutic anticoagulation, but intravenous
unfractionated heparin or subcutaneous injection of a low-
molecular-weight heparin should be initiated before
cardioversion by direct-current countershock or intravenous
antiarrhythmic medication.
Protection against late embolism may require continu-
ation of anticoagulation for a more extended period after
the procedure, and the duration of anticoagulation after
cardioversion depends both on the likelihood that AF will
recur in an individual patient with or without symptoms
and on the intrinsic risk of thromboembolism. Late events
are probably due to both the development of thrombus as
a consequence of atrial stunning and the delayed recovery
of atrial contraction after cardioversion. Pooled data from
32 studies of cardioversion of AF or atrial ﬂutter suggest
that 98% of clinical thromboembolic events occur within
10 d.212 These data, not yet veriﬁed by prospective
studies, support administration of an anticoagulant for at
least 4 wk after cardioversion, and continuation of anticoa-
gulation for a considerably longer period may be warranted
even after apparently successful cardioversion.
Stroke or systemic embolism has been reported in patients
with atrial ﬂutter undergoing cardioversion,730–732 and
anticoagulation should be considered with either the con-
ventional or TEE-guided strategy. TEE-guided cardioversion
of atrial ﬂutter has been performed with a low rate of sys-
temic embolism, particularly when patients are stratiﬁed
for other risk factors on the basis of clinical and/or TEE
features.600,733
8.3. Maintenance of sinus rhythm
Recommendations
Class I
Before initiating antiarrhythmic drug therapy, treatment
of precipitating or reversible causes of AF is recommended.
(Level of Evidence: C)
Class IIa
(1) Pharmacological therapy can be useful in patients with
AF to maintain sinus rhythm and prevent tachycardia-
induced cardiomyopathy. (Level of Evidence: C)
(2) Infrequent, well-tolerated recurrence of AF is reason-
able as a successful outcome of antiarrhythmic drug
therapy. (Level of Evidence: C)
(3) Outpatient initiation of antiarrhythmic drug therapy is
reasonable in patients with AF who have no associated
heart disease when the agent is well tolerated. (Level
of Evidence: C)
(4) In patients with lone AF without structural heart
disease, initiation of propafenone or ﬂecainide can be
beneﬁcial on an outpatient basis in patients with parox-
ysmal AF who are in sinus rhythm at the time of drug
initiation. (Level of Evidence: B)
(5) Sotalol can be beneﬁcial in outpatients in sinus rhythm
with little or no heart disease, prone to paroxysmal AF,
if the baseline uncorrected QT interval is less than
460 ms, serum electrolytes are normal, and risk factors
associated with class III drug-related proarrhythmia are
not present. (Level of Evidence: C)
(6) Catheter ablation is a reasonable alternative to pharma-
cological therapy to prevent recurrent AF in sympto-
matic patients with little or no LA enlargement. (Level
of Evidence: C)
Class III
(1) Antiarrhythmic therapy with a particular drug is not rec-
ommended for maintenance of sinus rhythm in patients
with AF who have well-deﬁned risk factors for proar-
rhythmia with that agent. (Level of Evidence: A)
(2) Pharmacological therapy is not recommended for main-
tenance of sinus rhythm in patients with advanced sinus
node disease or AV node dysfunction unless they have a
functioning electronic cardiac pacemaker. (Level of
Evidence: C)
8.3.1. Pharmacological therapy
8.3.1.1. Goals of treatment. Whether paroxysmal or
persistent, AF is a chronic disorder, and recurrence at some
point is likely in most patients704,734,735 (see Figure 13).
Many patients eventually need prophylactic antiarrhythmic
drug therapy to maintain sinus rhythm, suppress symptoms,
improve exercise capacity and hemodynamic function, and
prevent tachycardia-induced cardiomyopathy due to AF.
Because factors that predispose to recurrent AF (advanced
age, HF, hypertension, LA enlargement, and LV dysfunction)
are risk factors for thromboembolism, the risk of stroke
may not be reduced by correction of the rhythm
disturbance. It is not known whether maintenance of sinus
rhythm prevents thromboembolism, HF, or death in patients
with a history of AF.736,737 Trials in which rate- versus
rhythm-control strategies were compared in patients with
persistent and paroxysmal AF293,294,296,343,344 found no
reduction in death, disabling stroke, hospitalizations, new
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arrhythmias, or thromboembolic complications in the
rhythm-control group.296 Pharmacological maintenance of
sinus rhythm may reduce morbidity in patients with
HF,501,738 but one observational study demonstrated that
serial cardioversion in those with persistent AF did not
avoid complications.739 Pharmacological therapy to maintain
sinus rhythm is indicated in patients who have troublesome
symptoms related to paroxysmal AF or recurrent AF after
cardioversion who can tolerate antiarrhythmic drugs and
have a good chance of remaining in sinus rhythm over an
extended period (e.g., young patients without organic heart
disease or hypertension, a short duration of AF, and normal
LA size).293,740 When antiarrhythmic medication does not
result in symptomatic improvement or causes adverse
effects, however, it should be abandoned.
8.3.1.2. Endpoints in antiarrhythmic drug studies. Various
antiarrhythmic drugs have been investigated for maintenance
of sinus rhythm in patients with AF. The number and quality of
studies with each drug are limited; endpoints vary, and few
studies meet current standards of good clinical practice. The
arrhythmia burden and quality of life have not been assessed
consistently. In studies of patients with paroxysmal AF, the
time to ﬁrst recurrence, number of recurrences over a speci-
ﬁed interval, proportion of patients without recurrence
during follow-up, and combinations of these data have been
reported. The proportion of patients in sinus rhythm during
follow-up is a less useful endpoint in studies of paroxysmal
rather than persistent AF. Most studies of persistent AF
involved antiarrhythmic drug therapy administered before or
after direct-current cardioversion. Because of clustering of
recurrences in the ﬁrst few weeks after cardioversion,697,713
the median time to ﬁrst recurrence detected by transtelepho-
nic monitoringmay not differ between 2 treatment strategies.
Furthermore, because recurrent AF tends to persist, neither
the interval between recurrences nor the number of episodes
in a given period represents a suitable endpoint unless a serial
cardioversion strategy is employed. Given these factors, the
appropriate endpoints for evaluation of treatment efﬁcacy in
patients with paroxysmal and persistent AF have little in
common. This hampers comparative evaluation of treatments
aimed at maintenance of sinus rhythm in cohorts containing
patients with both patterns of AF, and studies of mixed
cohorts therefore do not contribute heavily to these guide-
lines. The duration of follow-up varied considerably among
studies and was generally insufﬁcient to permit meaningful
extrapolation to years of treatment in what is often a lifelong
cardiac rhythm disorder.
Recurrence of AF is not equivalent to treatment failure. In
several studies,594,598 patients with recurrent AF often
chose to continue antiarrhythmic treatment, perhaps
because episodes of AF became less frequent, briefer, or
less symptomatic. A reduction in arrhythmia burden may
therefore constitute therapeutic success for some patients,
while to others any recurrence of AF may seem intolerable.
Assessment based upon time to recurrence in patients with
paroxysmal AF or upon the number of patients with persist-
ent AF who sustain sinus rhythm after cardioversion may
overlook potentially valuable treatment strategies. Avail-
able studies are heterogeneous in other respects as well.
The efﬁcacy of treatment for atrial ﬂutter and AF is
usually not reported separately. Underlying heart disease
or extracardiac disease is present in 80% of patients with
persistent AF, but this is not always described in detail. It
is often not clear when patients ﬁrst experienced AF or
whether AF was persistent, and the frequencies of previous
AF episodes and cardioversions are not uniformly described.
Most controlled trials of antiarrhythmic drugs included few
patients at risk of drug-induced HF, proarrhythmia, or con-
duction disturbances, and this should be kept in mind in
applying the recommendations below.
The AFFIRM substudy investigators found that with AF
recurrence, if one is willing to cardiovert the rhythm and
keep the patient on the same antiarrhythmic drug, or cardi-
overt the rhythm and treat the patient with a different anti-
arrhythmic drug, about 80% of all patients will be in sinus
rhythm by the end of 1 y.570
8.3.1.3. Predictors of recurrent AF. Most patients with AF,
except those with postoperative or self-limited AF
secondary to transient or acute illness, eventually
experience recurrence. Risk factors for frequent recurrence
of paroxysmal AF (more than 1 episode per month) include
female gender and underlying heart disease.741 In one study
of patients with persistent AF, the 4-y arrhythmia-free
survival rate was less than 10% after single-shock direct-
current cardioversion without prophylactic drug therapy.735
Predictors of recurrences within that interval included
hypertension, age over 55 y, and AF duration longer than 3
mo. Serial cardioversions and prophylactic drug therapy
resulted in freedom from recurrent AF in approximately
30% of patients,735 and with this approach predictors of
recurrence included age over 70 y, AF duration beyond 3
mo, and HF.735 Other risk factors for recurrent AF include
LA enlargement and rheumatic heart disease.
8.3.2. General approach to antiarrhythmic drug therapy
Before administering any antiarrhythmic agent, reversible
precipitants of AF should be identiﬁed and corrected. Most
are related to coronary or valvular heart disease, hyperten-
sion, or HF. Patients who develop HF in association with
alcohol intake should abstain from alcohol consumption.
Indeﬁnite antiarrhythmic treatment is seldom prescribed
after a ﬁrst episode, although a period of several weeks
may help stabilize sinus rhythm after cardioversion. Simi-
larly, patients experiencing breakthrough arrhythmias may
not require a change in antiarrhythmic drug therapy when
recurrences are infrequent and mild. Beta-adrenergic antag-
onist medication may be effective in patients who develop
AF only during exercise, but a single, speciﬁc inciting
cause rarely accounts for all episodes of AF, and the majority
of patients do not sustain sinus rhythm without anti-
arrhythmic therapy. Selection of an appropriate agent is
based ﬁrst on safety, tailored to whatever underlying heart
disease may be present, considering the number and
pattern of prior episodes of AF.742
In patients with lone AF, a beta blocker may be tried ﬁrst,
but ﬂecainide, propafenone, and sotalol are particularly
effective. Amiodarone and dofetilide are recommended as
alternative therapies. Quinidine, procainamide, and diso-
pyramide are not favored unless amiodarone fails or is con-
traindicated. For patients with vagally induced AF, however,
the anticholinergic activity of long-acting disopyramide
makes it a relatively attractive theoretical choice. In that
situation, ﬂecainide and amiodarone represent secondary
and tertiary treatment options, respectively, whereas
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propafenone is not recommended because its (weak) intrin-
sic beta-blocking activity may aggravate vagally mediated
paroxysmal AF. In patients with adrenergically mediated
AF, beta blockers represent ﬁrst-line treatment, followed
by sotalol and amiodarone. In patients with adrenergically
mediated lone AF, amiodarone represents a less appealing
selection. Vagally induced AF can occur by itself, but more
typically it is part of the overall patient proﬁle. In patients
with nocturnal AF, the possibility of sleep apnea should be
considered (see Figure 15).
When treatment with a single antiarrhythmic drug fails,
combinations may be tried. Useful combinations include a
beta blocker, sotalol, or amiodarone with a class IC agent.
The combination of a calcium channel blocker, such as diltia-
zem, with a class IC agent, such as ﬂecainide or propafe-
none, is advantageous in some patients. A drug that is
initially safe may become proarrhythmic if coronary
disease or HF develops or if the patient begins other medi-
cation that exerts a proarrhythmic interaction. Thus, the
patient should be alerted to the potential signiﬁcance of
such symptoms as syncope, angina, or dyspnea and warned
about the use of noncardiac drugs that might prolong the
QT interval. A useful source of information on this topic is
the Internet site http://www.torsades.org.
The optimum method for monitoring antiarrhythmic drug
treatment varies with the agent involved as well as with
patient factors. Prospectively acquired data on upper
limits of drug-induced prolongation of QRS duration or QT
interval are not available. Given recommendations rep-
resent the consensus of the writing committee. With class
IC drugs, prolongation of the QRS interval should not
exceed 50%. Exercise testing may help detect QRS widening
that occurs only at rapid heart rates (use-dependent con-
duction slowing). For class IA or class III drugs, with the poss-
ible exception of amiodarone, the corrected QT interval in
sinus rhythm should be kept below 520 ms. During follow-
up, plasma potassium and magnesium levels and renal func-
tion should be checked periodically because renal insufﬁ-
ciency leads to drug accumulation and predisposes to
proarrhythmia. In individual patients, serial noninvasive
assessment of LV function is indicated, especially when clini-
cal HF develops during treatment of AF.
8.3.3. Selection of antiarrhythmic agents in patients with
cardiac diseases
Pharmacological management algorithms to maintain sinus
rhythm in patients with AF (see Figures 13–16) and appli-
cations in speciﬁc cardiac disease states are based on
available evidence and extrapolated from experience with
these agents in other situations.
8.3.3.1. Heart failure. Patients with HF are particularly
prone to the ventricular proarrhythmic effects of
antiarrhythmic drugs because of myocardial vulnerability
and electrolyte imbalance. Randomized trials have
demonstrated the safety of amiodarone and dofetilide
(given separately) in patients with HF,501,743 and these are
the recommended drugs for maintenance of sinus rhythm
in patients with AF in the presence of HF.
In a subgroup analysis of data from the Congestive Heart
Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT)
study,738 amiodarone reduced the incidence of AF over 4 y
in patients with HF to 4% compared with 8% with placebo.
Conversion to sinus rhythm occurred in 31% of patients on
amiodarone versus 8% with placebo and was associated
with signiﬁcantly better survival.
The Danish Investigations of Arrhythmias and Mortality on
Dofetilide in Heart Failure (DIAMOND-CHF) trial randomized
1518 patients with symptomatic HF. In a substudy of 506
patients with HF and AF or atrial ﬂutter,501,588 dofetilide
(0.5 mg twice daily initiated in hospital) increased the prob-
ability of sinus rhythm after 1 y to 79% compared with 42%
with placebo. In the dofetilide group, 44% of patients with
AF converted to sinus rhythm compared with 39% in the
placebo group. Dofetilide had no effect on mortality, but
the combined endpoint of all-cause mortality and HF hospi-
talization was lower in the treated group than with
placebo.501,588 Torsades de pointes developed in 25 patients
treated with dofetilide (3.3%), and three-quarters of these
events occurred within the ﬁrst 3 d of treatment.
Patients with LV dysfunction and persistent AF should be
treated with beta blockers and ACE inhibitors and/or angio-
tensin II receptor antagonists, because these agents help
control the heart rate, improve ventricular function, and
prolong survival.744–747 In patients with HF or LV dysfunction
post-MI, ACE inhibitor therapy reduced the incidence of
AF.36,748,749 In a retrospective analysis of patients with LV dys-
function in the SOLVD trials,38 enalapril reduced the inci-
dence of AF by 78% relative to placebo. In the CHARM and
Val-HeFT studies, angiotensin II receptor antagonists given
in combination with ACE inhibitors were superior to ACE
inhibitors alone for prevention of AF. A post hoc analysis of
the Cardiac Insufﬁciency Bisoprolol Study (CIBIS II),
however, found no impact of bisoprolol on survival or hospi-
talization for HF in patients with AF.750 In the Carvedilol
Post-Infarct Survival Control in Left Ventricular Dysfunction
(CAPRICORN)751 and Carvedilol Prospective Randomized
Cumulative Survival (COPERNICUS) trials,752 AF and atrial
ﬂutter were more common in the placebo groups than in
patients treated with carvedilol. Retrospective analysis of
patients in the U.S. Carvedilol Heart Failure Trial program
with AF complicating HF753 suggested that carvedilol
improved LV ejection fraction. In a study by Khand et al.,754
the combination of carvedilol and digoxin reduced symptoms,
improved ventricular function, and improved ventricular rate
control compared with either agent alone.
8.3.3.2. Coronary artery disease. In stable patients with
CAD, beta blockers may be considered ﬁrst, although their
use is supported by only 2 studies583,587 and data on efﬁcacy
for maintenance of sinus rhythm in patients with persistent
AF after cardioversion are not convincing.583 When anti-
arrhythmic therapy beyond beta blockers is needed for
control of AF in survivors of acute MI, several randomized
trials have demonstrated that sotalol,755 amiodarone,756,757
dofetilide,758 and azimilide651 have neutral effects on survi-
val. Sotalol has substantial beta-blocking activity and may
be the preferred initial antiarrhythmic agent in patients
with AF who have ischemic heart disease, because it is as-
sociated with less long-term toxicity than amiodarone.
Amiodarone increases the risk of bradyarrhythmia requiring
permanent pacemaker implantation in elderly patients with
AF who have previously sustained MI759 but may be preferred
over sotalol in patients with HF.755–757 Neither ﬂecainide nor
propafenone is recommended in these situations, but quini-
dine, procainamide, and disopyramide may be considered as
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third-line choices in patients with coronary disease. The
Danish Investigations of Arrhythmias and Mortality on Dofe-
tilide in Myocardial Infarction (DIAMOND-MI) trial758 involved
selected post-MI patients in whom the antiarrhythmic
beneﬁt of dofetilide balanced the risk of proarrhythmic tox-
icity, making this a second-line antiarrhythmic agent. In
patients with coronary disease who have not developed MI
or HF, however, it is uncertain whether the beneﬁt of dofe-
tilide outweighs risk, and more experience is needed before
this drug can be recommended even as a second-line agent
in such patients.
8.3.3.3. Hypertensive heart disease. Hypertension is the
most prevalent and potentially modiﬁable independent risk
factor for the development of AF and its complications,
including thromboembolism.760,761 Blood pressure control
may become an opportune strategy for prevention of
AF. Patients with LVH may face an increased risk of torsades
de pointes related to early ventricular afterdepolariza-
tions.742,762,763 Thus, class IC agents and amiodarone are
preferred over type IA and type III antiarrhythmic agents
as ﬁrst-line therapy. In the absence of ischemia or LVH, pro-
pafenone or ﬂecainide is a reasonable choice. Proarrhythmia
with one agent does not predict this response to another,
and patients with LVH who develop torsades de pointes
during treatment with a class III agent may tolerate a class
IC agent. Amiodarone prolongs the QT interval but carries
a very low risk of ventricular proarrhythmia. Its extracardiac
toxicity relegates it to second-line therapy in these individ-
uals, but it becomes a ﬁrst-line agent in the face of substan-
tial LVH. When amiodarone and sotalol either fail or are
inappropriate, disopyramide, quinidine, or procainamide
represents a reasonable alternative.
Beta blockers may be the ﬁrst line of treatment to maintain
sinus rhythm in patients with MI, HF, and hypertension. Com-
pared with patients with lone AF, those with hypertension are
more likely to maintain sinus rhythm after cardioversion of
persistent AF when treated with a beta blocker.764 Drugs
modulating the renin-angiotensin system reduce structural
cardiac changes,765 and ACE inhibition was associated with
a lower incidence of AF compared with calcium channel
blockade in patients with hypertension during 4.5 y of
follow-up in a retrospective, longitudinal cohort study from
a database of 8 million patients in a managed care
setting.42 In patients at increased risk of cardiovascular
events, therapy with either the ACE inhibitor ramipril766–768
or angiotensin receptor antagonist losartan769,770 lowered
the risk of stroke. A similar beneﬁt has been reported with
perindopril in a subset of patients with AF treated for preven-
tion of recurrent stroke.771 New-onset AF and stroke were sig-
niﬁcantly reduced by losartan compared with atenolol in
hypertensive patients with ECG-documented LVH, despite a
similar reduction of blood pressure.41 The beneﬁt of losartan
was greater in patients with AF than those with sinus rhythm
for the primary composite endpoint (cardiovascular mortality,
stroke, and MI) and for cardiovascular mortality alone.772 Pre-
sumably, the beneﬁcial effects of beta blockers and drugs
modulating the renin-angiotensin system are at least partly
related to lower blood pressure.
8.3.4. Nonpharmacological therapy for atrial ﬁbrillation
The inconsistent efﬁcacy and potential toxicity of anti-
arrhythmic drug therapies have stimulated exploration of a
wide spectrum of alternative nonpharmacological therapies
for the prevention and control of AF.
8.3.4.1. Surgical ablation. Over the past 25 y, surgery has
contributed to understanding of both the anatomy and
electrophysiology of commonly encountered arrhythmias,
including the WPW syndrome, AV nodal reentry, ventricular
tachycardia, and atrial tachycardia. A decade of research in
the 1980s demonstrated the critical elements necessary to
cure AF surgically, including techniques that entirely eliminate
macroreentrant circuits in the atria while preserving sinus
node and atrial transport functions. The surgical approach was
based on the hypothesis that reentry is the predominant
mechanism responsible for the development and maintenance
of AF,773 leading to the concept that atrial incisions at critical
locations would create barriers to conduction and prevent
sustained AF. The procedure developed to accomplish these
goals was based on the concept of a geographical maze,
accounting for the term ‘maze’ procedure used to describe
this type of cardiac operation.774
Since its introduction, the procedure has gone through 3
iterations (maze I, II, and III) using cut-and-sew techniques
that ensure transmural lesions to isolate the PV, connect
these dividing lines to the mitral valve annulus, and create
electrical barriers in the RA that prevent macroentrant
rhythms–atrial ﬂutter or AF–from becoming sustained.775
Success rates of around 95% over 15 y of follow-up have been
reported in patients undergoing mitral valve surgery.776
Other studies suggest success rates around 70%.777 Atrial trans-
port function is maintained and, when combined with amputa-
tion or obliteration of the LAA, postoperative thromboembolic
events are substantially reduced. Risks include death (less
than 1% when performed as an isolated procedure), the need
for permanent pacing (with right-sided lesions), recurrent
bleeding requiring reoperation, impaired atrial transport func-
tion, delayed atrial arrhythmias (especially atrial ﬂutter), and
atrioesophageal ﬁstula.
Variations of the maze procedure have been investigated
at several centers to determine the lesion sets necessary
for success. Studies in patients with persistent AF have
demonstrated the importance of complete lesions that
extend to the mitral valve annulus; electrical isolation of
the PV alone is associated with a lower success rate.
Bipolar radiofrequency,778 cryoablation, and microwave
energy have been used as alternatives to the ‘cut-and-sew’
technique. In one study, maintenance of sinus rhythm follow-
ing the maze procedure in patients with AF was associated
with improvement in some aspects of quality of life.348
Despite its high success rate, the maze operation has not
been widely adopted other than for patients undergoing
cardiac surgery because of the need for cardiopulmonary
bypass. A wide variety of less invasive modiﬁcations are
under investigation, including thoracoscopic and catheter-
based epicardial techniques.777 If the efﬁcacy of these adap-
tations approaches that of the endocardial maze procedure
and they can be performed safely, they may become accep-
table alternatives for a larger proportion of patients with AF.
8.3.4.2. Catheter ablation. Early radiofrequency catheter
ablation techniques emulated the surgical maze procedure
by introducing linear scars in the atrial endocardium.779
While the success rate was approximately 40% to 50%, a
relatively high complication rate diminished enthusiasm
for this approach.105 The observation that potentials arising
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in or near the ostia of the PV often provoked AF, and
demonstration that elimination of these foci abolished AF
escalated enthusiasm for catheter-based ablation.105 Initially,
areas of automaticity within the PV were targeted, and in a
series of 45 patients with paroxysmal AF, 62% became free of
symptomatic AF over a mean follow-up of 8 mo, but 70%
required multiple procedures.105 In another study, the
success rate was 86% over a 6-mo follow-up.780 Subsequent
research has demonstrated that potentials may arise in
multiple regions of the RA and LA, including the LA posterior
wall, superior vena cava, vein of Marshall, crista terminalis,
interatrial septum, and coronary sinus,109 and modiﬁcation of
the procedures has incorporated linear LA ablation, mitral
isthmus ablation, or both for selected patients.781
The technique of ablation has continued to evolve from
early attempts to target individual ectopic foci within the
PV to circumferential electrical isolation of the entire PV
musculature. In a series of 70 patients, 73% were free
from AF following PV isolation without antiarrhythmic medi-
cations during a mean follow-up of 4 mo, but 29 patients
required a second procedure to reach this goal. However,
postablation AF may occur transiently in the ﬁrst 2 mo.782
Advances involving isolation of the PV at the antrum using
a circular mapping catheter, guided by intracardiac echocar-
diography, have reportedly yielded approximately 80%
freedom of recurrent AF or atrial ﬂutter after the ﬁrst
2 mo in patients with paroxysmal AF,783 but success rates
were lower in patients with cardiac dysfunction.784 Still
another approach785,786 uses a nonﬂuoroscopic guidance
system and radiofrequency energy delivered circumferen-
tially outside the ostia of the PV. In a series of 26 patients,
85% were free of recurrent AF during a mean follow-up of
9 mo, including 62% taking no antiarrhythmic medications.
The accumulated experience involves nearly 4000
patients,786 with approximately 90% success in cases of par-
oxysmal AF and 80% in cases of persistent AF.784,787,788
Another anatomic approach to radiofrequency catheter
ablation targets complex fractionated electrograms,789
with 91% efﬁcacy reported at 1 y. Restoration of sinus
rhythm after catheter ablation for AF signiﬁcantly improved
LV function, exercise capacity, symptoms, and quality of life
(usually within the ﬁrst 3 to 6 mo), even in the presence of
concurrent heart disease and when ventricular rate control
was adequate before ablation.790 While that study lacked
a control group of patients with HF, in another study cath-
eter ablation of AF was associated with reduced mortality
and morbidity due to HF and thromboembolism.791
In selected patients, radiofrequency catheter ablation of
the AV node and pacemaker insertion decreased symptoms
of AF and improved quality-of-life scores compared with
medication therapy.363,387,388,792–794 Baseline quality-of-life
scores are generally lower for patients with AF or atrial
ﬂutter than for those undergoing ablation for other arrhyth-
mias.795 A meta-analysis of 10 studies of patients with AF389
found improvement in both symptoms and quality-of-life
scores after ablation and pacing. Although these studies
involved selected patients who remained in AF, the consist-
ent improvement suggests that quality of life was impaired
before intervention. Two studies have described improve-
ment in symptoms and quality of life after radiofrequency
catheter ablation of atrial ﬂutter.796,797 New studies com-
paring strict versus lenient rate control are under way to
investigate this issue further.
Despite these advances, the long-term efﬁcacy of cath-
eter ablation to prevent recurrent AF requires further
study. Available data demonstrate 1 y or more free from
recurrent AF in most (albeit carefully selected)
patients.798–800 It is important to bear in mind, however,
that AF can recur without symptoms and be unrecognized
by the patient or the physician. Therefore, it remains uncer-
tain whether apparent cures represent elimination of AF or
transformation into an asymptomatic form of paroxysmal AF.
The distinction has important implications for the duration
of anticoagulation therapy in patients with risk factors for
stroke associated with AF. In addition, little information is
yet available about the late success of ablation in patients
with HF and other advanced structural heart disease, who
may be less likely to enjoy freedom from AF recurrence.
8.3.4.2.1. Complications of catheter-based ablation. Com-
plications of catheter ablation include the adverse events
associated with any cardiac catheterization procedure in
addition to those speciﬁc to ablation of AF. Major compli-
cations have been reported in about 6% of procedures and
include PV stenosis, thromboembolism, atrioesophageal
ﬁstula, and LA ﬂutter.788 The initial ablation approach target-
ing PV ectopy was associated with an unacceptably high rate
of PV stenosis,780,801 but the incidence has dramatically
decreased as a result of changes in technique. Current
approaches avoid delivering radiofrequency energy within
the PV and instead target areas outside the veins to isolate
the ostia from the remainder of the LA conducting tissue.
Use of intracardiac echocardiographically detected micro-
bubble formation to titrate radiofrequency energy has also
been reported to reduce the incidence of PV stenosis.783
Embolic stroke is among the most serious complications of
catheter-based ablation procedures in patients with AF. The
incidence varies from 0% to 5%. A higher intensity of anti-
coagulation reduces the risk of thrombus formation during
ablation.802 A comparison of 2 heparin dosing regimens
found LA thrombus in 11.2% of patients when the activated
clotting time (ACT) was 250 to 300 s compared with 2.8%
when the ACT was kept greater than 300 s. Based on these
observations, it seems likely that more aggressive anticoa-
gulation may reduce the incidence of thromboembolism
associated with catheter-based ablation of AF.
Atrioesophageal ﬁstula has been reported with both the
circumferential Pappone approach803,804 and the Haissa-
guerre PV ablation techniques804 but is relatively rare. This
complication may be more likely to occur when extensive
ablative lesions are applied to the posterior LA wall, increas-
ing the risk of atrial perforation. The typical manifestations
include sudden neurological symptoms or endocarditis, and
the outcome in most cases is, unfortunately, fatal.
Depending on the ablation approach, LA ﬂutter may
develop during treatment of AF,805 and this is typically
related to scars created during catheter ablation. An incom-
plete line of ablation is an important predictor of postproce-
dural LA ﬂutter, and extending the ablation line to the
mitral annulus may reduce the frequency of this compli-
cation. In most cases, LA ﬂutter is amenable to further
ablation.806
8.3.4.2.2. Future directions in catheter-based ablation
therapy for atrial ﬁbrillation. Catheter-directed ablation
of AF represents a substantial achievement that promises
better therapy for a large number of patients presently
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resistant to pharmacological or electrical conversion to sinus
rhythm. The limited available studies suggest that catheter-
based ablation offers beneﬁt to selected patients with AF,
but these studies do not provide convincing evidence of
optimum catheter positioning or absolute rates of treatment
success. Identiﬁcation of patients who might beneﬁt from
ablation must take into account both potential beneﬁts
and short- and long-term risks. Rates of success and compli-
cations vary, sometimes considerably, from one study to
another because of patient factors, patterns of AF, criteria
for deﬁnition of success, duration of follow-up, and techni-
cal aspects. Registries of consecutive case series should
incorporate clear and prospectively deﬁned outcome vari-
ables. Double-blind studies are almost impossible to
perform, yet there is a need for randomized trials in which
evaluation of outcomes is blinded as to treatment modality.
A comprehensive evaluation of the favorable and adverse
effects of various ablation techniques should include
measures of quality of life and recurrence rates compared
with pharmacological strategies for rhythm control and,
when this is not successful, with such techniques of rate
control as AV node ablation and pacing. Generation of
these comparative data over relatively long periods of
observation would address the array of invasive and conser-
vative management approaches available for management
of patients with AF and provide a valuable foundation for
future practice guidelines.
8.3.4.3. Suppression of atrial ﬁbrillation through pacing.
Several studies have examined the role of atrial pacing,
either in the RA alone or in more than one atrial location,
to prevent recurrent paroxysmal AF. In patients with
symptomatic bradycardia, the risk of AF is lower with
atrial than with ventricular pacing.807 In patients with sinus
node dysfunction and normal AV conduction, data from
several randomized trials support atrial or dual-chamber
rather than ventricular pacing for prevention of AF.808–811
The mechanisms by which atrial pacing prevents AF in
patients with sinus node dysfunction include prevention
of bradycardia-induced dispersion of repolarization and
suppression of atrial premature beats. Atrial or dual-
chamber pacing also maintains AV synchrony, preventing
retrograde ventriculoatrial conduction that can cause
valvular regurgitation and stretch-induced changes in atrial
electrophysiology. When ventricular pacing with dual-
chamber devices is unavoidable because of concomitant
disease of the AV conduction system, the evidence is less
clear that atrial-based pacing is superior.
While atrial pacing is effective in preventing development
of AF in patients with symptomatic bradycardia, its utility as
a treatment for paroxysmal AF in patients without conven-
tional indications for pacing has not been proved.812 In the
Atrial Pacing Peri-Ablation for the Prevention of AF (PA3)
study, patients under consideration for AV junction ablation
received dual-chamber pacemakers and were randomized to
atrial pacing versus no pacing. There was no difference in
time to ﬁrst occurrence of AF or total AF burden.812 In a con-
tinuation of this study comparing atrial pacing with AV syn-
chronous pacing, patients were randomized to DDDR versus
VDD node pacing after ablation of the AV junction. Once
again, there was no difference in time to ﬁrst recurrence
of AF or AF burden, and 42% of the patients lapsed into per-
manent AF by the end of 1 y.813
It has been suggested that the incidence of AF may be
lower with atrial septal pacing or multisite atrial pacing
than with pacing in the RA appendage.814 Pacing at right
interatrial septal sites results in preferential conduction to
the LA via Bachmann’s bundle. Pacing from this site shortens
P-wave duration and interatrial conduction time. Clinical
trials of pacing in the interatrial septum to prevent episodes
of paroxysmal AF have yielded mixed results.815–817 While 2
small randomized trials found that atrial septal pacing
reduced the number of episodes of paroxysmal AF and the
incidence of persistent AF at 1 y compared with RA appen-
dage pacing,815,816 a larger trial showed no effect on AF
burden despite reduction in symptomatic AF.817
Both bi-atrial (RA appendage and either the proximal or
distal coronary sinus) and dual-site (usually RA appendage
and coronary sinus ostium) pacing have been studied as
means of preventing AF. A small trial of biatrial pacing to
prevent recurrent AF found no beneﬁt compared with con-
ventional RA pacing,818 and a larger trial revealed no
beneﬁt from dual-site compared with single-site pacing,
except in certain subgroups.819 The greater complexity
and more extensive apparatus required have limited the
appeal of dual-site pacing.
Several algorithms have been developed to increase the
percentage of atrial pacing time to suppress atrial premature
beats, prevent atrial pauses, and decrease atrial cycle length
variation in the hope of preventing AF. Prospective studies of
devices that incorporate these algorithms have yielded
mixed results. In one large trial, these pacemaker algorithms
decreased symptomatic AF burden, but the absolute differ-
ence was small, and there was no gain in terms of quality
of life, mean number of AF episodes, hospitalizations, or
mean duration of AF detected by the pacemaker’s automatic
mode-switching algorithm.820 Other trials have failed to show
any beneﬁt of atrial pacing in preventing AF.817,821
In addition to pacing algorithms to prevent AF, some
devices are also capable of pacing for termination of AF.
While efﬁcacy has been shown for termination of more
organized atrial tachyarrhythmias, there has been little
demonstrated effect on total AF burden.821,822
In summary, atrial-based pacing is associated with a lower
risk of AF and stroke than ventricular-based pacing in
patients requiring pacemakers for bradyarrhythmias, but
the value of pacing as a primary therapy for prevention of
recurrent AF has not been proven.
8.3.4.4. Internal atrial deﬁbrillators. In a sheep model of
internal cardioversion of AF,354 delivery of synchronous
shocks between the high RA and coronary sinus effectively
terminated episodes of AF. A clinical trial of a low-energy
transvenous atrial cardioverter that delivered a 3/3-ms
biphasic waveform shock synchronized to the R wave
established the safety of internal atrial cardioversion, but
the energy required in patients with persistent AF was
relatively high (mean 3.5 J).355 Intense basic and clinical
research to ﬁnd more tolerable shock waveforms led to
evaluation of an implantable device capable of both atrial
sensing and cardioversion and ventricular sensing and
pacing in 290 patients with mean LV ejection fraction
greater than 50% who had not responded satisfactorily to
therapy with 4 antiarrhythmic drugs.355 In total, 614
episodes of AF were treated with 1497 shocks (mean 2.4
shocks per episode), and the rate of conversion to sinus
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rhythm was 93%. As spontaneous episodes were treated
quickly, the interval between episodes of AF lengthened.
Several available devices combining both atrial cardiover-
sion and ventricular deﬁbrillation capabilities with dual-
chamber sensing and pacing have been designed to treat
both atrial and ventricular arrhythmias by pacing before
delivering low- or high-energy shocks. A number of other
techniques to terminate AF by pacing are also under investi-
gation, but indications may be limited to atrial tachycardia
and atrial ﬂutter. Because these units accurately record the
occurrence of AF, however, they provide valuable represen-
tation of AF control.
An important limitation of atrial deﬁbrillators, unrelated
to efﬁcacy, is that most patients ﬁnd discharge energies
over 1 J uncomfortable without sedation requiring a
medical setting, and the mean cardioversion threshold is
approximately 3 J, making such devices in their current
form unacceptable for wide clinical use. Optimal devices
would use atrial pacing to maintain sinus rhythm after cardi-
oversion, and some patients require additional therapy to
avoid frequent paroxysms of AF. Candidates for atrial cardi-
overters with infrequent episodes of poorly tolerated AF are
typically also candidates for catheter ablation. As a result,
implanted devices have limited utility, except for patients
with LV dysfunction who are candidates for implantable ven-
tricular deﬁbrillators.
8.4. Special considerations
8.4.1. Postoperative AF
Recommendations
Class I
(1) Unless contraindicated, treatment with an oral beta
blocker to prevent postoperative AF is recommended for
patients undergoing cardiac surgery. (Level of Evidence: A)
(2) Administration of AV nodal blocking agents is rec-
ommended to achieve rate control in patients who
develop postoperative AF. (Level of Evidence: B)
Class IIa
(1) Preoperative administration of amiodarone reduces the
incidence of AF in patients undergoing cardiac surgery
and represents appropriate prophylactic therapy for
patients at high risk for postoperative AF. (Level of Evi-
dence: A)
(2) It is reasonable to restore sinus rhythm by pharmaco-
logical cardioversion with ibutilide or direct-current car-
dioversion in patients who develop postoperative AF as
advised for nonsurgical patients. (Level of Evidence: B)
(3) It is reasonable to administer antiarrhythmic medi-
cations in an attempt to maintain sinus rhythm in
patients with recurrent or refractory postoperative AF,
as recommended for other patients who develop AF.
(Level of Evidence: B)
(4) It is reasonable to administer antithrombotic medication
in patients who develop postoperative AF, as recom-
mended for nonsurgical patients. (Level of Evidence: B)
Class IIb
Prophylactic administration of sotalol may be considered
for patients at risk of developing AF following cardiac
surgery. (Level of Evidence: B)
Although AF may occur after noncardiac surgery, the inci-
dence of atrial arrhythmias including AF after open-heart
surgery is between 20% and 50%,823–825 depending on deﬁ-
nitions and methods of detection. The incidence of post-
operative AF is increasing, perhaps more because of the
age of surgical patients than because of technical factors,
and this is associated with increased morbidity and costs.
8.4.1.1. Clinical and pathophysiological correlates.
Postoperative AF usually occurs within 5 d of open-heart
surgery, with a peak incidence on the second day. A
number of studies have examined the predictors of AF,
cost impact, length of hospital stay, and the effects of
various prophylactic interventions aimed at reducing the
incidence of AF,824,826–830 but many of these reﬂect earlier
models of patient management. In an observational study
of 4657 patients undergoing coronary artery bypass graft
(CABG) surgery at 70 centers between 1996 and 2000,
predictors of AF included age, a history of AF, COPD,
valvular heart disease, atrial enlargement, perioperative
HF, and withdrawal of either beta blocker or ACE inhibitor
medications before or after surgery831 (Table 24). Many
patients have none of these factors, however, and it is
likely that the greater collagen content of the atria in
older patients or other factors related to the biology of
aging are responsible825 for the greater propensity of
elderly patients to develop AF after cardiac surgery832
(Table 24). Other contributing factors are pericarditis826
and increased sympathetic tone. In a review of 8051
consecutive patients without previously documented AF
(mean 64 y, 67% males) undergoing cardiac surgery (84%
involving CABG only) between 1994 and 2004, there was a
strong, independent association between obesity (body
mass index over 30.1 kg/m2) and the development of
postoperative AF. During the index hospitalization, AF
developed in 22.5% of all cases, and 52% of those over age
85 y, compared with 6.2% of patients younger than
40 y. Among the extremely obese, the relative risk of
postoperative AF was 2.39. ‘Off-pump’ CABG was
associated with 39% lower likelihood of developing AF than
conventional on-pump surgery, and the risk of AF
correlated with the duration of cardiopulmonary bypass.833
The arrhythmia is usually self-correcting, and sinus rhythm
Table 24 Multivariate predictors of post-
operative atrial arrhythmias in patients
undergoing myocardial revascularization
surgery
Advanced age
Male gender
Digoxin
Peripheral arterial disease
Chronic lung disease
Valvular heart disease
Left atrial enlargement
Previous cardiac surgery
Discontinuation of beta-blocker medication
Preoperative atrial tachyarrhythmias
Pericarditis
Elevated postoperative adrenergic tone
Adapted with permission from the Society of
Thoracic Surgeons (Creswell LL, Schuessler RB,
Rosenbloom M, Cox JL. Hazards of postoperative
atrial arrhythmias. Ann Thorac Surg 1993;56:
539–49).824
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resumes in more than 90% of patients by 6 to 8 wk after
surgery,832 a rate of spontaneous resolution higher than for
other forms of AF. Patients with postoperative AF have a
higher inpatient mortality than patients without this
arrhythmia (4.7% vs. 2.1%) and longer hospital stay
(median difference 2 d).831 In another study, postoperative
AF was an independent predictor of long-term mortality
(adjusted odds ratio [OR] 1.5, p less than 0.001 in
retrospective cohort, and OR 3.4, p ¼ 0.0018 in a case-
control analysis) over 4 to 5 y.834
8.4.1.2. Prevention of postoperative AF. A meta-analysis of
13 randomized trials of prophylactic antiarrhythmic therapy
involving 1783 patients undergoing cardiac surgery in which
effects on hospital length of stay were addressed found that
while these consistently showed decreases in the incidence
of AF, the effects on hospital stay were less concordant
and amounted to a 1.0 plus or minus 0.2 d overall decrease
in length of hospital stay (p less than 0.001).835 A systematic
Cochrane database review found 58 studies with a total of
8565 participants in which interventions included amiodar-
one, beta blockers, solatol, and pacing. By meta-analysis,
the effect size for prevention of stroke by prophylactic
treatment for AF was not statistically signiﬁcant, nor was
the effect on length or cost of hospital stay. Beta blockers
had the greatest magnitude of effect across 28 trials (4074
patients).836 In a meta-analysis of 24 trials825 limited to
patients with ejection fraction greater than 30% undergoing
CABG, prophylactic administration of beta-blocker medi-
cation protected against supraventricular tachycardia (OR
0.28, 95% CI 0.21 to 0.36). In a meta-analysis of 27 trials
including 3840 patients, sotalol (80 or 120 mg twice daily)
was more effective in reducing postoperative AF than
either other beta-blocker medication or placebo,829 but
the results were not conﬁrmed in another study,491 in
which the difference between sotalol and beta-blocker
treatment was small.
When the prophylactic value of amiodarone, 600 mg per
day, initiated at least 7 d preoperatively, was evaluated in
124 patients undergoing cardiac surgery, the incidence of
AF was 25% in the treated group compared with 53% in
patients randomized to placebo (p ¼ 0.003).837 This approach
is impractical unless patients are identiﬁed and treatment
started at least 1 wk before surgery. The Amiodarone
Reduction in Coronary Heart (ARCH) trial involving 300
patients found that postoperative intravenous administration
of amiodarone (1 g daily for 2 d) reduced the incidence of
postoperative AF from 47% to 35% compared with placebo
(p¼ 0.01). The higher overall incidence of postoperative AF
and less pronounced prophylactic effect than in other
studies may have been partly related to less-frequent use
of beta blockers.838 More convincing evidence of the efﬁcacy
of amiodarone for prevention of AF in patients undergoing
cardiac surgery comes from the Prophylactic Oral Amiodarone
for the Prevention of Arrhythmias that Begin Early after
Revascularization, Valve Replacement, or Repair (PAPABEAR)
trial, in which a 13-d perioperative course of oral amiodarone
(10 mg/kg daily beginning 6 d before and continuing for 6 d
after surgery) halved the incidence of postoperative atrial
tachyarrhythmias, including AF patients undergoing CABG,
valve replacement, or valve repair surgery with or without
CABG surgery.839 Although efﬁcacy was evident whether or
not beta-blocking medication was given concurrently, rates
of beta-blocker therapy withdrawal were not reported;
hence, differential withdrawal of beta blockers from more
patients in the placebo group may have exaggerated the
apparent effect of amiodarone.840
Pretreatment with either digoxin or verapamil does not
reliably prevent postoperative AF.825,841,842 Results with pro-
cainamide have been inconsistent, and this drug is not
widely used for prevention of postoperative AF.843 One
report suggested that n-3 polyunsaturated fatty acids may
be effective for prevention of AF in patients undergoing
CABG surgery.844
There is limited evidence that single-chamber and biatrial
overdrive pacing prevents postoperative AF. In a randomized
trial involving 132 patients undergoing CABG, postoperative
biatrial pacing signiﬁcantly reduced the incidence of AF in
the biatrial pacing group by 12.5% compared with the
other 3 groups (36% LA pacing, 33% RA pacing, and 42%
without pacing; p , 0.05). The length of hospital stay was
also signiﬁcantly reduced in the biatrial pacing group.845 A
meta-analysis of 10 randomized trials comparing various
types of atrial pacing to routine care after CABG surgery
found that AF was reduced by RA pacing (OR 0.68, 95% CI
0.39 to 1.19), LA pacing (OR 57, 95% CI 0.28 to 1.16), and
biatrial pacing (OR 0.46, 95% CI 0.30 to 0.71), but the
number of enrolled patients was small and the pacing sites
and protocols varied.846 Available data suggest that biatrial
pacing may be superior to either LA or RA pacing for preven-
tion of postoperative AF, but evidence is insufﬁcient to
permit ﬁrm conclusions or recommendations about this pro-
phylactic modality.
8.4.1.3. Treatment of postoperative AF. Comorbidity
including adrenergic stress often makes it difﬁcult to
control the ventricular rate in patients with postoperative
AF. Short-acting beta-blocker agents are particularly useful
when hemodynamic instability is a concern. Other AV
nodal blocking agents, such as the nondihydropyridine
calcium channel antagonist agents, can be used as
alternatives, but digoxin is less effective when adrenergic
tone is high. Intravenous amiodarone has been associated
with improved hemodynamics in this setting.379
Given the self-limited course of postoperative AF, direct-
current cardioversion is usually unnecessary except when
the arrhythmia develops in the early hypothermic period.
In the highly symptomatic patient or when rate control is dif-
ﬁcult to achieve, cardioversion may be performed using the
same precautions regarding anticoagulation as in nonsurgical
cases. A variety of pharmacological agents, including amio-
darone,837,838,847 procainamide,841 ibutilide, and sotalol,
may be effective to convert AF to sinus rhythm. Although a
class III agent (e.g., ibutilide) was more effective than
placebo for treatment of postoperative AF in one study,848
oral sotalol is appealing in this situation because its beta-
blocking action slows the ventricular rate and proarrhythmic
toxicity is relatively infrequent, but this agent seems less
effective than others for cardioversion of AF.
A number of studies have shown an increased risk of
stroke in post-CABG patients. Accordingly, anticoagulation
with heparin or oral anticoagulation is appropriate when AF
persists longer than 48 h.849,850 This entails special challenges
because of the greater potential for bleeding in surgical
patients. The choice of drug, heparin and/or an oral anticoa-
gulant, must be based on the individual clinical situation.
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Atrial ﬂutter is less common than AF after cardiac
surgery,851 but pharmacological therapy is similar. Prevention
of postoperative atrial ﬂutter is as difﬁcult as prevention of
AF, but atrial overdrive pacing is generally useful for termin-
ation of atrial ﬂutter when epicardial electrodes are in place.
8.4.2. Acute myocardial infarction
Recommendations
Class I
(1) Direct-current cardioversion is recommended for
patients with severe hemodynamic compromise or
intractable ischemia, or when adequate rate control
cannot be achieved with pharmacological agents in
patients with acute MI and AF. (Level of Evidence: C)
(2) Intravenous administration of amiodarone is rec-
ommended to slow a rapid ventricular response to AF
and improve LV function in patients with acute MI.
(Level of Evidence: C)
(3) Intravenous beta blockers and nondihydropyridine
calcium antagonists are recommended to slow a rapid
ventricular response to AF in patients with acute MI
who do not display clinical LV dysfunction, bronchos-
pasm, or AV block. (Level of Evidence: C)
(4) For patients with AF and acute MI, administration of
unfractionated heparin by either continuous intravenous
infusion or intermittent subcutaneous injection is rec-
ommended in a dose sufﬁcient to prolong the activated
partial thromboplastin time to 1.5 to 2.0 times the
control value, unless contraindications to anticoagula-
tion exist. (Level of Evidence: C)
Class IIa
Intravenous administration of digitalis is reasonable to
slow a rapid ventricular response and improve LV function
in patients with acute MI and AF associated with severe LV
dysfunction and HF. (Level of Evidence: C)
Class III
The administ?h -1wration of class IC antiarrhythmic drugs
is not recommended in patients with AF in the setting of
acute MI. (Level of Evidence: C)
Estimates of the incidence of AF in patients with acute MI
vary depending on the population sampled. In the Coopera-
tive Cardiovascular Project, 22% of Medicare beneﬁciaries 65
y or older hospitalized for acute MI had AF.270 In the Trando-
lapril Cardiac Evaluation (TRACE) study of patients with LV
dysfunction associated with acute MI, 21% had AF.852 Lower
rates of AF were observed in patients selected for other pro-
spective trials, such as the Global Utilization of Streptoki-
nase and Tissue Plasminogen Activator for Occluded
Coronary Arteries (GUSTO-I) study, in which the incidence
was 10.4%,853 but this may reﬂect the younger age of
patients presenting with acute MI associated with ST-
segment elevation on the ECG. AF is more commonly associ-
ated with acute MI in older patients and those with higher
Killip class or LV dysfunction.
AF is associated with increased in-hospital mortality in the
setting of acute MI (25.3% with AF vs. 16.0% without AF), 30-
d mortality (29.3% vs. 19.1%), and 1-y mortality (48.3% vs.
32.7%).270 Patients who developed AF during hospitalization
had a worse prognosis than those with AF on admission.270
Stroke rates are also increased in patients with MI and AF
compared with those without AF.853 Outcomes for patients
with AF and acute MI have improved in the thrombolytic
era compared with prior experience, but a stroke rate of
3.1%853 emphasizes the importance of this association in
contemporary clinical practice.
Speciﬁc recommendations for management of patients
with AF in the setting of acute MI are based primarily on con-
sensus, because no adequate trials have tested alternative
strategies. The recommendations in this document are
intended to comply with the ACC/AHA Guidelines for the
Management of Patients With ST-Elevation Myocardial Infarc-
tion.854 Physicians should apply the guidelines for manage-
ment outlined elsewhere in this document with emphasis on
recognition of AF and risk stratiﬁcation and recognize the sig-
niﬁcance of the arrhythmia as an independent predictor of
poor long-term outcome in patients with acute MI.855,856
Urgent direct-current cardioversion is appropriate in acute
MI patients presenting with AF and intractable ischemia or
hemodynamic instability. Intravenous administration of a
beta blocker is indicated for rate control in patients with
acute MI to reduce myocardial oxygen demands. Digoxin is
an appropriate alternative for patients with acute MI associ-
ated with severe LV dysfunction and HF. Anticoagulants are
indicated in those with large anterior infarcts and in survivors
of acute MI who develop persistent AF. Treatment with ACE
inhibitors appears to reduce the incidence of AF in patients
with LV dysfunction after acute MI.857 In patients with
reduced LV systolic function after MI, the placebo-controlled
CAPRICORN trial demonstrated a signiﬁcant reduction in the
incidence of AF and/or atrial ﬂutter in patients treated
with carvedilol (5.4% vs. 2.3%).858
8.4.3. Wolff-Parkinson-White (WPW) preexcitation
Syndromes
Recommendations
Class I
(1) Catheter ablation of the accessory pathway is rec-
ommended in symptomatic patients with AF who have
WPW syndrome, particularly those with syncope due to
rapid heart rate or those with a short bypass tract
refractory period. (Level of Evidence: B)
(2) Immediate direct-current cardioversion is recommended
to prevent ventricular ﬁbrillation in patients with a
short anterograde bypass tract refractory period in
whom AF occurs with a rapid ventricular response associ-
ated with hemodynamic instability. (Level of Evidence: B)
(3) Intravenous procainamide or ibutilide is recommended
to restore sinus rhythm in patients with WPW in whom
AF occurs without hemodynamic instability in associ-
ation with a wide QRS complex on the ECG (greater
than or equal to 120-ms duration) or with a rapid preex-
cited ventricular response. (Level of Evidence: C)
Class IIa
Intravenous ﬂecainide or direct-current cardioversion is
reasonable when very rapid ventricular rates occur in
patients with AF involving conduction over an accessory
pathway. (Level of Evidence: B)
Class IIb
It may be reasonable to administer intravenous quinidine,
procainamide, disopyramide, ibutilide, or amiodarone to
hemodynamically stable patients with AF involving conduc-
tion over an accessory pathway. (Level of Evidence: B)
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Class III
Intravenous administration of digitalis glycosides or nondihy-
dropyridine calcium channel antagonists is not recommended
in patients withWPW syndrome who have preexcited ventricu-
lar activation during AF. (Level of Evidence: B)
Although the most feared complication of AF in patients
with WPW syndrome is ventricular ﬁbrillation and sudden
death resulting from antegrade conduction of atrial
impulses across a bypass tract, this actually occurs infre-
quently. The incidence of sudden death ranges from 0% to
0.6% per year in patients with WPW syndrome.460,634,823,859
In contrast, a large population-based study in Olmsted
County, Minnesota, found 4 newly diagnosed cases of WPW
syndrome per 100 000 people per year. There were only 2
sudden deaths over 1338 patient-y of follow-up, however.
Among 113 patients with WPW syndrome, 6 had documented
AF and 3 had atrial ﬂutter. Patients with WPW syndrome at
high risk of sudden death are those with short antegrade
bypass tract refractory periods (less than 250 ms) and
short R-R intervals during preexcited AF (180 plus or minus
29 ms).178,860 In patients prone to ventricular ﬁbrillation,
there is also a higher incidence of multiple pathways.178
When a patient with a preexcited tachycardia is clinically
stable, intravenous procainamide may be given to convert
AF to sinus rhythm. It is critically important to avoid
agents with the potential to increase the refractoriness of
the AV node, which could encourage preferential conduction
over the accessory pathway. Speciﬁcally, administration of
AV nodal blocking agents such as digoxin, diltiazem, or ver-
apamil is contraindicated. Beta blockers are ineffective in
this situation, and their administration via the intravenous
route may have adverse hemodynamic effects.
Flecainide can slow the ventricular rate in patients who
have AF associated with a very rapid tachycardia due to an
accessory pathway and may terminate AF861–864 by prolong-
ing the shortest preexcited cycle length during AF. Propafe-
none seems less effective in this respect.861
For patients with preexcitation syndromes and AF who
have syncope (suggesting rapid heart rate) or a short antero-
grade bypass tract refractory period, immediate direct-
current cardioversion followed by catheter ablation of the
accessory pathway is the preferred therapy.865 Ablation of
the bypass tract does not necessarily prevent AF, however,
especially in older patients, and additional pharmacological
therapy may be required. Once the accessory pathway has
been eliminated, the selection of pharmacological therapy
can parallel that for patients without preexcitation.
8.4.4. Hyperthyroidism
Recommendations
Class I
(1) Administration of a beta blocker is recommended to
control the rate of ventricular response in patients
with AF complicating thyrotoxicosis, unless contraindi-
cated. (Level of Evidence: B)
(2) In circumstances when a beta blocker cannot be used,
administration of a nondihydropyridine calcium
channel antagonist (diltiazem or verapamil) is rec-
ommended to control the ventricular rate in patients
with AF and thyrotoxicosis. (Level of Evidence: B)
(3) In patients with AF associated with thyrotoxicosis, oral
anticoagulation (INR 2.0 to 3.0) is recommended to
prevent thromboembolism, as recommended for AF
patients with other risk factors for stroke. (Level of
Evidence: C)
(4) Once a euthyroid state is restored, recommendations for
antithrombotic prophylaxis are the same as for patients
without hyperthyroidism. (Level of Evidence: C)
AF occurs in 10% to 25% of patients with hyperthyroidism,
more commonly in men and elderly patients than in women
or patients younger than 75 y.866 Treatment is directed pri-
marily toward restoring a euthyroid state, which is usually
associated with a spontaneous reversion to sinus rhythm.
Antiarrhythmic drugs and direct-current cardioversion are
generally unsuccessful while the thyrotoxic condition per-
sists.867,868 Beta blockers are effective in controlling the
ventricular rate in this situation, and aggressive treatment
with intravenous beta blockers is particularly important in
cases of thyroid storm, when high doses may be required.
Nondihydropyridine calcium channel antagonists may also
be useful.869 Although speciﬁc evidence is lacking in AF
caused by hyperthyroidism, oral anticoagulation is rec-
ommended to prevent systemic embolism.870
Several reports suggest that patients with AF in the
setting of thyrotoxicosis, which is often associated with
decompensated HF, are also at high risk,418,419,422 although
the mechanism underlying this enhanced embolic potential
is not clear.203,416,423 The notion of increased thromboem-
bolic risk in thyrotoxic AF has been challenged on the basis
of comparison with patients in sinus rhythm, and logistic
regression analysis found age the only independent predic-
tor of cerebral ischemic events.319 Although 13% of patients
with AF had ischemic cerebrovascular events (6.4% per year)
compared with 3% of those in normal sinus rhythm (1.7% per
year),203,268,320 there was no adjustment for duration of
observation or time to event. When TIAs are discounted,
the increased risk of stroke in patients with AF reached stat-
istical signiﬁcance (p ¼ 0.03).319 Although it remains contro-
versial whether patients with AF associated with
thyrotoxicosis are at increased risk of thromboembolic
cerebrovascular events,421 the authors of these guidelines
favor treatment with anticoagulant medication in the
absence of a speciﬁc contraindication, at least until a
euthyroid state has been restored and HF has been cured.
8.4.5. Pregnancy
Recommendations
Class I
(1) Digoxin, a beta blocker, or a nondihydropyridine calcium
channel antagonist is recommended to control the rate
of ventricular response in pregnant patients with AF.
(Level of Evidence: C)
(2) Direct-current cardioversion is recommended in preg-
nant patients who become hemodynamically unstable
due to AF. (Level of Evidence: C)
(3) Protection against thromboembolism is recommended
throughout pregnancy for all patients with AF (except
those with lone AF and/or low thromboembolic risk).
Therapy (anticoagulant or aspirin) should be chosen
according to the stage of pregnancy. (Level of Evidence: C)
Class IIb
(1) Administration of heparin may be considered during the
ﬁrst trimester and last month of pregnancy for patients
ACC/AHA/ESC Guidelines 717
Downloaded from https://academic.oup.com/europace/article-abstract/8/9/651/530495
by guest
on 02 April 2018
with AF and risk factors for thromboembolism. Unfrac-
tionated heparin may be administered either by continu-
ous intravenous infusion in a dose sufﬁcient to prolong
the activated partial thromboplastin time to 1.5 to 2
times the control value or by intermittent subcutaneous
injection in a dose of 10 000 to 20 000 units every 12 h,
adjusted to prolong the mid-interval (6 h after injec-
tion) activated partial thromboplastin time to 1.5
times control. (Level of Evidence: B)
(2) Despite the limited data available, subcutaneous admin-
istration of low-molecular-weight heparin may be con-
sidered during the ﬁrst trimester and last month of
pregnancy for patients with AF and risk factors for
thromboembolism. (Level of Evidence: C)
(3) Administration of an oral anticoagulantmay be considered
during the second trimester for pregnant patients with AF
at high thromboembolic risk. (Level of Evidence: C)
(4) Administration of quinidine or procainamide may be
considered to achieve pharmacological cardioversion in
hemodynamically stable patients who develop AF
during pregnancy. (Level of Evidence: C)
AF is rare during pregnancy and usually has an identiﬁable
underlying cause, such as mitral stenosis,875 congenital
heart disease,876 or hyperthyroidism.877 A rapid ventricular
response to AF can have serious hemodynamic consequences
for both the mother and the fetus.
In a pregnant woman who develops AF, diagnosis and treat-
ment of the underlying condition causing the arrhythmia are
the ﬁrst priorities. The ventricular rate should be controlled
with digoxin, a beta blocker, or a nondihydropyridine calcium
channel antagonist.878–880 All currently available anti-
arrhythmic drugs have the potential to cross the placenta
and enter breastmilk and should therefore be avoided if poss-
ible. Quinidine,879 sotalol,881 ﬂecainide,881 and amiodar-
one870,876–878 have all been used successfully during
pregnancy, however, in relatively small numbers of cases.
Quinidine has the longest record of safety in pregnant
women and remains the agent of choice for pharmacological
cardioversion of AF in this situation.497,879 In the event of
hemodynamic embarrassment, direct-current cardioversion
can be performed without fetal damage.879
The role of anticoagulation to prevent systemic arterial
embolism has not been systematically studied in pregnant
patients with AF, but the arrhythmia is frequently associated
with conditions that carry a high risk of thromboembolism,
including congenital or valvular heart disease. Consideration
should be given to avoiding warfarin because it crosses the
placental barrier and is associated with teratogenic embryo-
pathy in the ﬁrst trimester and with fetal hemorrhage in the
later stages of pregnancy.880–886 Heparin is the preferred
anticoagulant because it does not cross the placenta. The
safety and efﬁcacy of subcutaneous unfractionated heparin
or low-molecular-weight heparin in preventing ischemic
stroke in patients with AF during pregnancy have not been
proved, and experience with these agents mainly involves
patients with prosthetic heart valves or venous thromboembo-
lism. In patients with prosthetic valves who have AF, unfrac-
tionated heparin can be administered either by continuous
intravenous infusion or by twice-daily subcutaneous injections
in a dose between 10 000 and 20 000 units adjusted to prolong
the mid-interval activated partial thromboplastin time to 1.5
times the control value. The same strategies are proposed for
patients without prosthetic valves who have AF and risk
factors for thromboembolism.887,888
8.4.6. Hypertrophic cardiomyopathy
Recommendations
Class I
Oral anticoagulation (INR 2.0 to 3.0) is recommended in
patients with hypertrophic cardiomyopathy who develop
AF, as for other patients at high risk of thromboembolism.
(Level of Evidence: B)
Class IIa
Antiarrhythmic medications can be useful to prevent
recurrent AF in patients with hypertrophic cardiomyopathy.
Available data are insufﬁcient to recommend one agent over
another in this situation, but (a) disopyramide combined
with a beta blocker or nondihydropyridine calcium channel
antagonist or (b) amiodarone alone is generally preferred.
(Level of Evidence: C)
Opinions differ regarding the clinical signiﬁcance of AF in
the setting of HCM. In a retrospective series of 52 patients
studied between 1960 and 1985, 89% of those patients who
developed AF experienced hemodynamic deterioration that
was ameliorated by restoration of sinus rhythm.889 In a multi-
variate analysis of a population-based cohort of 37 patients
with HCM who experienced an annual cardiac mortality rate
of 5%, AF was associated with decreased survival.402 A lower
annual mortality rate (1.3%) was observed in a single-center
retrospective study of 277 patients with HCM. The prevalence
of AF was 18%. Among the 50 cases with AF, 15 deaths were
recorded, a third of which were attributed to stroke.890 The
natural history of HCM is better deﬁned by the combined
experience of 3 large centers following 717 cases for a
mean of 8 plus or minus 7 y, during which there were 86
deaths (12%), 51% of which were sudden (mean age 45 plus
or minus 20 y). Death was attributable to HF in 36% of the
patients (mean age 56 plus or minus 19 y) and to stroke in
13% (mean age 73 plus or minus 14 y). Although most
sudden deaths were attributed to ventricular arrhythmias,
cardiogenic embolism may have been underestimated as a
contributory mechanism. Ten of 11 fatal strokes were associ-
ated with AF. In a study of 480 patients the prevalence of AF
was 22% over 9 y. AF was associated with an increased risk of
HCM-related death (odds ratio 3.7) due to excess HF-related
mortality but not sudden cardiac death. AF patients were at
increased risk for stroke (odds ratio 17.7) and severe func-
tional limitation (odds ratio for NYHA Class III or IV 2.8).891
Studies of patients with HCM and AF892 have consistently
reported a high incidence of stroke and systemic embo-
lism.871–874 These retrospective longitudinal studies report
stroke or systemic embolism in 20% to 40% of patients with
HCM and AF followed up for a mean of 4 to 11 y, for a throm-
boembolism rate of 2.4% to 7.1% per year. In addition to AF,
other factors associated with systemic embolism in patients
with HCM include advanced age,874 hypertension,872 mitral
annular calciﬁcation, and LA enlargement.872 Bymultivariate
analysis, age and AF were independent predictors of throm-
boembolism.874 Although no randomized studies of anticoa-
gulant therapy have been reported, the incidence of
thromboembolism in patients with HCM and AF is high, war-
ranting consideration of anticoagulant medication when AF
persists for longer than 48 h or when recurrence is likely.
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There have been no systematic studies of the treatment
of AF in patients with HCM, but various antiarrhythmic
agents, including disopyramide, propafenone, and amiodar-
one, have been used. Deedwania et al.738 advocate admin-
istration of amiodarone both to prevent episodes of AF and
to modulate the rate of ventricular response. The use of
electrical pacing to prevent AF has not been studied.
8.4.7. Pulmonary diseases
Recommendations
Class I
(1) Correction of hypoxemia and acidosis is the recommended
primary therapeutic measure for patients who develop AF
during an acute pulmonary illness or exacerbation of
chronic pulmonary disease. (Level of Evidence: C)
(2) A nondihydropyridine calcium channel antagonist (diltia-
zem or verapamil) is recommended to control the ven-
tricular rate in patients with obstructive pulmonary
disease who develop AF. (Level of Evidence: C)
(3) Direct-current cardioversion should be attempted in
patients with pulmonary disease who become hemody-
namically unstable as a consequence of AF. (Level of
Evidence: C)
Class III
(1) Theophylline and beta-adrenergic agonist agents are not
recommended in patients with bronchospastic lung
disease who develop AF. (Level of Evidence: C)
(2) Beta blockers, sotalol, propafenone, and adenosine are
not recommended in patients with obstructive lung
disease who develop AF. (Level of Evidence: C)
Supraventricular arrhythmias, including AF, are common
in patients with COPD.893,894 AF has adverse prognostic
implications in patients with acute exacerbations of
COPD.895 Treatment of the underlying lung disease and cor-
rection of hypoxia and acid-base imbalance are of primary
importance in this situation. Theophylline and beta-adre-
nergic agonists, which are commonly used to relieve bronch-
ospasm, can precipitate AF and make control of the
ventricular response rate difﬁcult. Beta blockers, sotalol,
propafenone, and adenosine are contraindicated in patients
with bronchospasm. Rate control can usually be achieved
safely with nondihydropyridine calcium channel antagon-
ists896; digoxin offers no advantage over calcium channel
antagonists in this situation. Pharmacological anti-
arrhythmic therapy and direct-current cardioversion may
be ineffective against AF unless respiratory decompensation
has been corrected. Intravenous ﬂecainide may be efﬁca-
cious in restoring sinus rhythm in some patients,508
however, and direct-current cardioversion may be
attempted in hemodynamically unstable patients. In
patients refractory to drug therapy, AV nodal ablation and
ventricular pacing may be necessary to control the ventricu-
lar rate. Although anticoagulation has not been studied
speciﬁcally in patients with AF due to pulmonary lung
disease, the general recommendations for risk-based antith-
rombotic therapy apply.
8.5. Primary prevention
Although measures aimed at the primary prevention of AF
have not been widely investigated, it has been suggested
that atrial or AV synchronous pacing may reduce the inci-
dence of subsequent AF in patients with bradycardia com-
pared with ventricular pacing.807,808 On the other hand,
studies in patients with intermittent atrial tachyarrhythmias
failed to illustrate a general beneﬁt of atrial pacing.808,822,897
Another potential avenue for primary prevention has been
suggested following secondary analysis of placebo-controlled
trials of treatment with ACE inhibitors.36,749 In the LIFE41 and
CHARM898 trials, the angiotensin receptor antagonists losar-
tan and candesartan reduced the incidence of AF in hyper-
tensive patients with LVH41 and symptomatic HF,40,898
respectively. These results, together with their favorable
safety proﬁle compared with antiarrhythmic agents,
suggest a role for ACE inhibitors or angiotensin receptor
antagonists for primary prevention of initial or recurrent epi-
sodes of AF associated with hypertension, MI, HF, or diabetes
mellitus. An overview of 11 clinical trials involving more than
56 000 patients with different underlying cardiovascular dis-
eases suggests that ACE inhibitors or angiotensin receptor
blockers may reduce the occurrence and recurrence of AF.43
Yet inadequately explored, the use of statins has also
been suggested to protect against AF,335,899 and dietary
lipid components may inﬂuence the propensity of patients
to develop AF.900 In 449 patients with CAD followed for 5 y,
statin therapy reduced the incidence of AF—an effect not
observed with other lipid-lowering drugs.899 In a canine
sterile pericarditis model, atorvastatin prevented atrial
electrophysiological and structural changes associated with
inﬂammation and reduced the incidence of AF.119 Insufﬁ-
cient data are available at this time to permit recommen-
dations for primary prevention of AF in populations at risk
using dietary interventions, pharmacological interventions,
or pacing or other devices.
9. Proposed management strategies
9.1. Overview of algorithms for management of
patients with atrial ﬁbrillation
Management of patients with AF requires knowledge of its
pattern of presentation (paroxysmal, persistent, or perma-
nent), underlying conditions, and decisions about restor-
ation and maintenance of sinus rhythm, control of the
ventricular rate, and antithrombotic therapy. These issues
are addressed in the various management algorithms for
each presentation of AF (see Figures 13–16).
9.1.1. Newly discovered atrial ﬁbrillation
It is not always clear whether the initial presentation of AF is
actually the ﬁrst episode, particularly in patients with
minimal or no symptoms related to the arrhythmia. In
patients who have self-limited episodes of AF, antiarrhythmic
drugs are usually unnecessary to prevent recurrence unless
AF is associated with severe symptoms related to hypoten-
sion, myocardial ischemia, or HF. Regarding anticoagulation,
the results of the AFFIRM study296 indicate that patients with
AF who are at high risk for stroke on the basis of identiﬁed risk
factors generally beneﬁt from anticoagulation even after
sinus rhythm has been restored. Therefore, unless there is a
clear reversible precipitating factor for AF, such as hyperthyr-
oidism that has been corrected, the diagnosis of AF in a
patient with risk factors for thromboembolism should
prompt long-term anticoagulation.
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When AF persists, one option is to accept progression to
permanent AF, with attention to antithrombotic therapy
and control of the ventricular rate. Although it may seem
reasonable to make at least one attempt to restore sinus
rhythm, the AFFIRM study showed no difference in survival
or quality of life with rate-control compared with rhythm-
control strategies.296 Other trials that addressed this issue
reached similar conclusions.293,294,343,344 Hence, the
decision to attempt restoration of sinus rhythm should be
based on the severity of arrhythmia-related symptoms and
the potential risk of antiarrhythmic drugs. If the decision
is made to attempt to restore and maintain sinus rhythm,
then anticoagulation and rate control are important before
cardioversion. Although long-term antiarrhythmic therapy
may not be needed to prevent recurrent AF after cardi-
oversion, short-term therapy may be beneﬁcial. In patients
with AF that has been present for more than 3 mo, early
recurrence is common after cardioversion. In such cases,
antiarrhythmic medication may be initiated before cardio-
version (after adequate anticoagulation) to reduce the like-
lihood of recurrence, and the duration of drug therapy
would be brief (e.g., 1 mo).
9.1.2. Recurrent paroxysmal atrial ﬁbrillation
In patients who experience brief or minimally symptomatic
recurrences of paroxysmal AF, it is reasonable to avoid anti-
arrhythmic drugs, but troublesome symptoms generally call
for suppressive antiarrhythmic therapy. Rate control and
prevention of thromboembolism are appropriate in both
situations. In a given patient, several antiarrhythmic drugs
may be effective, and the initial selection is based mainly
on safety and tolerability (see Figure 15). For individuals
with no or minimal heart disease, ﬂecainide, propafenone,
or sotalol is recommended as initial antiarrhythmic
therapy because these drugs are generally well tolerated
and carry relatively little risk of toxicity. For patients with
recurrent episodes of symptomatic AF who tolerate these
agents, an as-needed, pill-in-the-pocket approach may
reduce the risk of toxicity compared with sustained
therapy. When these drugs prove ineffective or are associ-
ated with side effects, the second- or third-line choices
include amiodarone, dofetilide, disopyramide, procaina-
mide, or quinidine, all of which carry greater potential for
adverse reactions. As an alternative to treatment with amio-
darone or dofetilide when ﬁrst-line antiarrhythmic drugs fail
or are not tolerated, PV isolation or LA substrate modiﬁ-
cation may be considered. When a consistent initiating
scenario suggests vagally mediated AF, drugs such as disopyr-
amide or ﬂecainide are appropriate initial agents, and a
beta blocker or sotalol is suggested for patients with adre-
nergically induced AF. In particularly symptomatic patients,
nonpharmacological options such as LA ablation may be
considered when antiarrhythmic drug treatment alone fails
to control the arrhythmia.
Many patients with organic heart disease can be broadly
categorized into those with HF, CAD, or hypertension.
Other types of heart disease can be associated with AF,
and the clinician must determine which category best
describes the individual patient. For patients with HF,
safety data support the selection of amiodarone or dofeti-
lide to maintain sinus rhythm. Patients with CAD often
require beta blocker medication, and sotalol, a drug with
both beta-blocking activity and primary antiarrhythmic
efﬁcacy, is considered ﬁrst, unless the patient has HF. Amio-
darone and dofetilide are considered secondary agents, and
the clinician should consider disopyramide, procainamide,
or quinidine on an individual basis.
The selection of antiarrhythmic drugs for patients with a
history of hypertension is confounded by the dearth of
prospective, controlled trials comparing the safety and efﬁ-
cacy of drug therapy for AF. In patients with hypertension
without LVH, drugs such as ﬂecainide and propafenone,
which do not prolong repolarization or the QT interval,
may offer a safety advantage and are recommended ﬁrst.
If these agents either prove ineffective or produce side
effects, then amiodarone, dofetilide, or sotalol represents
an appropriate secondary choice. Disopyramide, procaina-
mide, and quinidine are considered third-line agents in
this situation. Hypertrophied myocardium may be prone
to proarrhythmic toxicity and torsades de pointes ventricu-
lar tachycardia. Amiodarone is suggested as ﬁrst-line
therapy in patients with LVH because of its relative safety
compared with several other agents. Because neither ECG
nor echocardiography reliably detects LVH as deﬁned by
measurement of myocardial mass, clinicians may face a
conundrum.
The scarcity of data from randomized trials of anti-
arrhythmic medications for treatment of patients with AF
applies generally to all patient groups. Accordingly, the
drug-selection algorithm presented here has been devel-
oped by consensus and is subject to revision as additional
evidence emerges.
9.1.3. Recurrent persistent atrial ﬁbrillation
Patients with minimal or no symptoms referable to AF who
have undergone at least one attempt to restore sinus
rhythm may remain in AF after recurrence, with therapy
for rate control and prevention of thromboembolism as
needed. Alternatively, those with symptoms favoring sinus
rhythm should be treated with an antiarrhythmic agent (in
addition to medications for rate control and anticoagula-
tion) before cardioversion. The selection of an anti-
arrhythmic drug should be based on the same algorithm
used for patients with recurrent paroxysmal AF. If patients
remain symptomatic with heart rate control, and anti-
arrhythmic medication is either not tolerated or ineffective,
then nonpharmacological therapies may be considered.
These include LA ablation, the maze operation, and AV
nodal ablation and pacing.
9.1.4. Permanent atrial ﬁbrillation
Permanent AF is the designation given to cases in
which sinus rhythm cannot be sustained after cardioversion
of AF or when the patient and physician have decided to
allow AF to continue without further efforts to restore
sinus rhythm. It is important to maintain control of the
ventricular rate and to use antithrombotic therapy, as out-
lined elsewhere in this document, for all patients in this
category.
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Appendix III Abbreviations
ACE angiotensin-converting enzyme
ACT activated clotting time
ACTIVE-W Atrial Fibrillation Clopidogrel Trial with Irbesartan
for Prevention of Vascular Events
ADONIS American-Australian Trial with Dronedarone in
Atrial Fibrillation or Flutter Patients for
Maintenance of Sinus Rhythm
AF atrial ﬁbrillation
AFASAK Copenhagen Atrial Fibrillation, Aspirin,
Anticoagulation
AF-CHF Atrial Fibrillation and Congestive Heart Failure
AFFIRM Atrial Fibrillation Follow-up Investigation of
Rhythm Management
AFI Atrial Fibrillation Investigators
ALFA Etude en Activite´ Libe´rale sur la Fibrillation
Auriculaire
ANP atrial naturetic peptide
APT Ablate and Pace Trial
ARCH Amiodarone Reduction in Coronary Heart
ATRIA Anticoagulation and Risk Factors in Atrial
Fibrillation
AV atrioventricular
BAATAF Boston Area Anticoagulation Trial for Atrial
Fibrillation
BNP B-type natriuretic peptide
CABG coronary artery bypass
CAD coronary artery disease
CAFA Canadian Atrial Fibrillation Anticoagulation
CAPRICORN Carvedilol Post-Infarct Survival Control in Left
Ventricular Dysfunction trial
CHADS2 Cardiac Failure, Hypertension, Age, Diabetes,
Stroke [Doubled]
CHAMP Combined Hemotherapy and Mortality Prevention
Study
CHARM Candesartan in Heart failure, Assessment of
Reduction in Mortality and morbidity
CHF-STAT Survival Trial of Antiarrhythmic Therapy in
Congestive Heart Failure
CI conﬁdence interval
CIBIS Cardiac Insufﬁciency Bisoprolol Study
COMET Carvedilol Or Metoprolol European Trial
CONSENSUS Co-operative North Scandinavian Enalapril
Survival Study
COPERNICUS Carvedilol Prospective Randomized Cumulative
Survival
COPD Chronic obstructive pulmonary disorder
CRP C-reactive protein
CTGF connective tissue growth factoru
CVF-1 type 1 collagen volume fraction
DIAMOND Danish Investigations of Arrhythmias and Mortality
on Dofetilide
DIAMOND-MI Danish Investigations of Arrhythmia and Mortality
on Dofetilide-Myocardial Infarction
EAFT European Atrial Fibrillation Trial
ECG electrocardiogram
ELAT Embolism in the Left Atrial Thrombi
EMERALD European and Australian Multicenter Evaluative
Research on Atrial Fibrillation Dofetilide
study
EP electrophysiological
ERK-2-mRNA >extracellular signal-regulated kinase
messenger-RNA
ERP effective refractory period
ESPS II European Stroke Prevention Study II
EURIDIS European Trial in Atrial Fibrillation or Flutter
Patients Receiving Dronedarone for Maintenance
of Sinus Rhythm
FFAACS The French Fluindione-Aspirin Combination in
High Risk Patients With AF
GESICA Grupo Estudio de la Sobrevida en la Insufﬁcienca
Cardiaca en Argentina (V)
GUSTO-1 Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary
Arteries
HCM hypertrophic cardiomyopathy
HF heart failure
HOT CAFE´ How to Treat Chronic Atrial Fibrillation
HRV heart rate variability
IMP-2 atrial insulin-like growth factor-II mRNA-binding
protein 2
INR international normalized ratio
IRAF immediate recurrence of atrial ﬁbrillation
IVC inferior vena cava
LA left atrium
LAA LA appendage
LASAF Low-dose Aspirin, Stroke, Atrial Fibrillation
LIFE Losartan Intervention For End Point Reduction in
Hypertension study
LMWH low-molecular-weight heparin
LV left ventricle
MERIT-HF Metropolol CR/XL Randomized Intervention Trial
in Congestive Heart Failure
MI myocardial infarction
MMP-2 matrix metalloproteinase 2
NASPEAF National Study for Prevention of Embolism in
Atrial Fibrillation
PAFAC Prevention of atrial ﬁbrillation after cardioversion
PAPABEAR Prevention of Arrhythmias that Begin Early after
Revascularization, Valve Replacement, or Repair
PATAF Prevention of Arterial Thromboembolism in Atrial
Fibrillation
PAVE Post AV Node Ablation Evaluation
PIAF Pharmacological Intervention in Atrial Fibrillation
PV pulmonary veins
RA right atrium
RAAS renin-angiotensin-aldosterone system
RACE Rate Control vs. Electrical cardioversion for
persistent atrial ﬁbrillation
RV right ventricular
SAFE-T Sotalol Amiodarone Atrial Fibrillation Efﬁcacy
Trial
SAFIRE-D Symptomatic Atrial Fibrillation Investigative
Research on Dofetilide
SEC spontaneous echo contrast
SIFA Studio Italiano Fibrillazione Atriale
SOLVD Studies of Left Ventricular Dysfunction
SOPAT Suppression of paroxysmal atrial
tachyarrhythmias
SPAF Stroke Prevention in Atrial Fibrillation
SPINAF Stroke Prevention in Nonrheumatic Atrial
Fibrillation
SPORTIF Stroke Prevention using an Oral Direct Thrombin
Inhibitor In Patients with Atrial Fibrillation
SRAF subacute recurrence of atrial ﬁbrillation
STAF Strategies of Treatment of Atrial Fibrillation
SVC superior vena cava
TEE transesophageal echocardiography
TGF-beta1 transforming growth factor-beta1
TIA transient ischemic attack
TRACE Trandolapril Cardiac Evaluation
UK-TIA The United Kingdom transient ischaemic attack
aspirin trial
Val-HeFT Valsartan Heart Failure Trial
VF ventricular ﬁbrillation
WPW Wolff-Parkinson-White
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